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3 .  A B S T R A C T  
Introduction 
Alongside an ageing population with an increasing prevalence of chronic liver disease (CLD) is an 
improved survival rate for younger people with CLD who are surviving into older age.  Older 
people often have different, more complex health service needs for which geriatric services exist.  
However, the rapidly expanding older CLD population may have specific needs or outgrow 
specialty specific services. 
Falls are more common with increasing age in the general population and represent a substantial 
burden for individuals, families, society and the economy.  People with CLD have multiple 
theoretical risk factors for falling, generating the hypothesis that falls and fall related injury will be 
common in older people with CLD.  However, in order for services to adapt to the changing 
demographic evidence is required; firstly for an evidence-based management approach for falls 
intervention and prevention studies and secondly to support setting up of services. 
Methods 
In Phase 1, self-complete data collection tools were mailed to existing, comprehensive databases of 
extant cases with primary biliary cirrhosis (PBC), primary sclerosing cholangitis and post-liver 
transplant (post-LT).  The same tools were completed by patients with non-alcoholic fatty liver 
disease and alcoholic liver disease in the clinic.  The tools provided data to define falls and fall 
related injury prevalence in an older (>65 years) and a younger CLD cohort.  An existing database 
of older, healthy community-dwelling adults was used as a control group.  In Phase 2, 
multidisciplinary falls assessments were performed in a group of people with CLD to explore 
possible modifiable fall associations in order to inform future intervention/prevention studies.  
Finally, potential barriers to multifactorial intervention were explored. 
Results 
Falls are common in older people with CLD with almost 50% having had a fall in the previous year, 
significantly more so than age- and sex- matched community controls.  Falling was unrelated to 
liver disease but was independently associated with orthostatic dizziness, lower limb strength and 
fear of falling.  Falls were most common in older people with PBC (58%) and least common in ALD 
(18%).  Fall prevalence post-LT is similar to other CLDs and significantly greater than in community 
  xi 
controls; it is associated with orthostatic dizziness and the nadir blood pressure on standing up.  
Transplantation appears to have no effect on falling.  Several barriers to intervention exist, 
confidence to exercise, understanding the benefits of physical activity, fatigue and FOF which was 
independently associated with levels of physical activity. 
Conclusion 
As falls are very common in older people with CLD and represent a substantial problem on an 
individual and societal level, current services will need to adapt.  Several fall associations have been 
identified, each of which is modifiable and provides evidence for future intervention studies and 
services.  In the general population orthostatic dizziness is amenable to conservative measures and 
lower limb strength and fear of falling can be improved through physiotherapy.  If future studies 
revealed these to be effective intervention methods a multidisciplinary team consisting of a 
physician, nurse and physiotherapist would be required. 
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4 .  L I S T  O F  F I G U R E S  
Figure 1.  Possible mechanisms behind the increased severity of injury in aged hepatocytes. 4 
Figure 2.  Common symptoms of ESLD and their treatment options. 15 
Figure 3.  The vicious cycle of falls and fear of falls. 19 
Figure 4.  Flow chart of the normal physiological response to orthostasis. 21 
Figure 5.  Visual impairment may result from CLD in several locations of the eye. 23 
Figure 6.  The odds ratio for falling while taking various medications. 24 
Figure 7. Diagram of the processes involved in designing and testing the hypotheses of this thesis. 
43 
Figure 8.  A schematic of the MDT assessment. 48 
Figure 9. Spectral analysis of HRV. 53 
Figure 10. The AUC of sBP upon standing. 55 
Figure 11. The typical distribution of fall count data distribution. 57 
Figure 12.  Flow chart of the Phase 1 recruitment. 59 
Figure 13.  Response rate of the Phase 1 cohorts. 60 
Figure 14.  The composition of the Phase 1 cohort. 61 
Figure 15.  Phase 2 recruitment. 64 
Figure 16.  CLD.  Falls prevalence. 68 
Figure 17.  CLD.  The number of falls experienced by Fallers. 69 
Figure 18.  CLD.  Fall related injury prevalence. 70 
Figure 19.  CLD.  The Fallers were significantly older than the Non-Fallers. 71 
Figure 20.  CLD.  Falls in Diabetics. 72 
Figure 21.  CLD.  The 95% CI for the ORs derived from the binary logistic regression model. 75 
Figure 22.  CLD.  The 95% CI for the ORs derived from the negative binomial regression model. 76 
Figure 23.  CLD.  Functional difficulty and falls. 77 
Figure 24.  NAFLD.  Falls prevalence. 87 
Figure 25.  NAFLD.  The 95% CI for the ORs derived from the binary logistic regression model. 91 
Figure 26.  NAFLD.  The 95% CI for the ORs derived from the negative binomial regression model. 
93 
Figure 27.  PBC.  Falls prevalence. 97 
Figure 28.  PBC.  The 95% CI for the ORs derived from the binary logistic regression model. 101 
Figure 29.  PBC.  The 95% CI for the ORs derived from the negative binomial regression model. 102 
  xiii 
Figure 30.  PBC.  Functional difficulty and falls. 103 
Figure 31.  ALD.  Falls prevalence. 107 
Figure 32.  ALD.  Albumin and falls. 108 
Figure 33.  PSC.  Falls prevalence. 110 
Figure 34.  Disease comparisons.  Falls prevalence. 114 
Figure 35.  Disease comparisons.  The number of falls experienced. 115 
Figure 36.  Disease comparisons.  Soft tissue injury. 116 
Figure 37.  Disease comparisons.  The 95% CI for the ORs derived from the binary logistic 
regression model. 119 
Figure 38.  Disease comparisons.  The 95% CI for the ORs derived from the negative binomial 
regression model. 121 
Figure 39.  LT.  Falls prevalence. 129 
Figure 40.  LT.  Orthostatic symptoms and falls. 132 
Figure 41.  LT.  Nadir sBP and falls. 133 
Figure 42.  LT.  The 95% CI for the ORs derived from the regression model. 134 
Figure 43.  LT.  Functional difficulty and falls. 135 
Figure 44.  LT.  Falls prevalence (Non- and Post-LT). 138 
Figure 45.  LT.  The 95% CI for the ORs derived from the binary logistic regression model. 142 
Figure 46.  LT.  The 95% CI for the ORs derived from the negative binomial regression model. 144 
Figure 47.  LT.  The 95% CI for the HRs derived from the Cox regression model. 148 
Figure 48.  LT.  Cumulative frequency of being fall free over time since LT. 149 
Figure 49.  TCD.  Normal response of cerebral arteriole diameter during a decline in BP 156 
Figure 50.  TCD.  The TCD probe insonates the right MCA via the right temporal window 157 
Figure 51.  TCD.  Recruitment of the TCD cohorts. 163 
Figure 52.  TCD.  Normal CBFV response to valsalva in a control subject. 165 
Figure 53.  TCD.  Abnormal CBFV response to valsalva in a PBC participant. 166 
Figure 54.  TCD.  Change in CBFV per change in sBP in the Controls. 167 
Figure 55.  TCD.  Change in CBFV per change in sBP in the PBC participants. 168 
Figure 56.  Barriers.  The proportion of individuals for each degree of difficulty with activity. 180 
Figure 57.  Barriers.  Associations between activity and potential barriers to it. 184 
Figure 58.  Barriers.  The 95% CI for the ORs derived from the ordinal logistic regression model. 186 
  xiv 
5 .  L I S T  O F  T A B L E S  
Table 1.  Clinical features more commonly seen in an older person with CLD. 7 
Table 2.  Autonomic dysfunction in specific liver diseases. 30 
Table 3.  Tests of autonomic function, and classification of severity. 34 
Table 4.  Representativeness of the Phase 1 CLD cohorts. 63 
Table 5.  Representativeness of the Phase 2 cohort. 64 
Table 6.  CLD.  Demographic details. 67 
Table 7.  CLD.  Fall related injury. 70 
Table 8.  CLD.  Phase 2 correlations with the number of falls. 73 
Table 9.  CLD.  Binary logistic regression model for Faller or Non-Faller. 74 
Table 10.  CLD.  Negative binomial regression model for number of falls. 76 
Table 11.  NAFLD.  Demographic details. 86 
Table 12.  NAFLD.  The number of falls experienced by Fallers. 87 
Table 13.  NAFLD.  Fall related injury prevalence. 88 
Table 14.  NAFLD.  Phase 2 correlations with the number of falls. 90 
Table 15.  NAFLD.  Binary logistic regression for Faller or Non-Faller. 91 
Table 16.  NAFLD.  Negative binomial regression model for number of falls. 92 
Table 17.  PBC.  Demographic details. 96 
Table 18.  PBC.  Fall related injury. 98 
Table 19.  PBC.  Phase 2 correlations with the number of falls. 99 
Table 20.  PBC.  Binary logistic regression model for Faller or Non-Faller. 100 
Table 21. PBC.   Negative binomial regression for the number of falls. 102 
Table 22.  ALD.  Demographic details. 106 
Table 23.  PSC.  Demographic details. 109 
Table 24.  PSC.  Phase 1 correlations with the number of falls. 111 
Table 25.  Disease comparisons.  Demographic data. 113 
Table 26.  Disease comparisons.  Fall related injury. 116 
Table 27.  Disease comparisons.  The binary logistic regression model for Faller or Non-Faller. 118 
Table 28.  Disease comparisons.  Negative binomial regression model for the number of falls. 120 
Table 29.  LT.  Demographic details. 128 
Table 30.  LT.  Fall-related injury prevalence. 130 
Table 31.  LT.  Negative binomial regression model for number of falls. 134 
  xv 
Table 32.  LT.  Demographic details (Non- and Post-LT). 137 
Table 33.  LT.  Fall related injury (Non- and Post-LT). 139 
Table 34.  LT.  Phase 2 correlations with the number of falls (all Phase 2 participants). 140 
Table 35.  LT.  Binary logistic regression model Faller or Non-Faller, including having had a 
transplant as a variable. 141 
Table 36.  LT.  Negative binomial regression model for number of falls, including having had a 
transplant as a variable. 143 
Table 37.  LT.  Falls Pre- and Post-LT. 145 
Table 38.  LT.  Phase 1 data for those who only fell before LT compared to those who only fell after 
LT. 146 
Table 39.  LT.  Phase 1 correlations with time to first fall after LT. 147 
Table 40.  LT.  Cox regression model for time until first fall following LT. 148 
Table 41.  TCD.  Descriptive data of the cohorts. 164 
Table 42.  TCD.  Indices of CA in PBC and Control participants. 169 
Table 43.  TCD.  Associations between CA and the OGS. 169 
Table 44.  TCD.  Association between CA and falls. 170 
Table 45.  Barriers.  Demographic details. 179 
Table 46.  Barriers.  The potential barriers to activity. 180 
Table 47.  Barriers.  The associations between activity and demographic details. 181 
Table 48.  Barriers.  Associations between difficulty with activity and potential barriers to activity. 
185 
Table 49.  Barriers.  The ordinal logistic regression model for difficulty with activity. 185 
Table 50.  Barriers NAFLD.  The ordinal logistic regression model for difficulty with activity. 187 
Table 51.  Barriers ALD.  The ordinal logistic regression model for difficulty with activity. 187 
Table 52.  Barriers PBC.  The ordinal logistic regression model for difficulty with activity. 188 
  xvi 
6 .  A B B R E V I A T I O N S  
↑, ↓ Increase, decrease 
αfp Alpha fetoprotein 
A1AT Alpha-1-antitrypsin 
AD Autonomic dysfunction 
AI Autoregulatory index 
ALD Alcoholic liver disease 
ALF Acute liver failure 
ALT Alanine transaminase 
ANS Autonomic nervous system 
ASI Autoregulatory slope index 
AST Aspartate transaminase 
AUC Area under the curve 
BEI Baro-reflex effectiveness index 
BMI Body mass index 
BP Blood pressure 
bpm Beats per minute 
BRS Baro-reflex sensitivity 
CA Cerebral autoregulation 
CAMCOG The Cambridge Cognition Examination 
CBF Cerebral blood flow 
CBFV Cerebral blood flow velocity 
CBT Cognitive behavioural therapy 
CI Confidence interval 
CLD Chronic liver disease 
cm/s Centimeters per second 
CO2 Carbon dioxide 
CPP Cerebral perfusion pressure 
CSS Carotid sinus syndrome 
CVR Cerebrovascular resistance 
dBP Diastolic blood pressure 
  xvii 
e.g. Exempli gratia (for example) 
ECG Electrocardiogram 
ESLD End stage liver disease 
FES-I Falls efficacy scale international 
FIS Fatigue impact scale 
g Gram 
HAAF Hypoglycaemia associated autonomic failure 
HBV Hepatitis B virus 
HCC Hepatocellular carcinoma 
HCV Hepatitis C virus 
HE Hepatic encephalopathy 
HF High frequency 
HFnu High frequency normalised units 
HH Hereditary haemochromatosis 
HOMA Homeostasis assessment model 
HR Heart rate 
HRV Hear rate variability 
Hz Hertz 
i.e. Id est (that is) 
IR Insulin resistance 
kg Kilogram 
L Litre 
LF Low frequency 
LFnu Low frequency normalised units 
LFT Liver function test 
LT Liver transplant 
MCA Middle cerebral artery 
MDT Multidisciplinary team 
mm Hg Millimeters of mercury 
mmol/L Millimoles per litre 
MRC Medical Research Council 
MRI Magnetic resonance imaging 
  xviii 
ms2 Milliseconds squared 
NAFLD Non-alcoholic fatty disease 
NASH Non-alcoholic steato-hepatitis 
NHS National health service 
OEES Outcome expectation for exercise scale 
OGS Orthostatic grading scale 
OH Orthostatic hypotension 
OR Odds ratio 
OT Occupational therapy/therapist 
PBC Primary biliary cirrhosis 
PET Positron emission tomography 
PI Pulsatility index 
PNS Parasympathetic nervous system 
POD Paracetamol overdose 
ProFaNE Prevention of falls network Europe 
PROMIS-HAQ Patient reported outcome measurement information system- 
Health assessment questionnaire 
PSC Primary sclerosing cholangitis 
POTS Postural tachycardia syndrome 
PSD Power spectral density 
RRI R-R interval 
sBP Systolic blood pressure 
SD Standard deviation 
SEES Self-efficacy for exercise scale 
SNS Sympathetic nervous system 
SPECT Single photon emission computed tomography 
STS Sit to stand test 
TCD Transcranial Doppler 
TIPS Transcutaneous intrahepatic porto-systemic shunt 
TUG Timed up and go 
VLF Very low frequency 
VVS Vasovagal syncope 
  xix 
7 .  A S S O C I A T E D  P E E R  R E V I E W E D  P U B L I C A T I O N S   
Frith J, Jones D, Newton J.  Chronic liver disease in an ageing population.  Age and Ageing 2009:  
38; 11-8 
Frith J, Newton J.  Autonomic dysfunction in chronic liver disease.  Liver International 2009:  29; 
483-9 
Frith J, Newton J.  Managing abnormal liver blood tests in older people.  Geriatrics and Ageing 
2009:  12; 295-300 
Frith J, Newton JL.  Liver disease in older people.  CME Geriatric Medicine 2009:  11; 89-128 
Frith J, Newton J.  Liver transplantation in more elderly age.  Transplant International 2009:  22; 
599-600 
Frith J, Day C, Henderson E, et al.  Non-alcoholic fatty liver disease in older people.  Gerontology 
2009:  55; 607-13 
Frith J, Day C, Robinson L, et al.  Potential strategies to improve uptake of exercise interventions in 
non-alcoholic fatty liver disease.  Journal of Hepatology 2010:  52; 112-16 
Frith J, Kerr S, Robinson L, et al.  Primary biliary cirrhosis is associated with falls and significant fall 
related injury.  QJM 2010:  103; 153-61 
Frith J, Newton JL.  Liver disease in older women.  Maturitas 2010:  65; 210-14 
Elliott C, Frith J, Newton JL.  Occupational therapy in chronic liver disease:  a preliminary study to 
explore the views of occupational therapists and physicians working in the acute medical setting.  
British Journal of Occupational Therapy 2010:  73; 116-20 
Hollingsworth K, Jones D, Taylor R, Frith J, et al.  Impaired cerebral autoregulation in primary 
biliary cirrhosis- implications for the pathogenesis of cognitive decline.  Liver International 2010:  
30; 878-85 
  xx 
8 .  A S S O C I A T E D  P E E R  R E V I E W E D  P U B L I S H E D  A B S T R A C T S  
Frith J, Robinson L, Jungerius D, et al.  Orthostatic grading scale is better than timed up and go at 
identifying fallers with primary biliary cirrhosis.  Age and Ageing 2008:  38; ii48 
Frith J, Robinson L, Jungerius D, et al.  Falls are common in primary biliary cirrhosis and associate 
with dysautonomia and lower limb weakness.  Hepatology 2008:  48; 1092 
Frith J, Jones DEJ, Newton J.  Regulation of cerebral blood flow is significantly impaired in primary 
biliary cirrhosis.  Journal of Hepatology 2009:  50; S246 
Frith J, Robinson L, Wilton K, et al.  Non-alcoholic fatty liver disease is associated with recurrent 
falls and significant injury.  Hepatology 2009:  50; 792A 
Frith J, Day C, Henderson E, et al.  Non-alcoholic fatty liver disease is more severe in the elderly.  
Age and Ageing 2009:  38; ii49 
Frith J, Robinson L, Elliott C, et al.  Recurrent falls and significant injury are common in non-
alcoholic fatty liver disease.  Age and Ageing 2010:  in press 
Frith J, Elliott C, Pairman J, et al.  Liver transplantation is not associated with significant 
improvement in functional ability or symptoms.  Hepatology:  in press 
Newton JL, Elliot C, Frith J, et al.  Appreciation of the benefits of exercise programmes in non-
alcoholic fatty liver disease:  implications of fatigue and impact upon activities of daily living.  
Hepatology 2008:  48; 1136 
Elliott C, Robinson L, Jones DEJ, Frith J, et al.  Functional impairment is significant in chronic liver 
disease.  Age and Ageing 2010:  in press 
 
  1 
I N T R O D U C T I O N  –  P A R T  O N E
   2 
9 .  T H E  A G E I N G  L I V E R  
9 . 1 .  I N T R O D U C T I O N  
All cells within the human body undergo changes related to advancing age, although different cell 
groups are affected differently.  The ageing process affects the liver on a molecular, cellular, tissue 
and macroscopic level and has implications for both the healthy and the diseased liver.  As 
management of adults with liver disease improves and the population ages we will see an 
increasing number of older people with longstanding liver disease, and older people presenting 
with liver disease for the first time.  It is essential therefore, that laboratory and clinical 
hepatologists, as well as geriatricians, have an understanding of the ageing liver. 
Cellular, tissue and physiologic age-related changes will be presented here while attempting to 
maintain a clinical focus.  This will lead on to general, clinically relevant issues relating to an older 
person with chronic liver disease, followed by disease specific age related considerations. 
Search Strategy and Selection Criteria 
The Ovid MEDLINE® database was searched for relevant publications, written in the English 
language, from 1950 to 2010.  Further publications were identified by selecting appropriate 
publications from reference lists of relevant papers.  Search terms were matched to Medical 
Subject Headings and consisted of:  ageing/aging, hepatocyte, liver function tests, acute liver 
failure, chronic liver disease, cirrhosis, alcoholic liver disease, fatty liver disease, autoimmune 
hepatitis, viral hepatitis, HBV, HCV, biliary cirrhosis, sclerosing cholangitis, hepatocellular 
carcinoma, liver transplant, alpha 1-anti-trypsin, Wilson’s disease, haemochromatosis, 
osteoporosis, bisphosphonates, portal hypertension. 
9 . 2 .  T H E  A G E I N G  H E P A T O C Y T E  A N D  H E P A T I C  S I N U S O I D  
Hepatocytes increase in size with advancing age, although it is unknown why this occurs it is often 
thought to be a compensatory hypertrophy related to the reduction in hepatocyte numbers which 
begins in the sixth decade with a more rapid loss in the eighth decade [1].  As with most ageing 
tissues within the body increasing numbers of polyploid cells are seen, reflecting the senescent state 
of the aged liver.  Little is known about how advancing age affects the intra-cellular organelles 
within the hepatocytes.  Mitochondria appear to mirror the response of hepatocytes by declining in 
number but increasing in size.  Mitochondrial ATP content is reduced, as is their overall activity 
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which declines further in response to oxidative stress [2].  Smooth endoplasmic reticulum is 
decreased in volume in rat hepatocytes which may have important implications for drug 
metabolism [1].  Some abnormality may be present in ribosomes and polysomes, with abnormal 
aggregation and binding to endoplasmic reticulum, resulting in abnormal cross-linking of amino 
acids and an accumulation of redundant proteins [1, 3].  These proteins are believed to be the 
explanation for the dark macroscopic appearance of the liver as the aged intra-cellular lysosomes 
are unable to process the accumulating proteins [3]. 
Age related changes also occur in the hepatic sinusoid, the site of substrate exchange between the 
blood and the liver.  Within the sinusoid the sinusoidal endothelial cells become thickened and 
defenestrated, collagen is deposited in increasing quantities in the space of Diss and increasing 
numbers of fat-rich, inactive stellate cells are seen.  These changes may result in an increased 
systemic exposure to toxic macromolecules due to impaired endocytosis.  There is also the potential 
for increased post-prandial hyperlipidaemia as the reduction in fenestrations leads to impaired 
transfer of lipoproteins [4]. 
9 . 3 .  A G E I N G  A N D  L I V E R  F U N C T I O N  
Liver blood flow is estimated to reduce by 35% between the age of 30 and 100 years and is 
unrelated to the decrease in liver volume [5, 6].  One rodent derived model, suggests that this 
reduction in blood flow is the result of increasing numbers of leukocytes within the sinusoids, 
stimulated by the up regulation of intercellular adhesion molecule 1 which occurs with advancing 
age [7].  This reduction in blood flow may impair hepatic function, particularly following 
laparoscopic cholecystectomy when there is prolonged recovery of hepatic blood flow following the 
raised intra-abdominal pressure during the procedure [5].   The reduction in blood flow correlates 
well with several measures of laboratory liver function (galactose elimination, aminopyrine 
demethylation, caffeine clearance), providing evidence for decreasing liver function with age [8, 9].  
However, these laboratory markers of liver function do not translate into clinically significant 
impairments.  For example, one very important function of the liver is the phase 1 metabolism of 
drugs.  Studies in rats have demonstrated an age associated decline in drug metabolism, which 
when interpreted alongside the aforementioned changes in liver blood flow, liver volume and 
laboratory function tests,  have lead to the widely held view that phase 1 drug metabolism is 
impaired with advancing age.  Actually, there is little human data to support this; indeed, CYP450 
enzyme concentration and activity appear not to decline with advancing age in human liver, 
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although some results are conflicting [10, 11].  Notwithstanding this, it is important to remember 
that the absorption, distribution and excretion of medications may be altered.  Similarly to CYP450, 
there is no age related reduction in the activity of hepatic alcohol dehydrogenase with the majority 
of changes in the metabolism of alcohol occurring in non-hepatic sites (e.g. the age associated 
reduction in gastric alcohol dehydrogenase) [12, 13].  Declining gastric alcohol dehydrogenase 
increases the availability of alcohol which, alongside a reduced volume of distribution increases 
blood alcohol levels per unit consumed [12, 13, 14]. 
9 . 4 .  A G E I N G  L I V E R  R E G E N E R A T I O N  A N D  R E C O V E R Y  
It seems likely that the aged liver has a reduced ability to cope with challenging physiological and 
pathological insults.  Figure 1 outlines the changes seen with advancing age which could, in theory, 
lead to an increased susceptibility to insults [2, 15, 16, 17, 18]. 
 
Figure 1.  Possible mechanisms behind the increased severity of injury in aged hepatocytes. 
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It is essential to remember that the liver has a remarkable ability to regenerate and that this ability 
persists into advanced age.  Many of the aforementioned observations are based on rodent livers 
and have only theoretical translation into humans.  Furthermore, many have been inconsistent and 
difficult to reproduce, highlighting the need for further good quality studies in ageing human 
hepatocytes.  The disadvantage of these molecular rat-based studies is that they have the potential 
to feed widely held misconceptions that older people will have reduced liver function and the 
wrongly held assumption that clinically-used laboratory liver function tests (LFTs) can be mildly 
abnormal as part of the normal ageing process. 
9 . 5 .  C H R O N I C  L I V E R  D I S E A S E  ( C L D )  I N  O L D E R  P E O P L E  
Studies relating to liver disease in older age are uncommon and evidence must therefore be 
extrapolated from studies of younger people or be based upon expert opinion and experience.  As 
with many diseases in old age, the presentation and clinical course can be subtle, non-specific and 
easily missed.  It is essential to be aware of these non-specific presentations and have a high index 
of suspicion.  Interpretation of hepatic investigations should be with the same vigilance as would be 
applied to a younger person, as most investigations and treatments are well tolerated and beneficial 
in the older person.  Acute liver failure (ALF) is rare in the older person and will not be covered in 
this work; however some basic details are provided in Box 1. 
Acute liver failure is exceptionally rare in older people and as such evidence based treatment 
is lacking and should follow that of younger people where appropriate.  In a Swedish 10 year 
study of new cases of ALF the eldest person to have the diagnosis was 59 years [19]. 
The most likely causes are viral and drug induced hepatitis but ischaemic hepatitis is 
increasingly being seen in older people [20].  Acute failure secondary to hepatitis A virus is 
more severe in the elderly with more complications and an increased mortality [21].  Drug-
induced ALF is most frequently caused by paracetamol with age over 40 years being 
associated with a poorer prognosis [22]. 
Ischaemic hepatitis is seen in approximately 1% of critical care patients and has a mean age of 
70 years.  Aminotransaminases and LDH levels rise dramatically as a result of hypoxia, 
hypotension, decreased perfusion or venous congestion.  While it is potentially reversible it 
carries a high mortality rate of 45%.  Although it is an increasing cause of hepatitis it is an 
exceedingly rare cause of liver failure in the elderly. 
Box 1.  Acute liver failure in the older person. 
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9.5.1. EPIDEMIOLOGY 
Medical management and liver transplantation has transformed the survival of patients with liver 
disease.  As the population ages and medical management of CLD improves, we can expect to see 
greater numbers of older people with liver disease. 
Twenty-eight percent of individuals with alcoholic liver disease (ALD) present over the age of 60 
years [23] and 26% of patients with non-alcoholic fatty liver disease (NAFLD) are aged over 60 
years [24].  Chronic, autoimmune liver diseases also commonly present for the first time in older 
age; 50% of patients with primary biliary cirrhosis (PBC) present for the first time over the age of 65 
years, and few patients with autoimmune hepatitis (AIH) present before the fifth decade [25].  The 
exact prevalence of drug-induced liver disease is difficult to define given its challenging diagnosis; 
however, it is thought to be more common in older age [26].  In line with these statistics, the 
demand for liver transplantation in older patients is increasing and age is now less of a 
contraindication (due to technical advances and increased life expectancy); the proportion of those 
over the age of 60 years who received a liver transplant during 1990–91 was 10%, doubling to 21% 
during 1997–99 [27]. 
Viral hepatitis is less common in older age, there are however several considerations with regard to 
older people.  Firstly, fewer older people are vaccinated against hepatitis B (HBV): 0.9% of over 65 
year-olds in one hospitalised group, compared with 21% in a 35-45 year-old group [28].  Outbreaks 
of HBV have been reported in residents of care homes, without the typical blood-borne route of 
transmission [29].  Possible sources include sharing bath brushes, sexual contact and razor blades 
[30, 31].  It could therefore be recommended that older people in care homes be vaccinated against 
HBV, however the response to the vaccine is significantly reduced in older people [32].  Hepatitis C 
virus (HCV) is also uncommon in older people but there may be a significant few who received 
blood transfusion prior to screening of donor blood. 
9.5.2. PRESENTATION AND CLINICAL FEATURES 
Presentation is, on the whole, non-specific, subtle and easily disregarded.  The commonest reason 
for referral (at any age) to a hepatologist is abnormal liver function tests (LFTs) of unknown cause.  
Fatigue, malaise, anorexia, nausea and vomiting can occur in any form of CLD.  However, certain 
features are more common in older people (Table 1).  In general, older people are more likely to 
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have signs of CLD on examination, possibly because they present later in the course of the disease 
or have had the disease for longer [23, 33, 34]. 
Disease Clinical feature 
ALD [23] Typically non-specific 
Dizziness more common with increasing age 
PBC [35] Typically asymptomatic 
Sjorgren’s syndrome, pruritus, weight loss, xanthalasma, fatigue, 
abdominal discomfort 
AIH [36] Typically non-specific 
50% have lethargy, pruritus, abdominal pain 
25% present with signs of hepatic failure 
20% asymptomatic  
HBV [37] Typically asymptomatic 
Anorexia, vomiting, jaundice 
HCV [38] Variceal bleeding, malaise, abdominal pain, oedema, pruritus 
Hepatocellular 
carcinoma [34] 
Weakness, abdominal pain, anorexia, weight loss, nausea 
Table 1.  Clinical features more commonly seen in an older person with CLD. 
 
9.5.3. INVESTIGATION 
As one of the commonest presentations in a person of any age is abnormal LFTs of unknown cause 
it is important to recognize that there are no age-associated changes in alkaline phosphatase, 
hepatic transaminases or bilirubin [39].  Therefore all abnormalities in LFTs should be treated with 
the same diligence in an older person as in a younger person.  If clinical features do not direct 
further investigations a full liver screen should be considered (Box 2). Ultrasound examination of 
the liver is useful to assess disease severity (specifically to look for a nodular liver and/or evidence 
of portal hypertension such as splenomegaly) or to identify focal liver lesions.  If diagnostic doubt 
remains a liver biopsy should be considered.  In England and Wales 6% of liver biopsies are 
performed in people aged over 80 years.  Mortality from liver biopsy in this age group is 
approximately 0.2%, with no increase in mortality seen with advancing age [40]. 
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Full blood count 
Coagulation 
Glucose and lipid profile 
Inflammatory markers 
Alkaline phosphatase sub typing 
Viral hepatitis markers 
Immunoglobulins 
Auto-antibodies 
Ferritin and/or HFE genotyping* 
Urinary copper/caeruloplasmin* 
Alpha 1-antitrypsin* 
Alpha fetoprotein (AFP) 
Abdominal/liver ultrasound 
Investigations marked with an asterisk may be unnecessary as their respective diseases rarely present in 
later life 
Box 2.  Investigations considered for an older person with abnormal liver function of unknown cause. 
9.5.4. SPECIFIC LIVER CONDITIONS 
9.5.4.1 Alcoholic Liver Disease 
Signs and symptoms are more severe on presentation in the older patient with ALD  [23, 41] and 
blood alcohol levels may be higher because of lower body water content.  Acute withdrawal may be 
easily missed, particularly in a population which may be judged to be less likely to consume 
alcohol.  However, 53% of males and 38% of females over the age of 60 years are current drinkers, 
[42] and almost 10% of acute care of the elderly admissions are abusers of alcohol [43]. 
9.5.4.2 Non-Alcoholic Fatty Liver Disease 
NAFLD is more common and more severe in older people [24].  Patients will typically display 
features of the metabolic syndrome.  Diagnosis can be made clinically, in the presence of risk factors 
(insulin resistance/diabetes, obesity, dyslipidaemia, and hypertension) and the absence of other 
causes.  Ultrasound showing an ‘echo bright’ liver supports the clinical diagnosis with a specificity 
of 95% [44].  Given its prevalence and the expected increase in cases in the older population more 
studies are required in this age group. 
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9.5.4.3 Autoimmune Hepatitis 
In general AIH has an insidious onset in the old and in the young.  AIH in older people is 
associated with fewer autoimmune diseases than in younger people.  The commonest disease 
associations in older age are rheumatoid arthritis, autoimmune thyroid disease and ulcerative 
colitis [45].  Treatment outcomes with prednisolone, azathioprine or a combination of both are 
similar for both older and younger people, and are generally excellent [45, 46]. 
9.5.4.4 Primary Biliary Cirrhosis 
PBC presents similarly in the old and young, although older people have fewer symptoms on 
presentation (Table 1).  Diagnosis can be confirmed without the need for biopsy if a positive serum 
anti-mitochondrial M2 antibody is positive and the clinical features are consistent with PBC.  
Treatment strategies are similar regardless of age.  Fatigue is a poor prognostic marker, being even 
more so in older people with PBC [47]. 
9.5.4.5 Primary Sclerosing Cholangitis (PSC) 
 Increasing age was found to be an independent risk factor for a poor outcome in one large PSC 
cohort [48].  However, very little data exists on PSC in the elderly, perhaps because the median age 
of diagnosis is 40 years with a median survival of 11.9 years, and because it is itself a rare disease.  
However, being that there is a second peak in the incidence of inflammatory bowel disease in the 
7th-8th decade [49], one might expect that with an ageing population, and survival of IBD patients 
similar to that of the general population, we may expect see more PSC in the elderly [50]. 
9.5.4.6 Viral Hepatitis B 
HBV is not common in older age and is less likely to be treated because markers of active viral 
replication (HBV DNA, HBeAg) tend be low or absent in older age [51].  The efficacy of some 
treatments has not been assessed specifically in the elderly, however some trials do include elderly 
subjects, including a meta-analysis of randomised controlled trials assessing the efficacy of 
combination interferon with lamivudine versus interferon alone – equally effective in younger and 
older groups [52].  Assessment of lamivudine in the elderly has been carried out showing that it is 
as effective in over 60s as in under 60s at reducing ALT and HBV DNA, with resistance no more 
prevalent in the older than in the young [53].   
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9.5.4.7 Viral Hepatitis C 
HCV presents with signs of severe liver disease in older people (Table 1), although studies are 
uncommon.  Recombinant interferon has a response rate (normalised ALT, improved liver 
histology) of 62% in the over 65s, compared to 57% in under 65 year olds.  Side effects however, are 
more common in older people (23%) compared to the young (19%) [54].  Combination interferon 
and ribavirin is as successful in the over 60 year olds as in those under 60 years, with a sustained 
virological response of 38% in the under 60 year olds and 32% in the over 60 year olds (p=0.36).  
Combination is also more effective than interferon alone, and is not associated with more side 
effects than the younger cohort [55]. 
9.5.4.8 Hepatocellular Carcinoma 
HCC is usually detected as an acute deterioration in liver function tests in the presence of existing 
chronic liver disease.  However, the commonest presenting features (if not identified on screening) 
in patients aged over 65 years are weakness, abdominal pain, anorexia, weight loss and nausea [34].  
Ninety per cent of patients with HCC, aged over 65 years, have an alpha-fetoprotein (αfp) level 
greater than 10 ng/ml [34].  One large, population-based study of older patients with HCC 
demonstrated some differences in treatment methods used when compared to younger patients 
(displayed in brackets): transplant 0.9% (1.5%), tumour resection 8.4% (5.9%), ablation 4.1% (4.4%), 
TACE 4.2% (6.3%) [56]. 
9.5.4.9 Hereditary Haemochromatosis (HH) 
HH is classically diagnosed in middle age, with an average survival of 21 years (with treatment) 
[57]. However, recent case reports and genetic studies have shown that it can present in old age, 
and males who are homozygous for the C282Y gene (the commonest genetic abnormally identified) 
are surviving into old age without clinical or biochemical abnormalities.  This is of importance to 
clinicians who should be aware that patients can present much later than previously thought [58].  
As might be expected, females who undergo earlier menopause have a greater concentration of 
hepatic iron, than females who undergo the menopause after the age of 50, as a result of therapeutic 
menstruation [59].   
Haemochromatosis must also be considered in older patients presenting with neurological 
complications, as iron overload may be misdiagnosed with movement disorders such as 
Parkinson’s disease or cerebellar syndromes [60].  Treatment by venesection may induce orthostatic 
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hypotension as a result of volume loss which is likely to be more severe in the elderly; concomitant 
infusion of intravenous fluids may reduce this risk in those with postural symptoms or drops in 
blood pressure. 
9.5.4.10 Alpha 1-Antitrypsin Deficiency (A1AT) 
A1AT is recognised as a possible cause of cirrhosis in older age.  In one case review describing 3 
patients, aged 66, 71 and 77 years, only one had obstructive airways disease, but each had 
abdominal swelling or hepatomegaly; with a raised ALP [61].  It can also present with isolated 
respiratory disease in the elderly, and is more likely to present later in life-long non-smokers [62]. 
9.5.4.11 Wilson’s Disease 
Wilson’s disease most commonly presents in adulthood with neuro-psychiatric symptoms rather 
than the hepatic dysfunction seen in childhood [63].  Reports of presentation in the elderly vary 
from neurological dysfunction in the absence of liver disease and Kaiser-Fleischer rings [64], liver 
disease with no neurological dysfunction [65], to non-specific presentation (weight loss) [66].  In 
one review comparing recent diagnoses of WD (1994-2003) to past diagnoses (1976-1993) the age at 
presentation was greater in the most recent period (35.1 vs. 16.7 years) [67]. 
9.5.5. MANAGEMENT 
9.5.5.1 General Principles 
General management strategies apply to people of any age with chronic liver disease, such as 
lifestyle modification in ALD and NAFLD.  Specific points relevant to older people are described 
below. 
9.5.5.1.1 Orthostatic Hypotension (OH) 
OH is more common in older people, but may also arise as a consequence of liver disease associated 
autonomic dysfunction, the processes behind this are discussed in detail in section 11.4 on page 28 
[68].  Fluid balance is also disturbed in older cirrhotic patients, and can be aggravated by fluid 
restriction, diuretics, laxatives and anorexia.  Care must be taken when treatments such as diuretics 
are administered to older patients with liver disease. 
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9.5.5.1.2 Polypharmacy 
This often results when patients develop cirrhosis.  They may be prescribed beta-blockers, diuretics, 
laxatives, vitamin supplements and disease specific medications (e.g. immunosuppressives in 
inflammatory liver disease).  Benzodiazepines can result in prolonged sedation as a result of 
relatively higher body fat in older people.  Adverse effects from benzodiazepines are also 
significantly more common with age [69].  Some general principles concerning medications used for 
symptomatic relief of liver disease are described below under palliation.  Urinary and faecal 
incontinence may be exacerbated by the use of diuretics and laxatives, but also as a result of 
adverse effects of medication such as ursodeoxycholic acid and colestyramine. 
9.5.5.1.3 Bone Disease 
Bone protection will be an issue facing many older people with CLD.  Osteoporosis is common in 
cirrhosis [70] and risk may increase with the use of steroids in autoimmune liver disease.   
9.5.5.1.4 Hepatic Encephalopathy (HE) 
HE specific to the older person has little to no evidence base.  As clinicians we must therefore 
extrapolate relevant data from trials concerning younger adults.  It can be anticipated that the 
diagnosis of HE in the elderly will be more challenging given that delirium and dementia 
secondary to increasing co-morbidity will be more common.  Clinicians should therefore consider 
the diagnosis in older patients presenting with delirium or dementia.  Lactulose is recommended in 
minimal HE to improve cognition and quality of life, however, evidence suggests it has no 
beneficial effect on survival or progression of HE [71, 72].  When prescribing laxatives in the elderly 
consideration should be made to the effects it will have on faecal incontinence,  gastrointestinal 
absorption, hydration and electrolyte homeostasis [73].  Previous claims that HE is more common 
after therapeutic transcutaneous intrahepatic porto-systemic shunting (TIPS) in >60 year olds seem 
unlikely [74, 75, 76] 
9.5.5.1.5 Oesophageal Varices 
There is evidence to suggest that older people should be treated as actively as in younger patients 
(when appropriate), as active management of varices has similar short term survival rates, and 
similar rates of long-term survival with respect to liver-related mortality [77].  Endoscopy is safe 
and well tolerated (see below).  One small trial has demonstrated higher re-bleeding rates, 
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complications and overall mortality of injection sclerotherapy in older people compared to younger 
people [78].  However, this trial was small and did not fully consider co-morbidities.  The use of 
octreotide and terlipressin in the elderly is not well evidence based.  They should be considered 
where appropriate, but may not always be suitable in view of the greater prevalence of heart 
disease and hypertension. 
9.5.5.2 Screening 
9.5.5.2.1 Bone densitometry 
Assessment of bone density should be considered in all patients who have CLD, particularly in the 
presence of cirrhosis [79].  However, there is no international consensus and local guidelines may 
differ.  It should be recommended for those who have had a fragility fracture or who are on long 
term steroid therapy [79] and should form part of the transplant screening process.  For patients 
with PBC bone densitometry is recommended at diagnosis [80]. 
9.5.5.2.2 Upper gastrointestinal endoscopy 
Endoscopy is safe and well tolerated in the older person [81].  The frequency of upper 
gastrointestinal endoscopies to screen for varices should follow established guidelines [82], 
regardless of age. 
9.5.5.2.3 Ultrasound examination and serum αFP 
These are recommended every 6 months in patients with cirrhosis where treatment for early HCC 
such as resection or ablation would still be feasible. Such treatment may be efficacious and well 
tolerated by patients over 70 years [56, 83, 84]. 
9.5.5.3 Liver Transplantation 
Following liver transplantation people aged over 60 years have no significant differences in length 
of hospital stay, repeat admissions, infections, rejection or repeat transplantation compared to 
younger people [85].  The same study also demonstrated a 5 year survival of 58.1% in transplants 
performed after 1991.  Although this survival rate was significantly less than the younger group 
(82.3%), a 58% 5 year survival rate must not be undervalued.  Some studies, although not all, 
demonstrate that there are no significant survival differences between older and younger patients if 
classified as low risk pre-treatment. Factors which contribute to significantly increased mortality in 
older age include inpatient status pre-transplant, low albumin, raised bilirubin, raised prothrombin 
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time and high Child-Pugh score [27, 85, 86].  The commonest cause of death in recipients aged over 
60 years is malignancy (35%) whereas younger patients are most likely to die from infection [85].  
Cerebro- and cardio-vascular death rates are similar in both age groups; the most likely explanation 
being that the older age group undergo more pre-transplant screening for co-morbidities [85]. 
9.5.5.4 Palliation 
Developments in liver transplantation have transformed the management of liver disease.  
However, those who are unable to undergo transplantation have almost been left behind in terms 
of available evidence-based treatments.  Transplantation is often denied because of co-morbidities 
or frailty, resulting in the older person with end stage liver disease (ESLD) requiring palliation.  
Quality of life is poor for patients with ESLD, with sleep disturbance, pruritus, muscle cramps, 
ascites, fatigue, pain and cognitive decline [87, 88].  Physicians are perhaps less well able to care for 
the patient with ESLD than for end stage malignancy, for example.  This situation is worse for older 
patients as most available evidence relates to younger patients.  Figure 2 describes the management 
of some symptoms  commonly seen in ESLD [89]. 
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Figure 2.  Common symptoms of ESLD and their treatment options. 
 
9.5.6. PROGNOSIS 
Not all CLDs increase mortality in older people.  The majority of deaths in older people with AIH, 
PBC and HCV are unrelated to the liver [35, 36, 90].  However, ALD, NAFLD, and older, fatigued 
PBC patients all demonstrate age-associated increased risk of death [41, 47, 91].  Both HBV and 
HCV in older people are associated with increased risk of hepatocellular carcinoma [90, 92]. 
9.5.7. SUMMARY 
Clinicians can expect to see increasing numbers of older people with liver disease.  Detecting liver 
disease in older people relies on a high index of suspicion given that presentation is often non-
specific.  All hepatic investigations should be interpreted with diligence as there are no clinical 
changes resulting from age alone.  There are several considerations when treating older people and 
transplantation is an option.  Those diagnosed with cirrhosis who are otherwise fit should undergo 
6-monthly surveillance for HCC. Evidence-based management of end stage liver failure is scanty, 
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but can be extrapolated from trials in younger people.  Prognosis is variable, but the majority of 
older people with liver disease die of non-liver related causes. 
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1 0 .  F A L L S  I N  C L D  
1 0 . 1 .  I N T R O D U C T I O N  
As has been highlighted in the previous section, an increasingly ageing population and the 
improving treatments of CLD is leading to an older CLD population.  Health care services need to 
be aware of this as the needs of ageing patients change; it may be anticipated that an older CLD 
population will face the same ‘geriatric syndromes’ (e.g. falls) as the general ageing population but 
that neither geriatricians nor hepatologists will be equipped to deal with these evolving needs.  It is 
therefore essential to begin to define the problems which may be faced in order to develop services 
appropriately. 
Alongside the liver-related problems which affect people with CLD there are significant extra-
hepatic sequelae.  These non-liver manifestations include bone disorders [79], cardiac and skeletal 
muscle abnormalities [93, 94], neurological disorders [95, 96, 97] and cognitive disorders [98, 99, 
100, 101].  Many of these extra-hepatic manifestations and their consequences are established risk 
factors for falls and could therefore, in theory, be putting those with CLD at an increased risk of 
falls. 
Accidental falls are estimated to cost the UK National Health Service close to £1 billion annually 
[102].  Such high costs occur due to the extensive physical, psychological and social sequelae of 
falls.  Approximately 5% of falls, in the general population, result in a fracture, with increasing 
injury occurring with advancing age such that 15% of over 80 year olds sustain a fall-related injury 
[103].  Furthermore, 95% of hip fractures in older women are caused by falling and over 80% of 
older women would rather die than lose their independence from hip fracture [104, 105].  In 
addition to the morbidity, the mortality associated with falling is also increased; the odds ratio of 
death at one year following a fall is 2.6 (95% CI 1.4-4.7) [106]. 
It is not just the physical injury which contributes to the increased morbidity in falls.  Psychosocial 
consequences of falling include loss of confidence, activity avoidance, social isolation and an 
increased risk of being admitted to long term care facilities [107, 108, 109, 110].  Fear of falling is a 
particularly complex consequence of falls as fear of falling leads to falls and a vicious cycle is 
created (Figure 3).  It is also independently associated with an increased risk of institutional care 
[111, 112, 113]. 
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Figure 3.  The vicious cycle of falls and fear of falls. 
 
1 0 . 2 .  F A L L S  I N  C L D  -  E V I D E N C E  &  T H E O R Y  
The complexity of falls aetiology and a lack of effective targeted single-interventions is highlighted 
by the number of identified fall risk factors, over 400 [114].  As it would be impossible to consider 
every risk factor in all individuals undergoing a falls assessment, the National Institute for Clinical 
Excellence (NICE) has produced a clinical guideline detailing an appropriate multifactorial falls risk 
assessment.  The falls risk factors discussed here will be based on this NICE guideline, which is 
specific to older people [115]. 
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Search Strategy and Selection Criteria 
The Ovid MEDLINE® database was searched for relevant publications from 1950 to 2010.  Papers 
were excluded if they were not written in the English language or were based on paediatric 
populations.  Chronic liver disease in general was used as a search term as well as searching 
specifically for fatty liver disease, alcoholic liver disease, primary biliary cirrhosis, autoimmune 
hepatitis, viral hepatitis, hepatocellular carcinoma and primary sclerosing cholangitis.  These 
search terms were matched to Medical Subject Headings and then searches were combined with 
the following terms:  accidental falls, gait (and ataxia), balance (postural instability), mobility, 
muscle weakness (and strength), fear of falling, vision, cognition (and cognitive impairment), 
environment (and home hazard), footwear, assistive devices and polypharmacy. 
 
10.2.1. NEURO-CARDIOVASCULAR INSTABILITY 
Orthostatic hypotension (OH), vasovagal syncope (VVS) and carotid sinus syndrome (CSS) can 
each cause falls as a consequence of syncope, pre-syncope or a loss of balance.  Although syncope 
may be thought of as a separate entity to falls, syncope and falls are closely related.  CSS and VVS 
are more common in people with unexplained falls and the treatment of OH leads to a reduction in 
unexplained falls [116, 117, 118, 119]. 
The prevalence of neuro-cardiovascular abnormalities in CLD is well documented  and represents a 
major risk factor for falling in CLD with the prevalence of autonomic dysfunction as high as 87% in 
some liver disease populations [68, 94, 97, 120, 121, 122, 123, 124].  The importance of autonomic 
dysfunction in CLD is discussed further in section 11.  A summary of the normal, orthostatic, 
neuro-cardiovascular process is displayed below in Figure 4. 
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Figure 4.  Flow chart of the normal physiological response to orthostasis. 
 
10.2.2. GAIT AND BALANCE 
Abnormal gait and balance are associated with an increased risk of falling in the general elderly 
population and may be the result of a variety of mechanisms [125, 126].  Studies specific to gait and 
balance in CLD are rare.  Gait speed is a commonly used screening tool to identify those at risk of 
falling, with slower speeds being associated with falling [127].  The search strategy above identified 
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no publications describing gait speed in people with CLD, although there is evidence that walking 
distance is impaired [128]. 
Evidence concerning postural balance in CLD is limited to ALD and Wilson’s disease, in which 
ataxia may be seen [129, 130].  There is surprisingly little data relating to postural instability 
secondary to cerebellar disease in ALD.  While there is a lack of data in CLD theoretically balance 
may be impaired due to orthostatic intolerance.  Postural dizziness is known to be associated with 
poor balance, is common in both NAFLD and PBC and could contribute to an increase in postural 
instability in CLD [131]. 
10.2.3. MUSCLE WEAKNESS 
Muscle strength is strongly associated with falls via its influence on gait and balance [132].  While 
there is much evidence for the biological abnormalities seen in the muscles of people with CLD this 
has not been translated into pragmatic studies of muscle function and strength in humans with the 
exception of one study [133].  This was a small study of people with NAFLD which found that all of 
their participants (n 37) had reduced muscle strength.  Although the authors did not suggest a 
cause, theoretically muscle weakness could occur in those with insulin resistance which, via 
increasingly resistant GLUT-4 transporters, reduces glucose uptake in myocytes [134].  
Mitochondria in skeletal muscle appear to have abnormal function in people with PBC and this 
degree of dysfunction appears to correlate with the degree of exercise performed [93].  Potentially, 
this abnormality of bioenergetics in the skeletal muscle could result in muscle weakness and 
thereby, falls. 
10.2.4. PREVIOUS FALLS 
Those who have fallen are significantly more likely to do so.  Those who have fallen recurrently are 
at particular risk of falling again with a relative risk of falling within the year of 2.4 (95% CI 1.7-7) 
[135].  Furthermore, recurrent falls are associated with a decline in muscle strength and worsening 
balance [136, 137]. 
10.2.5. VISUAL IMPAIRMENT 
The risk of falling is doubled in those with visual impairment [138], although interventions to 
improve vision do not always prevent further falls; indeed some studies have demonstrated an 
increase in falls following correction of visual impairment [139, 140, 141].  There are several reasons 
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why people with CLD may develop visual impairment and be at increased risk of falling [142, 143, 
144, 145, 146].  These impairments, all of which are uncommon, are summarized in Figure 5 below. 
 
Figure 5.  Visual impairment may result from CLD in several locations of the eye. 
 
10.2.6. MEDICATION 
Figure 6 displays the odds ratio for having a fall while taking different medications identified from 
a meta-analysis of studies involving people aged 60 years or more [147].  Individuals who use over 
3 medications are also at increased risk of falling, regardless of the class of drug that they’re taking 
[148]. 
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Figure 6.  The odds ratio for falling while taking various medications. 
 
The risk of falling in people with CLD who are taking psychotropic drugs may be exaggerated.  For 
the most part psychotropic medications are eliminated by the liver and are associated with dose-
dependant adverse reactions [149].  As such those with liver disease may have an increased risk of 
falling while taking these.  A literature search was unable to reveal any data concerning the 
prevalence of polypharmacy in CLD, but it is possible given the multiple symptomatology in 
conditions such as PBC. 
10.2.7. ENVIRONMENT, ASSISTIVE DEVICES AND FOOTWEAR 
The majority of falls, particularly those that are injurious, occur in the home [150].  Environmental 
hazards are involved in approximately 50% of home-based falls, but the number of hazards present 
does not appear to increase the risk of falling [151].  There is a lack of data concerning 
environmental hazards, assistive devices and footwear in people with CLD and it is difficult to find 
a theoretical basis for an increased risk of falling secondary to these risk factors. 
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10.2.8. COGNITIVE IMPAIRMENT 
The odds of falling in people with cognitive impairment are 5 times higher than in those without 
cognitive impairment (OR 5, 95% CI 1.8-13.7) [125].  Cognitive deficits are present in a number of 
CLDs independently of disease severity [99, 101, 152, 153]; an increase in falls related to cognitive 
impairment could therefore be anticipated. 
1 0 . 3 .  S U M M A R Y  
There is little to no data available concerning falls in CLD.  The data available concerning risk 
factors are, on the whole, theoretical only.  The high prevalence of autonomic abnormalities in CLD 
may represent the most important potential risk for falls; particularly as autonomic function plays a 
role in gait, balance and cognition, each of which is associated with falls. 
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I N T R O D U C T I O N  -  P A R T  T H R E E
   27 
1 1 .  A U T O N O M I C  D Y S F U N C T I O N  I N  C H R O N I C  L I V E R  D I S E A S E  
1 1 . 1 .  I N T R O D U C T I O N  
Autonomic dysfunction in the context of CLD has been of increasing interest over the last 15 years.  
During this time it has become widely accepted as a complication of CLD, and a major contributor 
to the symptomatic burden.  As the prevalence may be as high as 67%, and it is associated with an 
increased mortality, it is of great importance to clinicians who encounter CLD [154].  The autonomic 
nervous system is complex, with many investigations available.  With its high prevalence and 
clinical significance it is important that clinicians recognise dysautonomia and initiate appropriate 
investigation and management.  In the context of an ageing CLD population, dysautonomia could 
lead to increased prevalence of cognitive deficits, poor mobility and increased falls and fall related 
injury. 
Search Strategy and Selection Criteria 
Journal articles from 1950 to date were searched using Ovid MEDLINE® database.  Search terms 
used included autonomic nervous system, autonomic nervous system diseases, chronic liver 
disease, fatty liver disease, alcoholic liver disease, biliary cirrhosis, sclerosing cholangitis, viral 
hepatitis, hepatocellular carcinoma, autoimmune hepatitis and liver transplantation.  Search 
terms were matched to Medical Subject Headings.  Excluding non-English papers, 17 
publications were identified with additional relevant papers identified through reference lists.  
Where there is a lack of evidence in the literature regarding a specific point, general principles 
and expert opinion are applied; these comments are explicit when included. 
1 1 . 2 .  T H E  A U T O N O M I C  N E R V O U S  S Y S T E M  ( A N S )  
The autonomic nervous system comprises the sympathetic (SNS) and parasympathetic nervous 
systems (PNS).  They are largely responsible for involuntary, subconscious control of viscera, 
smooth muscle and secretory glands.  The autonomic efferent neurones originate in the spinal cord 
or brain stem (pregangionic), but differ from the somatic nerves in that the second neurone 
originates in an autonomic ganglion outside the central nervous system (postganglionic). 
The sympathetic preganglionic neurones are limited to the thoracic and first three lumbar segments 
of the spine.  The postganglionic neurones of the sympathetic system make up the sympathetic 
chain, found alongside the spine, and the celiac and mesenteric plexuses.  Sympathetic 
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preganglionic neurones release acetylcholine, whereas postganglionic neurones transmit 
noradrenalin (with the exception of sweat glands which are cholinergic, and the adrenal medulla 
which directly synapses with preganglionic neurones).  The physiological responses of sympathetic 
nervous stimulation are increased heart rate (HR) and blood pressure (BP); dilatation of the 
bronchi; vasodilatation to skeletal muscle; vasoconstriction to the gastrointestinal tract; decreased 
gastrointestinal motility; increased sweating; smooth muscle sphincter contraction and pupillary 
mydriasis. 
Parasympathetic preganglionic neurones are located in the 3rd, 7th, 9th and 10th cranial nerve nuclei 
as well as 2nd, 3rd and 4th sacral cord segments.  Again the postganglionic neurones are found 
outside the central nervous system contributing to plexuses such as Auerbach’s (myenteric) and 
Meissner’s (sub mucosal).  The neurotransmitter of the parasympathetic nervous system is 
acetylcholine, through which the following clinical responses occur:  decreased HR and 
contractility; vasodilatation; bronchial constriction; increased gastrointestinal motility; relaxation of 
smooth muscle sphincters and pupilary miosis. 
1 1 . 3 .  A U T O N O M I C  D Y S F U N C T I O N  
AD is a change in normal functioning of the ANS which adversely affects health.  It can be primary 
or secondary, acute or chronic and transient or progressive.  This review will focus on chronic, 
secondary AD as a result of CLD. 
1 1 . 4 .  P A T H O G E N E S I S  
The patho-physiological basis of AD secondary to liver disease is largely unknown.  Immunological 
and metabolic abnormalities may play a role, but the resultant decreased parasympathetic and 
increased sympathetic activity may in part be explained by the following mechanisms. 
In CLD there is a decreased response to vasoconstrictors which may be caused by increased 
concentration of vasodilators such as nitric oxide.  An increase in portal blood pressure, even mild, 
can lead to an up regulation of nitric oxide synthatase [155].  An increase in vasodilator production, 
a diseased liver and a porto-systemic circulation bypassing hepatic metabolism will contribute to 
increased levels of circulating vasodilators.  Circulating vasodilators will activate the renin-
angiotensin-aldosterone system and increase plasma levels of the vasoconstrictor angiotensin II.  
Plasma concentrations of angiotensin II, are raised in patients with CLD, and correlate with disease 
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severity [156].  Understanding angiotensin II in relation to control of the glomerular filtration rate is 
well understood, but it may also interact with the parasympathetic control of heart rate variability 
(HRV).  Infusion of angiotensin II causes a decrease in HRV and a reduction in vagal discharges to 
the heart; if the vagus nerve is severed there is no change in HRV when it is infused.  
Administration of an angiotensin converting enzyme inhibitor improves the HRV confirming that 
angiotensin II plays a role in AD [157].  In addition, administration of antioxidants to people with 
CLD seems to reverse blunted BP responses suggesting that oxidative stress may also play a role in 
AD [158]. 
Diabetes, which is a common cause of AD is common in CLD [159, 160].  In diabetics who suffer 
iatrogenic hypoglycaemia there is a hypoglycaemia associated autonomic failure (HAAF) [161].  
This is a result of decreased response of adrenaline and the SNS to hypoglycaemia.  It may be 
possible that the hypoglycaemia induced by severe hepatic dysfunction may bring about HAAF.  
The resultant AD creates hypoglycaemic unawareness, and therefore a vicious circle of worsening 
AD [162]. 
AD  in advanced liver disease is associated with decreased baro-receptor sensitivity to hypotension, 
leading to impaired BP and HR responses [163].  Advanced liver disease and cirrhosis result in 
other complex cardiovascular abnormalities, such as arterio-venous communications, altered 
sodium handling and cirrhotic cardiomyopathy.  These changes will exaggerate the abnormal 
effects of AD, but are outside the scope of this review.   
1 1 . 5 .  P R E S E N T A T I O N  O F  A D  I N  C L D  
Disease specific features of AD are described in Table 2 [97, 120, 121, 164, 165, 166]. 
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Disease Features 
Primary Biliary Cirrhosis PNS dysfunction in 71%, SNS dysfunction in 57%.  AD is 
associated with cognitive decline and fatigue in PBC, but not 
with disease severity.   
Primary Sclerosing Cholangitis Orthostatic intolerance in 5%. 
Alcoholic Liver Disease PNS dysfunction in 72% of patients, SNS dysfunction in 40%.  
Prevalence greater in more severe disease.  Quantity of alcohol 
consumed correlates with degree of AD and worsens AD in 
existing CLD. 
HbsAg positive liver disease PNS dysfunction in 86%, SNS dysfunction in 43%. 
Anti-HCV positive liver 
disease 
PNS dysfunction in 58%, SNS dysfunction in 42%. 
Table 2.  Autonomic dysfunction in specific liver diseases. 
 
The clinical picture of a patient with chronic liver disease presenting with AD is similar for chronic 
AD of any cause.  However, with the aforementioned cardiovascular changes the presentation can 
be more complex and difficult to distinguish from other sequelae of CLD, such as hypovolaemia 
(resulting from sepsis, blood loss or over-diuresis). 
11.5.1. ORTHOSTATIC HYPOTENSION 
One of the commonest consequences of AD in CLD is OH, with 33% of patients having dizziness on 
standing [122, 123].  The patient typically complains of dizziness or light-headedness on standing 
from a sitting or lying position.  Other symptoms include blurring of vision, discomfort of head, 
neck or shoulder- the so called ‘coat hanger’ headache, fatigue and in severe cases, syncope. 
11.5.2. FATIGUE 
Fatigue is a common complaint of patients with CLD and ranges from slight impairment of daily 
living to severe debilitation.  Liver function tests (LFTs) are often performed in the patient who 
presents with ‘tiredness all the time’ and fatigue may therefore be a presenting symptom of CLD.  It 
can develop at any time in patients with existing liver disease, but it does not correlate with disease 
severity [167, 168].  The severity of fatigue experienced by patients correlates with increasingly 
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severe autonomic dysfunction, which must therefore be a major contributing factor in the aetiology 
of this symptom [169].  Other contributing factors may include metabolic disturbance, anaemia, 
altered sleep patterns and medication (benzodiazepines, antidepressants, beta-blockers). 
11.5.3. EXERCISE INTOLERANCE 
In addition to fatigue, autonomic dysfunction can also reduce exercise tolerance.  In patients with 
dysautonomia secondary to diabetes a blunted response of HR, BP, adrenaline and noradrenalin is 
seen [170].  The same response could be anticipated in those with AD in CLD. 
11.5.4. URINARY SYMPTOMS 
Bladder dysfunction is a feature of AD; 10% of patients with CLD have symptoms of ‘bladder 
disturbance’ and 14% of pre-transplant patients use incontinence pads [123, 171].  Although there is 
very little data concerning bladder dysfunction in CLD we know from other AD associated diseases 
that it may also manifest as urinary frequency, hesitation or retention; the consequences of which 
include urinary tract infections, renal failure and indignity [172].  Incontinence in CLD may be 
exacerbated by prescribing diuretics. 
11.5.5. GASTRIC SYMPTOMS 
In patients with CLD there is both delayed gastric emptying of liquids and solids and a prolonged 
transit time from mouth to caecum [173, 174].  Symptoms include early satiety, nausea, vomiting, 
weight loss and epigastric pain.  The decrease in small bowel motility resulting from AD is 
particularly important as it can cause bacterial overgrowth, with increased risk of HE and 
peritonitis.  Delayed gastric emptying is associated with post-prandial hypoglycaemia, and may 
therefore worsen AD [175].  Changes in gastrointestinal motility alongside disturbances of 
sphincter control can cause diarrhoea, constipation and incontinence which may be exaggerated by 
laxatives. 
11.5.6. SEXUAL DYSFUNCTION 
Similar to fatigue LFTs may be performed when investigating a patient who presents with sexual 
dysfunction, and may identify liver disease (13% of men presenting with erectile dysfunction have 
abnormal LFTs) [176].  Sexual problems may arise either from fatigue, altered body image, AD, 
haemodynamic changes or from alterations in circulating sex hormones.  Females show higher 
levels of dysfunction in end stage liver disease, although in cirrhotic patients males place greater 
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importance on it [177, 178].  Diuretics, beta-blockers and antidepressants can all exacerbate sexual 
dysfunction. 
11.5.7. HIDROSIS 
Despite 5% of patients with CLD have sweating abnormalities it is uncommon to encounter either a 
patient who complains of excess or impaired sweating as it has little impact on daily life [123].  
Unless questioned specifically patients may not appreciate the significance of symptoms of 
temperature regulation and sweating. Clinically the usefulness of this in relation to diagnosing AD 
is questionable. 
1 1 . 6 .  I N V E S T I G A T I N G  T H E  A N S  
The simplest, clinical method to test for AD is to test for OH.  Baseline BP is recorded in a resting 
supine position; the patient then stands and the BP is recorded immediately and repeated at 3 
minutes standing.  A diagnosis of OH is made if there is a systolic drop in BP of ≥20mmHg or a 
diastolic drop of ≥10mmHg within 3 minutes [179].  In patients with CLD, before a diagnosis of OH 
is made, hypovolaemia should be excluded (typically hypovolaemia will cause an isolated systolic 
drop with no diastolic drop in pressure, however this is unreliable) and causal medications should 
be reviewed. 
Another simple clinical test is a resting electrocardiogram.  A normal resting HR would lay between 
60 and 80 bpm, levels above this could indicate parasympathetic dysfunction.  However anaemia, 
hyperthyroidism, sepsis, hypovolaemia, arrhythmias and phaeochromocytomas can also cause 
resting tachycardias.  The presence of rate limiting medication can also mask parasympathetic 
dysautonomia. 
Other tests of autonomic function are available (Table 3), but these are specialised and not 
practicable in every clinic [180]. However an understanding of them is of value in order to 
understand specialist investigation and research.  Measuring autonomic function is unreliable in 
those patients who are on beta-blockers, as normal sympathetic responses will be blunted. 
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Using ECG monitoring, the patient rests supine for a 
stable HR.  The patient then stands up with the ECG 
monitoring.  The ratio of longest RRI (around the 
30th beat) to the shortest RRI (around the 15th beat) 





Response to deep 
breathing 
(Parasympathetic) 
After resting in a sitting position, whilst recording 
the HR, the patient breathes deeply and evenly at 6 
breaths per minute.  The maximum and minimum 
HR during each breath cycle is noted for 3 
consecutive cycles.  The mean difference between 
maximum and minimum HR is calculated. 
>9 bpm normal (age 
>60) 
≥15 bpm normal (age 
<60) 
11-14 bpm borderline 
≤10 bpm abnormal 
Valsalva 
(Parasympathetic) 
After resting in a sitting position, with HR 
monitoring, the patient expires for 15 seconds 
against a closed glottis (pressure of 40 mm Hg).  The 
ratio of the longest RRI just after releasing the 
valsalva, and the shortest RRI during it is calculated. 
≥1.11 normal (age >60) 




The same method as for valsalva (parasympathetic) 
but BP is recorded. 
Normally there will be a 
BP overshoot shortly 




Using a dynamometer, hand grip is maintained at 
30% of maximum grip for 5 minutes.  An alternative 
is to ask the patient to sit up from supine position, 
leaving their legs on the couch.  Baseline diastolic 
pressure is measured before exercise and just before 
releasing the grip, the difference is calculated. 
≥16 mmHg normal 
11-15 mmHg borderline 
≤10 mmHg abnormal 
Cold pressor 
(Sympathetic) 
One hand is held in iced water for 1 minute.  
Diastolic BP is measured, before and after, the 
increase is calculated. 
≥15 mmHg normal 
11-14 mmHg borderline 
≤10 mmHg abnormal 
Table 3 continues… 
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Using Ewing and Clarke’s criteria, severity of dysautonomia is classified as: 
Normal:  all tests normal or borderline 
Early dysautonomia:  one abnormal HR test or two borderline 
Definite dysautonomia:  two or more abnormal HR tests 
Severe dysautonomia:  two or more HR rate tests abnormal, plus one borderline or abnormal BP test 
Atypical:  any other combination of abnormal tests 
Table 3.  Tests of autonomic function, and classification of severity. 
 
1 1 . 7 .  T R E A T I N G  A D  I N  C L D  
There are numerous factors which complicate the treatment of dysautonomia in the patient with 
CLD.  Patients may be on diuretics, beta-blockers, antidepressants or sedatives all of which affect 
the autonomic nervous system.  Lactulose and diuretics as discussed previously can contribute to 
incontinence or sexual dysfunction, and a risk/benefit analysis may need to be undertaken with the 
patient. 
Pronounced splanchnic vasodilatation following paracentesis of ascitic fluid results in a prominent 
activation of the SNS [181] leading to, at worst, circulatory collapse [182].  This is avoided by 
infusion of intravenous albumin to maintain a normovolaemic circulation [181]. 
11.7.1. ORTHOSTATIC HYPOTENSION 
Specific treatment options for patients with CLD and OH are lacking, therefore therapeutic options 
for OH of other causes may be applied with expert opinion.  OH is often the most troublesome of 
dysautonomic symptoms but is usually treated successfully with conservative measures.  A typical 
recommendation for patients with OH of any cause is to maintain their intravascular volume by 
drinking at least 2 – 2.5 litres of fluid per day.  This may however, complicate CLD, especially those 
who are fluid overloaded but who are unable to maintain their fluid in the intravascular 
compartment.  Compression stockings help to redistribute extra-vascular fluid, and also prevent 
peripheral venous pooling on assuming an upright posture.  Large meals should be avoided to 
minimise postprandial hypotension, and all patients should adopt a slow, gradual staged 
movement on rising into standing position.  Pharmacological options are available for those few 
who do not respond to conservative measures.  Fludrocortisone can improve OH of any cause by 
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causing sodium and water retention, but may be contraindicated or used with great caution in CLD 
where secondary hyperaldosteronism may already be present.  Midodrine, an α1-adrenoreceptor 
agonist, which is used off-licence in the UK, may be used to treat OH.  Extreme caution should be 
taken when using in patients with CLD, as it can worsen liver function.  Other agents which have 
been used for OH (but not specifically used in CLD) are beta-blockers, clonidine, pyridostigmine, 
erythropoietin and selective serotonin re-uptake inhibitors. 
11.7.2. FATIGUE 
Fatigue is often multi-factorial and difficult to manage.  In CLD associated fatigue patients should 
be encouraged to adopt a steady state of activity, and avoid intense bouts of activity when energy is 
present.  In resistant cases of Primary Biliary Cirrhosis (PBC) where fatigue is associated with 
excessive daytime sleepiness modafinil has been used successfully [183].  It is relatively 
contraindicated in hypertensive patients, and BP should be monitored while on treatment.  Starting 
dose is 50-100mg and titrated accordingly.  Side effects include headaches, sleep disturbance and 
hypertension.  In those who suffer from insomnia a sedative may improve sleep thereby improving 
daytime wakefulness.  In those who suffer broken sleep or display risk factors for sleep apnoea a 
referral for sleep studies should be considered.  In patients on beta-blockers a risk/benefit analysis 
should be undertaken on an individual basis, as beta-blockers can cause profound fatigue [184]. 
11.7.3. GASTROINTESTINAL SYMPTOMS 
Current treatments for delayed gastric emptying are, on the whole, disappointing.  There are no 
trials addressing this issue in CLD specifically and evidence must therefore be taken from trials 
assessing delayed gastric emptying of other causes.  Medical management includes erythromycin 
which improves motility but does not improve symptoms, and domperidone which seems to be 
more effective at symptom control, in diabetic patients with gastroparesis [185].  Surgical options as 
yet are limited as trials have been retrospective and uncontrolled, but gastrostomy, botulinum 
neurotoxin and implantable electrodes to stimulate motility have shown promise [185, 186, 187]. 
Gastrointestinal mobility disorders may be initially managed with diet, followed by medications 
such as laxatives or bulking agents, and constipating agents with planned enemas, although 
specific evidence in relation to CLD is lacking, expert opinion would suggest using the above 
simple measures as a first line treatment.  For severe, resistant cases with significant impact on 
daily living surgical options exist (evidence not specific to CLD).  For incontinence the anal 
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sphincter can be repaired or substituted, but with disappointing long term success [188].  For 
incontinence and constipation colectomy with or without stoma formation may improve symptoms 
[189]. 
11.7.4. URINARY SYMPTOMS 
Treatment options for neurogenic bladder dysfunction are generic and expert opinion allows us to 
apply the evidence to any causal disease.  Evidence suggests that urodynamic studies will help 
direct appropriate management [190].  First line treatment for urinary frequency includes bladder 
retraining (increasing time between voiding) or regular toileting (micturating every 2-4 hours) 
[172].  Pharmacological treatments include antimuscarinics which can worsen AD and alpha-
blockers which can cause profound OH [191].  For severely hypotonic bladders intermittent 
catheterization may reduce incontinence, infections and renal failure [192]. 
11.7.5. SEXUAL DYSFUNCTION 
It is difficult to distinguish between AD, medication adverse effects and psychological disturbance 
as the cause of sexual dysfunction.  Contributing medications should be reviewed.  Despite lower 
levels of testosterone and increased levels of oestrogen, supplementing testosterone is not effective 
at improving erectile dysfunction [193].  Unsurprisingly sexual dysfunction does improve in 
alcoholic men who abstain [194].  The incidence of erectile dysfunction more than doubles in men 
who undergo TIPS [195].  There is evidence that the pharmacokinetics of phosphodiesterase type-5 
inhibitors in those with hepatic impairment is not altered [196], however there are also case reports 
of hepatotoxicity associated with sildenafil [197]. 
11.7.6. HYPERHIDROSIS 
Although not specific to CLD, disorders of sweating, especially axillary, palmar and gustatory 
hyperhidrosis, may respond to treatment with botulinum neurotoxin [198]. 
1 1 . 8 .  A U T O N O M I C  F U N C T I O N  F O L L O W I N G  L I V E R  
T R A N S P L A N T A T I O N  
The majority (87%) of patients who undergo liver transplantation suffer from AD [124].  The degree 
of dysautonomia improves after liver transplantation in 63% of patients at 6-7 months; however in a 
very small number it gets worse despite successful grafting and in patients whose allograft function 
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is impaired dysautonomia persists [124, 199].  Although the aforementioned studies had relatively 
short follow up, studies of spontaneous baro-reflex sensitivity have shown improvements which 
remain at 18 months [200]. 
The effects of LT on sexual and urinary dysfunction are much less impressive, with no 
improvements in symptoms.  This confirms the complex nature of these problems with medication 
and psychological factors perhaps having a greater effect than AD [171, 177]. 
1 1 . 9 .  P R O G N O S I S  
The association between liver disease severity and the incidence of AD is equivocal with conflicting 
results [95, 96, 154, 201].  Mortality is increased in patients with CLD and AD; 4 year mortality is 
30% in CLD with AD compared to 6% in CLD without AD [202].  AD is an independent risk factor 
for mortality in both compensated and decompensated cirrhotic patients [154].  In one study which 
followed patients awaiting LT for 10 months, 6 patients died, each had AD leading the authors to 
conclude that consideration should be given for early LT in those with AD [154].  In addition to 
increased mortality in those with cardiovascular abnormalities, patients with PBC who suffer from 
fatigue have an increased mortality [203]. 
The aforementioned sequelae of AD add significantly to poorer quality of life in patients already 
burdened with chronic disease.  Recent studies are also beginning to define additional potential 
consequences of AD in those with liver disease such as cognitive impairment [99].  As 
dysautonomia is increasingly common in older age we should expect to see more consequences of 
AD as the liver disease population ages.  Falls, OH, incontinence and cognitive impairment are all 
more common with age and will pose significant problems in this population. 
Although the increase in mortality associated with AD is significant, hepatologists should not solely 
focus on survival or laboratory markers, but address symptomatic burden and quality of life.  
Challenging, vague symptoms can often be improved through active listening and empathy, 
improving patients’ expectations and satisfaction.  If patient care is to be improved, outcome 
measures which enable patients to represent the treatment effects which make a real difference to 
their lives must be incorporated into routine clinical practice [204]. 
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1 1 . 1 0 .  C O N C L U S I O N S  
Although greater understanding of the pathogenesis of AD in CLD is required its effects on patients 
are becoming increasingly recognised.  The symptomatic burden of patients with CLD and 
dysautonomia is high, but may be overlooked in favour of laboratory markers of disease severity.  
Many of the symptoms, such as fatigue and sexual dysfunction, pose difficulties for clinicians, as 
they may be considered low priority, ubiquitous and un-modifiable.  Simple measures such as 
reviewing medications (beta-blockers, diuretics, and antidepressants) may lead to improvements in 
the patients’ symptoms and quality of life.  Recognising AD will help to identify those patients who 
are at increased risk of death, and may contribute to the consideration for LT. 
The role of autonomic dysfunction in older people with CLD who fall remains to be seen.  It seems 
likely that abnormal blood pressure responses to standing could contribute to falls in CLD and if so, 
represents a potential therapeutic and preventative target. 
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I N T R O D U C T I O N  –  P A R T  F O U R
   40 
 
1 2 .  O R I G I N A L  H Y P O T H E S E S  
• Falls are common in older people with CLD 
• Factors contributing to falls in older people with CLD include autonomic dysfunction, 
muscle abnormalities, gait and balance impairments and cognitive decline 
• Fall related injuries are severe due poor protective mechanisms resulting from a transient 
loss of consciousness caused by autonomic dysfunction  
1 3 .  A I M S  
• To define the prevalence of falls and recurrent falls in older people with CLD 
• To establish the prevalence of fall related injury in older people with CLD 
• To identify modifiable factors associated with falling in older people with CLD 
1 4 .  S E C O N D A R Y  A I M S  
• To determine if falls prevalence differs between specific CLDs 
• To explore fall associations in specific CLDs to identify whether associations contribute to 
falls differently in different CLDs 
• To define the prevalence of falls in a post-LT population 
• To explore the effect of transplantation on falls 
• To understand the relationship between falls and fall associations 
• To identify potential barriers to uptake and adherence to a falls prevention/ intervention 
programme 
• To produce evidence to support the design of a future falls prevention/ intervention 
programme 
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M E T H O D S  –  P A R T  O N E
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1 5 .  M E T H O D O L O G Y  
1 5 . 1 .  B A C K G R O U N D  
The Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University in 
collaboration were awarded Biomedical Research Centre status in 2007.  The National Institute for 
Health Research Biomedical Research Centre in Newcastle is one of 12 Biomedical Research Centres 
in the UK, but is unique in its specialist status of Ageing; the centre is composed of seven strands, 
one of which is Liver Disease in Ageing.  The importance of such a theme has been described earlier 
in the introduction to this thesis. 
One of the principle aims of the Liver Disease in Ageing Strand is to define the burden of liver 
disease and to establish therapeutic needs with the overarching aim of having direct benefits to 
patients.  The work presented in this thesis addresses this aim in relation to falls and fall-related 
injury. 
1 5 . 2 .  R E S E A R C H  D E S I G N  
Although the Medical Research Council (MRC) came under criticism for being narrow and 
misconceived with it’s framework for developing and evaluating complex interventions in 2000, it 
has stimulated and promoted discussion about research methodologies and helped researchers to 
contextualise their research [205, 206].  Context is crucial to understand whether a problem exists, 
the extent of that problem and whether the problem could be susceptible to intervention [207].  
Context can be set through literature review, seeking expert opinion and undertaking 
epidemiological research.  While the MRC updated its guidance in 2008 there was little reference to 
the ‘contextualising phase’ of research apart from the updated cyclical/non linear model of the 
research process.  Although the linear model in the original framework was criticised for being too 
rigid with no feedback loops it is often useful to think of research in stages and the linear model 
assists understanding of the context of this thesis.  Figure 7 attempts to explain how the work of this 
thesis fits into the service development and research setting, although it is important to recognise 
that the process is rarely linear and realistically would have many feedback loops.  The top row of 
the Figure represents generic research stages; the middle row represents the stages involved in 
forming this thesis and the bottom row displays the 2 phases which will be used to present the 
findings. 
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Figure 7. Diagram of the processes involved in designing and testing the hypotheses of this thesis.   
 
The first stage of literature review, expert opinion and hypothesis generation is covered in the 
introduction of this thesis. 
15.2.1. PHASE 1- DEFINING FALLS AND INJURY PREVALENCE 
To define the extent of the problem of falls and fall related injury in CLD an epidemiological cross 
sectional approach was undertaken.  The CLD population would be identified from the 
comprehensive databases of patients maintained by the Hepatobiliary department of Newcastle 
upon Tyne Hospitals NHS Trust.  These databases provide an ideal method of data collection on a 
relatively large scale as they hold details on all existing cases. 
In order to specifically define the problem in relation to older people with CLD the cohort was 
divided into 2 age groups, a younger age group (aged <65 years) and an older group (aged ≥65 
years).  Data collected from the over 65 years CLD group could then be age and sex matched to 
non-liver disease cases in an existing community control database, in which data concerning falls is 
stored.  Further details are described below. 
15.2.2. PHASE 2- MULTIDISCIPLINARY ASSESSMENT 
Once the scale of the problem was defined, falls and injury associations could be explored in detail 
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1 5 . 3 .  E T H I C A L  A P P R O V A L  
15.3.1. PHASE 1 
Each of the CLD databases has approval from the Newcastle Upon Tyne Hospitals NHS Trust 
Caldicott Guardian.  The Caldicott Principles were reviewed at outset and strictly adhered to 
during all stages of the study.  The databases were interrogated for patient identifiable data only 
when absolutely necessary and on a strictly need to know basis.  All participants who were 
contacted had provided prior, fully informed consent to be contacted regarding audit, service 
evaluation and research purposes. 
The existing community control falls database contained no patient identifiable data and 
permission for the recruitment of this cohort and the data collection was granted by County 
Durham and Darlington Local Research Ethics Committee in April 2002. 
15.3.2. PHASE 2 
The study design was submitted to Newcastle and North Tyneside 1 Research Ethics Committee for 
consideration.  Permission to perform the study was granted in the form of Service Development.  
The principles behind service development/evaluation allowed collection of data from individuals 
who would typically benefit from the existing service, where the service is typical of and 
unchanged from usual service delivery.  The MDT assessments used in phase 2 of this study were 
based on best current practise and were performed in the Falls and Syncope Service of Newcastle 
upon Tyne Hospitals NHS Trust.  In order to adhere to the ethical principles of service evaluation 
participants who underwent MDT assessment were typical of usual service users in that they had 
either fallen or had risk factors for falling.  Data collected from the assessment could, ethically, be 
used for research as long as the data was anonymous, results from data analysis could not be used 
to identify individuals and the results could not cause harm or distress. 
The service development was undertaken with participants aged over 18 years residing in the 
North East of England between December 2007 and December 2009. 
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1 5 . 4 .  S A M P L E  S I Z E  
Using available databases, which have a total population size of 871, a response size of 267 would 
be required to establish the estimated population prevalence of falls with a 95% confidence level 
and a sampling error of ±5%. 
Estimating that the prevalence of falls in the community control group would be similar to those in 
the published falls literature (~30%) and using a power level of 0.8 with an alpha of 0.05, to detect a 
difference of 10% between the controls and those with CLD aged ≥65 years would require sample 
sizes of 356.  However, as there are 229 individuals aged ≥65 years in the full database population it 
would not be possible to reach this sample size.  With identical power and alpha, to detect a 
difference of 20% would require a sample size of 93 in the CLD group aged over 65 years which 
was considered achievable as a response rate of 41% would be required. 
1 5 . 5 .  I D E N T I F Y I N G  C O H O R T S  
Databases of prospectively diagnosed patients with CLD who attend the Newcastle upon Tyne 
Freeman Hospital liver outpatient clinics are continuously updated.  When the databases were 
established existing cases were identified from the following sources:  patient lists of Consultant 
Gastroenterologists practising in the area, the health authority hospital admission data, 
autoantibody records (for autoimmune cases of CLD) stored in the immunology laboratory and 
data from death certificates from the office of national statistics.  Patients who met the diagnostic 
criteria, as described below, and who provided fully informed consent for their data to be stored, 
used for research and to be contacted regarding future studies are included.  Data stored on the 
databases include contact details, date of birth, sex, medical history, drug history and results of 
investigations. 
15.5.1. NON-ALCOHOLIC FATTY LIVER DISEASE 
All patients who attend the outpatient liver clinic who meet the inclusion criteria are included on 
this existing database.  To be eligible for a diagnosis of NAFLD, and therefore included in the 
database, patients had to have 1) elevated aminotransferases (either ALT or AST), 2) a liver biopsy 
which showed at least 10% of hepatocytes were steatosed, 3) exclusion of other liver diseases with 
clinical, biochemical, radiological or histological data, 4) a weekly alcohol intake of less than 140 g 
for females and less than 210 g in males (reported by patient, a close relative in most cases and 
measurement of random serum alcohol level). 
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In addition to the data described above the NAFLD database also includes BMI, insulin resistance 
level [graded with the homeostasis assessment index (HOMA) [208]], lipids and histological grade 
(steatosis, NASH or cirrhosis). 
15.5.2. ALCOHOLIC LIVER DISEASE 
All patients with ALD attending the outpatient liver clinic are included in this existing database, if 
eligible and consenting.  Patients are eligible if they had consumed at least 80 g of alcohol per day 
for the previous 10 years and had had other causes of liver disease excluded on the basis of clinical, 
biochemical, radiological or histological data.  Diagnosis was confirmed histologically in all 
patients. 
15.5.3. PRIMARY BILIARY CIRRHOSIS 
The existing PBC database comprises patients who reside within the postal codes NE1 to NE25 and 
who meet the inclusion criteria described here.  The rationale behind this is that the geographical 
cohort enables descriptions based on a well defined population irrespective of hospital attendance, 
and thus a more accurate reflection of the population rather than hospital attendees.   Patients on 
the PBC database are eligible for inclusion if they meet at least 2 out of the  following recognised 
criteria:  1) evidence of a serum anti-mitochondrial antibody or PBC specific anti-nuclear antibody 
at a titre of ≥1:40 by immunofluorescence, 2) a cholestatic abnormality of LFTs, 3) compatible liver 
histology [209, 210]. 
15.5.4. PRIMARY SCLEROSING CHOLANGITIS 
The existing PSC database is also defined geographically by the postal code NE1 to NE25 and 
includes individuals who have had a diagnosis confirmed by magnetic resonance 
cholangiopancreatography or endoscopic retrograde cholangiopancreatography and had 
confirmation of PSC on liver biopsy. 
15.5.5. POST LIVER TRANSPLANTATION 
Details of those liver transplant recipients who received their liver transplant, in Newcastle upon 
Tyne Hospitals NHS Trust, within the previous 5 years, for any reason, are stored in an existing 
database.  As Newcastle Upon Tyne Hospitals NHS Trust is one of 5 centres which perform liver 
transplantation in the UK patients on this database includes individuals living anywhere within the 
UK. 
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15.5.6. CONTROLS 
An existing database of community dwelling individuals who had previously undergone 
multidisciplinary falls assessment was used to identify controls.  The participants were recruited 
from a single primary care provider in the North East of England, within the same postal code as 
the CLD databases.  A computer-generated random sample of patients was identified from the 
primary care provider’s patient list, and contacted via post.  Those living in residential or nursing 
home were excluded prior to recruitment.  Those who responded were offered a clinical assessment 
which included medical history drug history and falls history.  The database was interrogated to 
identify and thereby exclude participants with a history of liver disease. 
1 5 . 6 .  D A T A  C O L L E C T I O N  
15.6.1. DEFINING THE PREVALENCE OF FALLS AND INJURY 
In order to quantify the problem of falls in this novel service development programme a self-
reporting falls and injury screening tool was posted out to the participants on the databases.  Its 
purpose was to identify those who had not fallen in the previous year, a Non-Faller and those who 
had fallen, Fallers.  Those who had fallen were then considered as either a Single-Faller (one fall in 
the previous year) or as a Recurrent-Faller (2 or more falls).  Data concerning fall-related injury was 
also collected (soft tissue injury, attendance at Accident and Emergency, bone fractures and 
hospital admission, 32, page 219).  A pre-paid return envelope was included alongside the postal 
tool, along with a letter explaining the purpose of the data collection.   
This tool was used for the PBC, PSC and transplanted cohorts.  This data was already available on 
the existing controls database.  As response rates to postal data collection are notoriously low for 
ALD and NAFLD cohorts a different approach was used to collect falls and injury prevalence.  All 
consecutive patients with ALD and NAFLD attending the liver outpatient clinics in June 2009 were 
asked to complete the falls and injury self-reporting tool while in the waiting room, irrespective of 
whether they had fallen or not. 
15.6.2. MULTIDISCIPLINARY ASSESSMENT 
All participants who attended for MDT assessment refrained from caffeine and nicotine to reduce 
possible effects on circulating, serum catecholamine levels and ate a light breakfast only [211].  All 
assessments took place in the morning to remove the influence of diurnal autonomic variation, in a 
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clinic which was kept at constant room temperature.  Evaluation took approximately 75 minutes 
and is summarised in Figure 8.  This is followed by a more detailed description of the assessments. 
 
Figure 8.  A schematic of the MDT assessment. 
 
15.6.2.1  Medical Assessment 
This included self-reported past medical history, systems review, autonomic symptom review, falls 
and injury review, social history, medication review and a neuro-cardiovascular examination which 
included visual acuity and a cognitive assessment.  Vision was classed as normal or abnormal 
[cataracts, retinopathy, binocular acuity less than 6/9 (which is the local falls service trigger for 
further optical testing)].  Clinical records were examined for serum albumin, bilirubin, ALP and 
ALT levels.  Participants with NAFLD, ALD and PSC were considered to have cirrhosis if there was 
evidence on biopsy.  In PBC cirrhosis was considered if there was evidence on biopsy, or if biopsy 
had not been performed, it was considered if an individual had bilirubin over 18 μmol/L, albumin 
below 40 g/L, platelets below 222 x109 and spleen length over 12 cm on ultrasound [212]. 
Cognition was assessed with the cognitive component of the Cambridge Examination for Mental 
Disorders (CAMCOG) [213].  This sensitive, specific and comprehensive cognition scale is 
comprised of 11 subsections which make up the total CAMCOG score out of a possible 105.  The 
sensitivity of this tool was particularly advantageous over other cognitive tools as the aim was not 
to screen for dementia but to detect small differences between individuals in order to accurately 
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identify differences between individuals.  The sensitivity is particularly useful at discriminating 
between individuals who perform at the higher end of cognitive ability and is therefore useful, in 
the absence of a ceiling effect, in these populations where dementia was not expected to be a large 
occurrence [213]. 
The Orthostatic Grading Scale is a 10 item scale on which participants rate the severity of their 
dizziness, if any, from 0 (never experiences) to 4 (always experience severe dizziness) in various 
postural situations.  It is fully validated against full physiological autonomic function testing [214]. 
15.6.2.2 Nursing Assessment 
Participants’ height, weight, BMI and the Trail Making Test [215] were recorded.  A 12 lead ECG 
was performed (Philips Page Writer 300 PI) and reviewed by the Physician, to identify participants 
with arrhythmias which would preclude them from HRV analysis.  The participant was then 
connected to the continuous ECG and beat-to-beat blood pressure monitoring equipment 
(Taskforce® Monitor 3040i, CN systems Medizintechnik GmbH, Graz, Austria) for analysis of the 
ANS. 
Participants rested in the supine position, undisturbed, for 10 minutes whilst wearing the 
Taskforce® Monitor equipment.  Following 10 minutes rest the participants were helped into a 
standing position where they remained for 3 minutes.  Following the active stand a valsalva was 
performed.  Detailed methodology concerning analysis of autonomic function is described below. 
15.6.2.3 Physiotherapy Assessment 
Muscle strength was assessed using a digital handheld dynamometer (TKK 5401 GRIP-D; Smedley, 
Takei, Tokyo, Japan).  Participants were positioned in a straight-backed chair, shoulders adducted 
in a neutral position, arms unsupported and feet flat on the floor.  The elbows were flexed at 90 
degrees with the forearm in neutral position (neither prone nor supinated) and the wrist was 
dorsiflexed 0 to 30 degrees with 0 to 15 degrees of ulnar deviation.  Once in the correct position, 
participants held the dynamometer in their dominant hand, and when instructed flexed their 
fingers to achieve maximal grip strength.  The strongest grip of three attempts was recorded (unit 
of measurement kg), with a 15 second interval between each attempt.   
Dynamic lower limb strength was also recorded using the Sit to Stand Test (STS).  Participants sat 
in a standard clinic chair with no armrests and were asked to cross both arms across their chest.  
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Participants were then asked to stand up and sit down 5 times without the use of their arms; the 
length of time taken from first attempting to stand up until the final seated position was recorded.  
The Sit to Stand Test is predominantly a measure of lower limb strength, but it must be 
acknowledged that there will be some degree of sensory influence (for example proprioception and 
vestibular function) on the outcome.  As this test is performed under time higher values (measured 
in seconds) indicate weaker lower limbs. 
A timed walking test, the Timed Up and Go Test (TUG), was performed as gait speed is associated 
with falls.  Participants began in a sitting position, with their back against a standard clinic chair, 
upper limbs placed on the arm rests and walking aid at hand, if required.  Participants were then 
asked to stand up and walk at their usual pace to a mark on the floor 3 meters away, turn around, 
walk back and sit down [216].  This is performed twice so that the first attempt familiarises the 
participant with the procedure; the second attempt is scored.  As the test is timed (in seconds) a 
longer value indicates a slower ‘up and go’ and is associated with an increased risk of falling [127]. 
The performance orientated assessment of mobility was performed by each participant [217].  This 
provides a measure of both gait and balance and has previously been shown to have sound levels 
of validity and reliability [218].  Nine gait manoeuvres are performed and scored 0 (abnormal) or 1 
(normal) to give a total possible gait score of 9.  The balance component is comprised of 13 
manoeuvres, each of which is scored 0 (abnormal), 1 (adaptive) or 2 (normal), giving a total possible 
balance score of 26. 
15.6.2.4 Occupational Therapy (OT) Assessment 
As part of the novel, multidisciplinary service development programme participants also 
underwent an OT assessment.  The resulting information gained from this will be presented in a 
separate thesis by the Occupational Therapist working in the Newcastle Biomedical Research 
Centre Liver Theme. 
15.6.2.5 Symptom Assessment Tools 
Falls Efficacy Scale International (FES-I) is a self-completed tool which quantifies an individual’s 
concerns about falling while performing 16 different activities [219].  Participants rate their concern 
as ‘not concerned at all’ (scored 1) through to ‘very concerned’ (scored 4) giving a minimum score 
of 16 and maximum score of 64.  One disadvantage of this tool is that it is not fully validated in 
younger individuals.  However, no such tool for younger people exists.  The FES-I is considered the 
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best available validated tool to assess fear of falling and is recommended by ProFaNE, a European 
falls prevention network [220]. 
The Patient Reported Outcome Measurement Information System- Health Assessment 
Questionnaire (PROMIS-HAQ) allows quantification of functional ability [221].  Individuals rate 
their ability to complete 20 different functional activities from ‘completely’ (scored 0) through to 
‘not at all’ (scored 4).  This tool is reliable, valid and sensitive to change [222]; it is particularly 
useful at identifying how disease impacts upon functional ability rather than quality of life in 
general.  The advantage of exploring functional ability is that it highlights key areas of weakness 
which are modifiable, whereas quality of life measurement does not specifically identify modifiable 
targets. 
15.6.3. AUTONOMIC FUNCTION TESTING 
The MDT nurse, trained and experienced in the use of the Task Force® Monitor performed all 
cardiovascular assessments.  Three electrodes (CNSystems Medizintechnik GmbH, accessory 01616) 
were attached to each individual; 1 on the anterior surface of the left shoulder, 1 on anterior surface 
of the right shoulder and 1 over the lower left thorax in the anterior axillary line, providing a 3 
channel ECG.  For continuous beat-to-beat BP recording the appropriate size “Flying-V” finger cuff 
and oscillometric BP cuff were selected.  The appropriate finger cuff was then connected to the 
“Task Force® Vascular Unloading Monitor” and placed over 2 fingers, proximally, while the “Task 
Force® Vascular Unloading Monitor” was attached to the forearm using a Velcro fixing cuff.  The 
oscillometric BP cuff was placed on the opposite upper arm. 
ECG recordings were based on the bipolar principles of Einthoven with anti-drift to 
suppress/compensate electromagnetic noise.  The manufacturer stated level of accuracy is ± 5 μV 
and is able to measure band width frequencies between 0.08 and 150 Hz.  Oscillometric and 
continuous beat-to-beat BP recording has an accuracy of ± 5 mm Hg between 50 and 250 mm Hg. 
Task Force® Monitor programme version 2.2 was used to record and analyse ECG and BP 
recordings.  This provides a report for each individual detailing, for each intervention/time period, 
the mean heart rate [bpm (beat per minute)], mean systolic BP (sBP, mm Hg), mean diastolic BP 
(dBP, mm Hg), mean LFnu (low frequency normalised units, %), mean VLF (very low frequency, 
ms2), mean LF (ms2), mean HF (ms2), mean power spectral density [PSD, ms2), LFnu:HFnu, LF:HF, 
baro-receptor slope mean (ms/mm Hg) and BEI (%). 
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15.6.3.1 Heart Rate Variability 
The Fast Fourier Transformation, performed by the Task Force® Monitor programme version 2.2, 
produces a measure of how variance distributes as a function of frequency rather than time [223].  
This method separates the HR fluctuations into the LF, VLF and HF spectral bands, which together 
comprise PSD.  Figure 9 displays this graphically using an example from an individual; the z axis 
relates to time with a 10 minute supine rest between 4 and 14 minutes.  During this time the 
parasympathetic predominance can be seen as the large peaks (y axis) between 0.15 and 0.4 Hz (x 
axis).  Following the rest period the individual stands upright at 15 minutes.  The parasympathetic 
withdrawal and sympathetic activation can be seen as the peaks change from high to low frequency 
(0.04 to 0.15 Hz). 
This method is not recommended for analysis of recordings lasting less than 5 minutes but is a 
justified method for the 10 minute recordings collected during the individuals’ 10 minute supine 
rest [223].  In addition to providing the 3 frequency domains the Task Force® Monitor programme 
also provides normalised units of the LF and HF spectral components (LFnu and HFnu 
respectively).  The normalised values provide a measure of the proportion that each domain 
contributes towards total PSD minus the contribution of VLF.  Therefore normalised units provide a 
measure of the balance of the 2 arms of the ANS, particularly when expressed as a ratio 
(LFnu:HFnu). 
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Figure 9. Spectral analysis of HRV. 
 
15.6.3.2 Baro-reflex Sensitivity 
Task Force® Monitor programme version 2.2 uses the sequence method to calculate a measure of 
BRS.  This method identifies consecutive increases or decreases in sBP which occur in association 
with a prolonged RRI or shortened RRI for 3 or more beats.  The gradients of the resulting sBP-RRI 
associations are calculated and a mean value is provided for the 10 minute supine rest and is 
referred to as the slope mean.  In addition to the baro-receptor slope mean the baroreceptor 
effectiveness index (BEI) is calculated.  This is the ratio of spontaneous sBP increases or decreases to 
the corresponding, appropriate changes in RRI and is a proportion (%) of how many times the baro-
reflex is effective [224]. 
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15.6.3.3 Active Standing 
An orthostatic challenge can provide both a measure of the sympathetic and parasympathetic 
nervous system.  The degree to which sBP or dBP drops on standing is a measure of the 
sympathetic nervous system; international consensus defines an abnormal BP response to standing 
as a sBP drop of ≥20 mm Hg or a dBP drop of ≥10 mm Hg; if either of these criteria are met a 
diagnosis of OH can be made [179].  However, these strict criteria do not take into account 
prolonged smaller drops in BP.  For example, an asymptomatic 5 second sBP drop of 22 mm Hg 
could be considered an abnormal response to standing but a symptomatic 60 second sBP drop of 15 
mm Hg with a prolonged recovery could be, strictly, considered as a normal response.  For this 
reason, in place of a formal diagnosis of OH, the area under the curve (AUC) has been determined.  
This is calculated in software developed by the medical physics department of Newcastle upon 
Tyne Hospitals NHS Trust and is demonstrated in Figure 10:  The dotted horizontal line represents 
the baseline sBP and is based on the stable sBP values at the end of the supine rest period.  The 
dotted vertical line indicates the point of standing erect from the supine position, this coincides 
with a drop in sBP which reaches it’s nadir at the horizontal dashed line.  The vertical dashed line is 
the moment when sBP returns to baseline.  From this the AUC can be calculated and is represented 
by the shaded area. 
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Figure 10. The AUC of sBP upon standing.  
 
A measure of dynamic, parasympathetic activity during active standing is the 30:15 ratio.  This is 
the ratio of the longest RRI around the 30th beat to the shortest RRI around the 15th QRS complex 
immediately on standing with smaller ratios considered as abnormal.  In a normally functioning 
ANS there would be parasympathetic (vagal) withdrawal on standing resulting in an unopposed 
sympathetic drive to increase the HR followed by a return in parasympathetic activity and a 
slowing of the HR, this is similar to the response seen in Figure 9, the difference being that Figure 9 
is based on frequency domain analysis whereas the 30:15 ratio is based on time analysis. 
15.6.3.4 Valsalva 
Following the active standing the participant sat on the edge of the bed quietly for 2 minutes to 
regain cardiovascular stability.  The valsalva was clearly explained to the participants to optimise 
good technique.  The plunger of a 10 ml syringe was discarded and the syringe tube was pierced 
with a pin so that the circuit was not fully closed.  The circuit was created by connecting the tip of 
the syringe to an aneroid sphygmomanometer (manual, dial display, non-mercury) via plastic 
tubing.  The sphygmomanometer provided a visual display to guide the nurse/physician and 
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participant to maintain a constant expiratory pressure of 40 mm Hg.  Participants placed the ‘open 
plunger-end’ into their mouth and were asked to form a strong seal with their lips, they then blew 
into the syringe for 15 seconds while watching the sphygmomanometer display and were 
encouraged by the nurse/physician if pressure deviated from 40 mmHg.  Two attempts were made 
with a 2 minute quiet rest between each attempt to regain cardiovascular stability; the 2 attempts 
were reviewed on the basis of participant effort/technique and visually on the Task Force® Monitor 
programme, if they were considered poor then a 3rd attempt was made.  A normal cardiovascular 
response to valsalva includes a sympathetically driven BP overshoot on release of the strain and an 
appropriate increase in heart rate followed by a decrease in heart rate (parasympathetic). 
1 5 . 7 .  D A T A  A N A L Y S I S  
All data analysis was performed using Statistical Package for Social Sciences (SPPS) version 17.  To 
classify distribution of data as normal or non-parametric histograms were plotted and interpreted 
alongside the Kolmogorov-Smironov normality test.  Where data is considered as normally 
distributed it is summarised with mean and standard deviation (SD) whereas non-parametric data 
is described as median with the minimum and maximum. 
Relationships between 2 categorical variables were assessed by performing the chi-square test.  If 
20% or more of the expected frequencies of the categorical variables were less than 5 then Fisher’s 
exact test (FET) was performed.  Chi-square is reported with its statistic alongside the degrees of 
freedom and significance level [χ2 (df), p].  For 2 sets of related categorical data McNemar’s test was 
used to examine marginal homogeneity; to identify changes in a dichotomous, categorical response. 
To compare the location between 2 non-parametrically distributed samples the Mann-Whitney test 
was used and is described with the Mann Whitney U and z statistics alongside the significance 
value.  As the Mann-Whitney test is not well powered for small sample sizes the Kolmogorov-
Smirnov Z test was used when comparing 2 non-parametric data sets with numbers less than 25 per 
group. 
Where multiple comparisons were made between non-parametric data sets the Kruskal-Wallis test 
was performed, the result of this is displayed with the Kruskal-Wallis statistic (H), degrees of 
freedom and significance level. 
Non-parametric associations are described using the Spearman rho (rs) alongside a significance 
value. 
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Negative binominal regression was performed when the dependent variable was count data (for 
example number of falls) and the distribution of the count was highly skewed to the right (Figure 
11).  The negative binominal model is more accurate than a multiple linear regression model when 
the variance of the dependent variable is greater than the mean, taking into account large numbers 
of zero counts and the possibility of recurrent episodes (for example recurrent falls) [225].  The 
model fit will be described with the likelihood ratio χ2, degrees of freedom and p value.  The model 
will be tabulated with the unstandardised beta coefficient (b), standard error (SE), odds ratio (OR) 
with the 95% confidence intervals (CI) and p. 
To identify variables which are independent predictors of a dichotomous, categorical, dependent 
variable binary logistic regression was performed.  Assumptions which were verified were 
multicollinearity of the independent variables and linearity of the continuous independent 
variables with the natural log of the dependent variable.  Independent variables violating these 
assumptions were excluded from the model.  The goodness of fit of the model is described with 
Cox’s R2, the -2 log-likelihood and its associated χ2 statistic and significance value (a χ2 statistic 
below 0.05 indicates that the model is a significant fit of the data).  The regression coefficient (b), 
standard error (SE) the significance level (p), the odds ratio (OR) and the 95% confidence intervals 
are tabulated. 
 
Figure 11. The typical distribution of fall count data distribution.
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M E T H O D S  –  P A R T  T W O
   59 
1 6 .  R E C R U I T M E N T  
1 6 . 1 .  P H A S E  1  R E C R U I T M E N T  
The process of Phase 1 recruitment is displayed in Figure 12.  A number of individuals who are 
included on the databases had previously expressed a wish not to be contacted for research, service 
evaluation or teaching and as such were excluded.  The remaining individuals from the PBC and 
PSC databases were contacted via post as described in section 15.6.1, page 47.  The NAFLD and 
ALD individuals were recruited from the clinic and the rationale for this was detailed in section 
15.6.1, page 47.  The LT cohort were considered separately as it may be considered that those post-
LT no longer have CLD. 
 
Figure 12.  Flow chart of the Phase 1 recruitment. 
 
The response rates (which is the number of completed data collection tools expressed as a 
percentage of the number of individuals in the corresponding database) for each cohort are 
displayed in Figure 13, bearing in mind the differing methods of recruitment. 
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Figure 13.  Response rate of the Phase 1 cohorts. 
 
The final Phase 1 cohort, which consisted of 281 individuals was composed of 4 CLDs.  The 
proportion that each disease contributed to the cohort is displayed in Figure 14. 
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Figure 14.  The composition of the Phase 1 cohort. 
 
In an attempt to analyse whether the responders were representative of the populations they were 
compared to the demographic data of those who did not respond.  The results are displayed in 
Table 4.  In general, those who responded were similar to those who did not.  The exceptions were a 
slighty lower albumin in those who responded with NAFLD and a lower age of those with PBC 
who responded. 
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 Demographics Responders Non-responders Significance (U, Z, p) 
Age [years] 59 (19-79) 60 (19-85) 8872, -0.732, 0.464 
Female 55 40 5.833 (1), 0.016 
Albumin [g/L] 44 (35-50) 45 (31-54) 7794, -2.115, 0.041 
Bilirubin [μmol/L] 9 (3-37) 10 (1-107) 8009, -1.785, 0.074 
ALP [U/L] 92 (11-246) 91 (39-468) 8822, -0.545, 0.586 
NAFLD 
ALT [U/L] 56 (15-267) 60 (13-504) 8668, -0.778, 0.436 
Age 58 (31-83) 58 (19-77) 3510, -0.027, 0.978 
Female 14 230 0.012 (1), 0.913 
Albumin 38 (29-46) 38 (20-49) 1152, -0.333, 0.74 
Bilirubin 14 (8-79) 15 (4-316) 1151, -0.163, 0.871 
ALP 95 (40-300) 91 (47-392) 2021, -1.828, 0.068 
ALD 
ALT 39 (11-248) 39 (11-3210) 1599, -3.529, <0.001 
Age 68 (40-95) 73 (42-95) 1463, -2.186, 0.029 
Female 94 93 0.036 (1), 0.85 
Albumin 41 (26-49) 42 (29-47) 746, -0.083, 0.934 
Bilirubin 9 (4-75) 8 (4-49) 670, -0.026, 0.979 
ALP 148 (48-1033) 124 (69-1149) 750, -0.039, 0.969 
PBC 
ALT 34 (10-220) 29 (10-148) 706, -0.47, 0.639 
Age 59 (27-80) 53 (29-64) 574, -0.781, 0.435 
Female 33 15 2.798 (1), 0.094 
Albumin 42 (30-51) 41 (30-46) 156, -0.641, 0.521 
Bilirubin 12 (7-67) 12 (6-40) 171, -0.365, 0.715 
ALP 161 (60-981) 190 (90-759) 175, -0.26, 0.795 
PSC 
ALT 41 (11-189) 59 (24-206) 116, -1.794, 0.073 
Table 4 continues… 
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 Demographics Responders Non-responders Significance (U, Z, p) 
Age 60 (27-79) 52 (20-74) 1761, -4.612, <0.001 
Female  41 42 0.049 (1), 0.825 
Albumin 43 (30-50) 43 (21-48) 1371, -0.242, 0.809 
Bilirubin 9 (3-46) 9 (2-32) 1393, -0.31, 0.757 
ALP 110 (50-799) 111 (48-919) 1404, -0.244, 0.807 
LT 
ALT 27 (8-235) 23 (7-123) 1339, -0.624, 0.533 
Statistics are calculated with Mann-Whitney U with the exception of Female, in which case 
the χ2 (df) was used 
Table 4.  Representativeness of the Phase 1 CLD cohorts. 
 
16.1.1. MATCHING 
The CLD participants were divided into the 2 age groups resulting in 143 (38%) participants in the 
≥65 years group and 229 (62%) in the <65 years group.  Each of the participants in the ≥65 years 
group was matched for identical age and gender to a participant in the Community Control group.  
Once those who had sustained a fall had been identified they were then age and sex matched to an 
individual who had fallen in the community control group in order to compare injury prevalence in 
matched cases. 
1 6 . 2 .  P H A S E  2  R E C R U I T M E N T  
As part of Phase 1 recruitment individuals were able to express an interest in undergoing a MDT 
assessment.  From the 281 respondents 107 indicated they would be willing to be contacted to 
discuss the assessment.  This process is summarised in Figure 15. 
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Figure 15.  Phase 2 recruitment. 
 
The differences between the Phase 1 and Phase 2 cohorts are described below (Table 5) in order to 
consider the representativeness of the Phase 2 cohort.  Liver disease severity was similar between 
the cohorts with the exception of age, in which case the Phase 2 cohort was significantly older.  This 
difference was considered when performing statistical analyses and where appropriate age was 
controlled for. 
 Phase 1 Cohort Phase 2 Cohort U, z, p 
Age [years] 60 (19-95) 66 (31-81) 13117, -3.281, 0.001 
Albumin [g/L] 42 (26-51) 43 (29-51) 11837, -1.274, 0.203 
Bilirubin [μmol/L] 10 (3-75) 9 (4-44) 11769, -1.048, 0.294 
ALP [U/L] 108 (11-1033) 114 (39-477) 12800, -0.372, 0.71 
ALT [U/L] 38 (8-267) 41 (10-357) 12762, -0.412, 0.68 
Cirrhosis (%) 63 (17) 8 (9) χ2 (1), 0.088 
Table 5.  Representativeness of the Phase 2 cohort. 
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Although there were no exclusion criteria for the recruitment of the Phase 2 participants it is 
notable that no participant within the Phase 2 cohort was encephalopathic.  Medical history and/or 
clinical notes were reviewed and in all cases no individual had had a history of HE.  In addition, at 
the time of MDT assessment no individual displayed clinical feature suggestive of encephalopathy, 
which alongside the result of the Trail Test [median total 121 seconds (49-424), allowed confidence 
in excluding clinical HE. 
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R E S U L T S  -  P A R T  O N E
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1 7 .  F A L L S  I N  C H R O N I C  L I V E R  D I S E A S E  
1 7 . 1 .  C H A P T E R  A I M S  
• To define falls prevalence in older people with CLD 
• To establish the prevalence of fall related injury in older people with CLD 
• To explore factors associated with falling in older people with CLD 
1 7 . 2 .  I N T R O D U C T I O N  
This chapter concerns CLD as a whole and is divided into the younger and older age groups in 
order to address the main objective, falls in older people with CLD.  In addition to the younger 
CLD group the Community Control group is used for comparison. 
Table 6 describes each cohort in terms of demographic data and liver disease severity.  Individuals 
in the older CLD group are matched for age (± 0 years) and sex to individuals in the Community 
Control group (with the exception of the oldest CLD participants who was 4 years older than the 
eldest community control). 
 
 CLD <65 
years (n 169) 
CLD ≥65 
years (n 111) 
Community 
controls (n 111) 
Differences 
Age [years] 55 (19-64) 72 (65-95) 72 (65-91)  
Female (%) 83 (49) 82 (74) 82 (74) χ2 (2) 25.288, <0.001 
Diabetic (%) 83 (49) 23 (21) 8 (7) χ2 (2) 62.298, <0.001 
Albumin [g/L] 43 (26-50) 41 (28-47) 43 (36-49) H (2) 18.563, <0.001 
Bilirubin 
[μmol/L] 
12 (4-75) 10 (4-68) 7 (2-24) H (2) 30.941, <0.001 
ALP [U/L] 104 (11-1033) 129 (57-879) 74 (45-142) H (2) 67.723, <0.001 
ALT [U/L] 51 (12-267) 34 (10-204) 19 (9-45) H (2) 115.855, <0.001 
Cirrhosis (%) 63 (37) 24 (22) 0 χ2 (2) 53.853, <0.001 
Table 6.  CLD.  Demographic details. 
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1 7 . 3 .  F A L L S  P R E V A L E N C E  
The greatest proportion of Fallers was seen in the older CLD group, this group also demonstrated 
the greatest proportion of Recurrent-Fallers.  The proportion of Fallers in the older CLD group was 
significantly greater than in both the younger CLD group [χ2 (1) 9.927, p 0.002] and in the 
Community Control group [χ2 (1) 4.22, p 0.04].  The same observation is also true when comparing 
the proportion of Non-, Single- and Recurrent-Fallers in the older CLD group to the younger CLD 
group [χ2 (2) 11.523, p 0.003] but not when comparing the older CLD group to the Community 
Control group [χ2 (2) 4.417, p 0.110].  These differences can be seen in Figure 16. 
 
 
Figure 16.  CLD.  Falls prevalence. 
While this data suggests that falls are very common in older people with CLD (47% fallen in the 
previous year), it also suggests that recurrent falls are also common.  In order to explore this further 
the number of falls in those who had fallen was compared between the cohorts.  There was no 
significant difference across the groups with similar number of falls [CLD <65 years median 2 (1-
52), CLD >65 years 1 (1-10) and Community controls 1 (1-50), H (2) 3.607, p 0.165], Figure 17. 
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Figure 17.  CLD.  The number of falls experienced by Fallers. 
 
1 7 . 4 .  I N J U R Y  P R E V A L E N C E  
Individuals in the older CLD group who had fallen were then matched to a community control who 
had fallen.  Individuals were matched for age (± 1 year) and sex with the exception of the eldest 
CLD Faller who was 9 years older than the eldest control and was therefore excluded from analysis. 
Given the high prevalence of falls in the previous year it could be expected that the older CLD 
group would sustain more injuries.  Indeed, the more serious injuries of fractures and admission to 
hospital were more common in the older CLD group, but not significantly so (Figure 18,Table 7).  
Unexpectedly the frequency of soft tissue injury was significantly more common in the Community 
Controls.  However some consideration must be given to the limited numbers and the impact that 
this has upon statistical analysis. 
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Figure 18.  CLD.  Fall related injury prevalence. 
 
 CLD <65 years 
(n 48) 
CLD >65 years 
(n 51) 
Community 
controls (n 51) 
χ2 (df), p 
Any injury 22 27 36 0.5 (1), 0.48A 
3.363 (1), 0.067B 
Soft tissue injury 16 25 35 2.508 (1), 0.113A 
4.048 (1), 0.044B 
Accident and 
Emergency 
13 13 10 0.032 (1), 0.857A 
0.505 (1), 0.477B 
Fracture 5 11 6 2.27 (1), 0.132A 
1.765 (1), 0.184B 
Admitted 4 9 4 1.88 (1), 0.17A 
2.204 (1), 0.138B 
A= CLD<65 years versus CLD>65 years, B= CLD>65 years versus Community Controls 
Table 7.  CLD.  Fall related injury. 
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1 7 . 5 .  F A L L  A S S O C I A T I O N S  
Identifying modifiable factors which were associated with falling was particularly important once it 
became established that falls were a common event in the older CLD group.  As age and markers of 
liver disease (albumin, bilirubin, ALP, ALT) were available in the Phase 1 cohort these associations 
were explored first.  The remaining associations were explored with the comprehensive MDT 
assessment data.  Non significant correlations are displayed in Appendix B.1, page 220. 
17.5.1. PHASE 1- ASSOCIATION WITH AGE AND DISEASE SEVERITY 
There was a significant difference in age between Fallers and Non-Fallers when analysing the Phase 
1 cohort as whole [66 (19-95) and 60 (19-91), U 7090.5, z -2.942, p 0.003], Figure 19, and this 
difference was also demonstrated through correlation analysis with number of falls (rs 0.154, p 0.01).  
It was interesting to demonstrate that there was no association between number of falls and 
albumin, bilirubin, ALP or ALT.  Consistent with this finding there was no difference in the number 
of falls between those with cirrhosis [0 (0-12)] and those without cirrhosis [0 (0-52), U 3470.5, z -
1.175, p 0.241]. 
 
 
Figure 19.  CLD.  The Fallers were significantly older than the Non-Fallers. 
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17.5.2. PHASE 2- MDT ASSOCIATIONS 
Data from the MDT assessments were analysed including all ages.  All ages were included in order 
to maximise sample size.  However, as a significant association was demonstrated between age and 
number of falls, age would be adjusted for in further analyses.  There were 71 participants in the 
MDT cohort:  Twenty-one (30%) were diabetic, 43 (61%) were on antihypertensive medication, 8 
(11%) were cirrhotic, 30 (42%) had abnormal vision and 9 (13%) were being treated for osteoporosis. 
The results from the physician assessment which included medical history, medications and vision 
were as follows.  There was a significant difference in the number of falls between diabetics and 
non diabetics [0 (0-12) and 0 (0-8), U 381.5, z -2.215, p 0.024, Figure 20].  Between those taking or not 
taking antihypertensives there was no significant difference in the number of falls [0 (0-12) and 0 (0-
8), U 468, z -1.931, p 0.054] although this difference did approach significance.  Falls were no more 
prevalent in those with normal vision compared to those with abnormal vision [0 (0-8) and 0 (0-12), 
U 517.5, z -1.39, p 0.167], nor were falls more common in those with osteoporosis [0 (0-1)] compared 
to those without [0 (0-12), z 0.638, p 0.272]. 
 
 
Figure 20.  CLD.  Falls in Diabetics. 
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On autonomic assessment it was interesting to find that symptoms of postural dizziness were 
associated with number of falls in the previous year (Table 8) whereas all other autonomic 
measures showed no association.  The physiotherapy assessment revealed several measures which 
were associated with falling (Table 8). 
 








Sit to Stand Test 0.379 
0.001 








Fear of falling 0.536 
<0.001 
Table 8.  CLD.  Phase 2 correlations with the number of falls. 
 
Two regression models were analysed to identify independent associations with falling.  Firstly, 
binary logistic regression which has a dependent variable of fall or no fall and secondly negative 
binomial regression which is a form of linear regression more appropriate when analysing data 
which have a high frequency of negative counts. 
Binary logistic regression was performed to identify factors which were independently associated 
with whether a participant had fallen in the previous year or not.  Variables included in the model 
are shown in Table 9 which displays the model parameters.  The variables which remained in the 
model did not violate the assumptions of binary logistic regression.  The 4 residual cases were not 
removed from the model as they did not exhibit any extreme results which could potentially affect 
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the model.  The final model, which had a poor overall fit, is displayed in Table 9, with the ORs and 










Constant -14.296 7.973 0   0.073 
Age 0.015 0.044 1.015 0.932 1.106 0.73 
OGS -0.04 0.148 0.961 0.719 1.284 0.786 
Diabetes 0.366 1.049 1.441 0.185 11.257 0.727 
STS 0.22 0.103 1.246 1.018 1.526 0.033 
TUG -0.215 0.224 0.806 0.52 1.251 0.337 
Balance 0.309 0.245 1.362 0.843 2.199 0.207 
Gait -0.211 0.402 0.81 0.368 1.782 0.6 
FES-I 0.145 0.06 1.156 1.029 1.299 0.015 
R2 0.356 (Cox), Hosmer & Lemeshaw χ2 (8) 5.895, p 0.659 
Table 9.  CLD.  Binary logistic regression model for Faller or Non-Faller. 
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Figure 21.  CLD.  The 95% CI for the ORs derived from the binary logistic regression model. 
 
Table 9 and Figure 21 show that Sit to Stand time (STS, lower limb strength) and fear of falling 
(FES-I) were statistically independent associations with the binary outcome.  The model corrects for 
age and diabetes which were found not to be independent associations.  This result has important 
implications as both lower limb strength and fear of falling are modifiable. 
Negative binomial regression was performed to identify factors associated with the number of falls 
in the previous year.  No cases were excluded due to undue influence or being significant outliers 
and the variables met regression analysis assumptions.  The model is displayed in Table 10 and 
Figure 22. 
 
   76 
95% confidence 
interval (OR) 






Constant -13.172 4.536 1.903 2.619 0.014 0.004 
Age 0.007 0.024 1.007 0.96 1.057 0.761 
Diabetes -0.302 0.726 0.74 0.178 3.068 0.678 
OGS 0.169 0.085 1.185 1.002 1.4 0.047 
STS 0.157 0.061 1.17 1.039 1.318 0.01 
TUG -0.085 -0.356 0.919 0.701 1.205 0.54 
Balance 0.187 -0.102 1.206 0.903 1.611 0.205 
Gait 0.359 -0.228 1.432 0.796 2.577 0.231 
FES-I 0.073 0.007 1.075 1.007 1.148 0.03 
Model likelihood ratio χ2 (8) 46.713, p <0.001 
Table 10.  CLD.  Negative binomial regression model for number of falls. 
 
 
Figure 22.  CLD.  The 95% CI for the ORs derived from the negative binomial regression model. 
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The model is a significant fit of the data and demonstrates several significant and independent 
associations which exist independently of age and diabetes.  These were orthostatic symptoms, 
lower limb strength/function and fear of falling. 
1 7 . 6 .  F A L L S  A N D  F U N C T I O N A L  A B I L I T Y  
As physical injury is not the only significant consequence of falling, quality of life was estimated.  
Functional ability was assessed in the older CLD Phase 1 cohort using the PROMIS-HAQ tool. 
The number of falls in the previous year was strongly related to functional ability (rs 0.303, p 0.008) 
such that increasing number of falls correlated with increasing difficulty.  Dividing the cohort into 
Recurrent-Fallers, Single-Fallers and those who had not fallen in the previous year there was a 
significant difference in functional ability [Non-fallers 3.75 (0-75), Single-Fallers 7.5 (0-43.75) and 
Recurrent-Fallers 46.88 (0-72.5), H (2) 7.345, p 0.025 (Figure 23)]. 
 
 
Figure 23.  CLD.  Functional difficulty and falls. 
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1 7 . 7 .  S U M M A R Y  
Falls are common in older people with CLD with almost 50% having had a fall in the previous year, 
and significantly more common than in age and sex matched Community Controls.  Fall related 
injury rates were similar between the cohorts; however there were significantly more soft tissue 
injuries seen in Community Controls than the older CLD group.  There was a tendency for the more 
serious injuries to be more common in the CLD participants but this difference did not reach 
statistical significance. 
Falls were not associated with markers of liver disease severity but were associated with age, 
diabetes, orthostatic symptoms, lower limb strength, walking speed, balance, gait and fear of 
falling.  Regression analyses revealed three independent associations, lower limb strength, 
orthostatic symptoms and fear of falling. 
1 7 . 8 .  D I S C U S S I O N  
This unique study is the first of its kind, in the English language, to describe falls, fall related injury 
and fall associations in people with CLD, specifically older people with CLD.  The need for this 
type of study is great given the expansion of the older population, the increasing prevalence of CLD 
(particularly NAFLD) and the possible ‘double-whammy’ effect of these factors combined.  As falls 
and fall-related consequences cost the UK NHS approximately £1 billion per year it is essential to 
identify groups at risk of falling and potential therapeutic/preventative strategies [102, 226].  Older 
people with CLD represent an ideal population to study given the aforementioned changing 
demographics. 
The results provided here highlight the importance of this study.  With close to 50% of older people 
with CLD falling in the previous year the results can not and should not be ignored.  It comes as 
quite a surprise to reveal such a high prevalence of falls in the absence of any other existing 
literature on the subject.  While it may be anticipated that some would argue that the falls 
prevalence is high because the participants are elderly, the falls prevalence was significantly greater 
than in age matched, non-liver disease Community Controls.  The falls prevalence was also 
significantly higher than in the younger CLD cohort which may suggest that there is a combined 
effect of CLD and ageing which contributes to falling. 
The study was unable to demonstrate a significantly increased rate of fall-related injury in older 
people with CLD.  This finding was contrary to the original hypothesis which anticipated fall-
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related injury would be common as a result of the increased prevalence of autonomic dysfunction 
in CLD.  Fracture rates and hospital admissions did appear to be more common but, perhaps 
because of low numbers, the difference was not significant.  There was a surprisingly significant 
difference between the older CLD cohort and the Community Controls with regard to the 
proportion of Fallers who sustained a soft-tissue injury.  However, it is recognised that numbers 
were small and the analysis was likely underpowered.  In addition, caution is required when 
interpreting soft-tissue injury as this type of injury is felt to be a poor reflection of falls and injury 
prevalence because of the lack of rapid and independent assessment [227].   
It is short sighted to regard physical injury as the sole important consequence of falling.  There are 
personal, social and societal consequences which must be considered.  Although this study does not 
describe each of these it does demonstrate a significant association between falling and functional 
ability.  While it is not possible to determine whether the functional ability contributes to falls or 
whether it is falling which results in functional impairment, it is likely that both factors interact 
bidirectionally.  Furthermore, the relationship between fear of falling and falls is strong and as was 
described in section 10.2 fear of falling can result in activity restriction, social isolation, frailty and 
an increased chance of being admitted to institutional care [228]. 
An important observation demonstrated in this study is that liver disease severity, as judged by the 
LFTs and the presence of cirrhosis, is unrelated to falling and falls can occur at any stage of disease.  
As such, if services were to be developed for people with CLD it would be important not to use 
markers of liver disease severity, such as LFTs, as a tool for identifying appropriate service users.  
The observation is in keeping with other quality of life issues faced by people with CLD; for 
example, fatigue and symptoms of cognitive dysfunction in CLD are unrelated to liver disease 
severity [99, 167, 229].  Accordingly, this study contributes to the emerging wealth of data that 
quality of life issues are substantial and of importance to the patient who is sitting in clinic, 
regardless of their LFT, ultrasound or biopsy result. 
As described in section 15.2 context is crucial to understand whether a problem exists, the extent of 
that problem and whether it could be susceptible to intervention.  The Phase 1 data provides 
evidence that there is a substantial problem and rather valuably, the Phase 2 data provides 
evidence for the susceptibility to intervention.  Indeed, as the Phase 2 MDT assessments were based 
on the NICE guidelines each fall association which was identified is potentially modifiable. 
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Although causation can not be determined from this cross-sectional study the associations with 
falling in CLD which were found are age, diabetes, postural dizziness, lower limb strength, gait 
abnormality, gait speed, balance and fear of falling.  With the exception of age, each of these falls 
risk factors is modifiable with the potential to prevent falls and fall related sequelae.  The range of 
associations identified here would suggest that an appropriate therapeutic/preventative strategy 
would be to employ the skills of a multidisciplinary team.  The UK NICE Clinical Guideline 21 
recommends a MDT assessment and intervention of older people who are at risk of falls.  This 
would seem appropriate for the older CLD population with input from a physician to optimise 
diabetic control and diabetes related complications such as neuropathy and retinopathy.  A 
physician could also to address orthostatic symptoms/orthostatic hypotension which would need 
input from nursing staff to assess blood pressure responses.  Physiotherapy would be required for 
gait, balance, muscle strength and fear of falling.  An additional intervention for fear of falling 
would be cognitive behavioural therapy (CBT).  The NICE falls guidelines do not recommend the 
use of CBT to prevent falls, however, CBT can reduce fear of falling and the activity avoidance 
associated with fear of falling [230].  Indeed, one large, recent, randomized controlled trial which 
compared usual care to a multicomponent CBT intervention demonstrated a significantly greater 
reduction in fear of falling and activity avoidance at 8 months follow-up and a continued reduction 
in fear of falling at 14 months.  This trial is in conflict to previous similar studies which did not 
show sustained improvements following intervention [231].  Furthermore, the recent trial had high 
drop out rates and a relatively intense and time-demanding intervention, the cost benefits of which 
are unknown.  The NICE guidelines also recommend employing the skills of an occupational 
therapist for home hazard assessment and intervention.  While this study does not comment on 
home hazards it does demonstrate an increase in functional difficulty in those who fall and that OT 
input may be required to improve daily functional ability.  Overall, it appears that MDT assessment 
and intervention would be the most appropriate service for older people with CLD who fall or who 
are at risk of falling. 
1 7 . 9 .  L I M I T A T I O N S  
This study was prospectively powered to detect a significant difference of 20% in falls prevalence.  
As the difference between the older CLD group and the Community Controls was 14%, this study 
was not adequately powered to detect this difference as significant.  This limitation is exaggerated 
when analysing for differences in the prevalence of fall-related injury, given the smaller numbers.  
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The lack of significance may be due to small numbers of Fallers sustaining an injury, but it must 
also be considered that the hypothesis of increased fall-related injury in CLD is incorrect. 
Comparison of the CLD group with the Community Control group is somewhat limited.  The 
existing database of falls and injury in community controls was collated in 2002, before the NICE 
guidelines for the prevention of falls were published.  However, the falls prevalence seen in this 
control cohort is similar to rates expressed in falls literature and has the advantage when compared 
to the CLD cohorts because it is derived from the same geographical region.  Furthermore, it allows 
for age and sex matching of individuals and for exclusion of individuals with a history of liver 
disease. 
Retrospective recall of falls is well known to have its limitations.  Restricting retrospective recall to 
the previous year was an attempt to temper these limitations, but nevertheless they remain.  
However, as the principle limitation of retrospective recall is under-reporting of events it is likely 
that the falls prevalence demonstrated is an underestimate and the true prevalence is higher, albeit 
in each cohort [232].  Approximately 27% of falls studies use retrospective recall, however a 
preferable method of data collection would be to collect it prospectively [233].  However, this is not 
without its own limitations such as lengthy data collection periods, lack of validity and some 
degree of retrospective recall (e.g. monthly reporting of falls) and would likely have resulted in a 
smaller sample size than seen in this study [233].  The self-reporting of injuries also is subject to the 
limitations of recall, but is also subject to unconfirmed diagnoses.  For example, a person who has 
fallen and has injured their chest may be informed by their General Practitioner, or indeed conclude 
for themselves, that they have fractured their ribs, without radiological evidence of such an injury.  
Conversely, some may fall and sustain an injury but disregard it as negligible, whereas another 
individual with the same injury may seek urgent medical attention 
A prospective sample size calculation was not performed with respect to the Phase 2 MDT 
assessments.  This phase was intended to be exploratory and used to inform future therapeutic or 
preventative studies if appropriate.  A number of factors limited the number of MDT assessments 
which could be carried out.  The principle limiting factor was the availability of the MDT team.  
Sessions were booked when each team member was available so that the participants would have 
to attend only once.  Two sessions per week were scheduled but this was often not practicable due 
to annual leave, study leave, sick leave and other factors.  Furthermore, the number of MDT 
assessments was limited by cancellations, non-attendance and the length of time of a full MDT 
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assessment.  As each participant was evaluated by three team members, in a ‘rotating clinic’, during 
each session it was only possible to see three participants. 
It is appreciated that while efforts were made to prevent bias, those who responded to the data 
collection tools may have been those who have had problems with falls as they may have felt most 
likely to benefit from the study.  This bias may have been further exaggerated in the Phase 2 MDT 
assessments, and while attempts were made to assess a wide spectrum of ‘phenotypes’ bias can not 
be completely excluded. 
During the Physician assessment the participants self-reported their past medical history and 
medications.  In nearly all cases this was verified from the participants’ clinical records but in a 
couple of cases, where clinical records were not available, medical history was dependent on the 
participants’ recall.  Where medical records were available, blood results and evidence of cirrhosis 
were noted.  In the majority of cases blood results were available within 4-6 months of the MDT 
assessment.  In the few participants who did not have results within 6 months of the assessment 
their closest sample was used, but only if the results had previously been stable and the participant 
was stable clinically. 
It seems likely, in retrospect, that the physiotherapy assessment was limited by the ceiling effect 
during the gait and balance assessment.  The tool, which is widely used in clinical practice, may 
have lacked sensitivity to identify subtle gait or balance abnormalities.  However, whether subtle 
gait and balance abnormalities would have a significant association with falls is unknown. 
Unfortunately the FES-I has only been validated in older people.  No such tool exists for younger 
people and as such it seems an appropriate choice especially as it widely used and recommended 
by the European Falls Prevention Network.  However, if it had have been practicable, it would have 
been preferable to perform at least a small validity study in younger people prior to data collection. 
Limitations to the autonomic assessment were minimal.  The Task Force® equipment is reliable 
within a range of 50-250 mm Hg BP which was not an issue for any of the participants assessed.  
Where limitations may have arisen was in the quality of an individual’s valsalva.  A poor valsalva 
could cause erroneously abnormal BP and HR responses from a lack of increase in intra-thoracic 
pressure.  In participants who were judged to have a poor technique the best of three attempts was 
selected, but this may still have been poor. 
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As has been mentioned, some of the statistical analyses were limited by the small sample sizes, 
particularly once the cohorts had been divided into Fallers and Non-Fallers and then sub-divided 
into injured or not injured.  The goodness-of-fit Chi squared statistic for the binary logistic 
regression model had a p value of greater than 0.05 and as such this model was no better at 
predicting the outcome (Faller) than using the constant alone (i.e. including the variables in the 
equation does not improve the model).  Conversely, the model-fit of the negative binomial 
regression was significantly better than the constant alone and the results of this model are 
significant. 
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R E S U L T S  –  P A R T  T W O
   85 
1 8 .  N O N - A L C O H O L I C  F A T T Y  L I V E R  D I S E A S E  
1 8 . 1 .  C H A P T E R  A I M S  
• To define the prevalence of falls in a NAFLD population 
• To identify modifiable fall associated risk factors 
• To establish whether falling in NAFLD is related to the presence of diabetes 
• To establish the rate of fall related injury 
1 8 . 2 .  I N T R O D U C T I O N  
The previous chapter demonstrated that the number of falls was significantly more common in 
those with diabetes and as such, the high prevalence of diabetes in the NAFLD population could be 
expected to contribute to high rates of falls.  This hypothesis is supported by the multiple falls risk 
factors which can result from diabetes: visual impairment, sensory disturbance, autonomic 
dysfunction and polypharmacy.  Diabetes was not independently associated with falling however 
and there may be other factors contributing to falls in this population. 
1 8 . 3 .  D E M O G R A P H I C S  
In Phase 1 there were 32 individuals with NAFLD who were aged 65 years or more (31% of Phase 1 
NAFLD cohort) and each of these was age and sex matched to a community control.  Details of 
these cohorts are displayed in Table 11.  It was not surprising to note that diabetes was more 
common than in the community controls. 
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  NAFLD <65 
years (n 72) 
NAFLD ≥65 





Age [years] 54 (19-64) 70 (65-79) 70 (65-79)  
Female (%) 39 (56) 17 (53) 17 (53) χ2 (2) 0.015, p 1 
Diabetic (%) 45 (63) 19 (59) 1 (3) χ2 (2) 33.551, p <0.001 
Albumin [g/L] 44 (38-50) 44 (35-47) 44 (40-48) χ2 (2) 3.72, p 0.156 
Bilirubin 
[μmol/L] 
11 (4-37) 9 (4-24) 9 (4-18) H (2) 0.087, p 0.957 
ALP [U/L] 83 (11-233) 102 (57-150) 78 (48-112) H (2) 11.031, p 0.004 
ALT [U/L] 64 (19-210) 47 (15-204) 21 (9-35) H (2) 50.028, p <0.001 
Cirrhosis (%) 17 (24) 11 (35) 0 χ2 (2) 12.419, p 0.002 
Table 11.  NAFLD.  Demographic details. 
 
1 8 . 4 .  F A L L S  P R E V A L E N C E  
The relatively small size of the older NAFLD group resulted in small numbers in each of the fall 
categories and interpretation of the statistical comparisons must take this into consideration.  In the 
older NAFLD group 12 (38%) individuals had fallen in the previous year.  There were significantly 
more Fallers in the older NAFLD cohort than in the matched Community controls [χ2 (1) 3.925, p 
0.048, Figure 24]; this significance remained when the Fallers were sub-divided into Single- and 
Recurrent-Fallers [χ2 (2) 5.515, p 0.019].  These differences were not demonstrated between the older 
and younger NAFLD groups [χ2 (1) 1.686, p 0.194 and χ2 (2) 1.929, p 0.381]. 
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Figure 24.  NAFLD.  Falls prevalence. 
 
To investigate the difference found between the three different fall categories in the cohorts the 
number of falls in those who had fallen was compared.  No difference was identified (Table 12). 
 
 NAFLD <65 
years (n 18) 
NAFLD >65 
years (n 12) 
Community 
controls (n 5) 
H (df), p 
Median number 
of falls (range) 
2 (1-52) 2 (1-10) 2 (1-2) 1.301 (2), 0.534 
Table 12.  NAFLD.  The number of falls experienced by Fallers. 
 
1 8 . 5 .  I N J U R Y  P R E V A L E N C E  
Individuals from the older NAFLD group who had fallen were age- (±0 years) and sex-matched to 
community controls.  However there were only 12 Fallers from the older NAFLD group and 
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although the fall related injury counts have been displayed in Table 13, it is not possible to draw 
statistical conclusions as the numbers are too small. 
 
 NAFLD <65 
years (n 18) 
NAFLD >65 
years (n 12) 
Community 
controls (n 12) 
Any injury (%) 6 4 10 
Soft tissue injury 
(%) 
3 3 10 
Accident & 
Emergency (%) 
4 3 3 
Fracture (%) 2 2 1 
Hospital 
admission (%) 
0 2 1 
Table 13.  NAFLD.  Fall related injury prevalence. 
 
1 8 . 6 .  F A L L  A S S O C I A T I O N S  
NAFLD is the most common cause of abnormal liver function in the Western world and its 
prevalence is increasing, with this in mind the need for falls intervention in NAFLD may increase 
[234, 235].  Given that the prevalence of falls is significantly greater in NAFLD than in Community 
Controls it became important to explore possible associations. 
18.6.1. PHASE 1- ASSOCIATION WITH AGE AND DISEASE SEVERITY 
Increasing age showed no association with number of falls in the previous year; nor was falling 
associated with the LFTs which suggests that falls are unrelated to NAFLD severity; however this 
could be explored further using the histological staging in the Phase 2 cohort. 
18.6.2. PHASE 2- MDT ASSOCIATIONS 
As 28 individuals with NAFLD underwent MDT assessment, associations were analysed in the 
whole group in order to maximise numbers.  The aforementioned Phase 1 results demonstrated that 
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age was not associated with falls and therefore the younger participants were included in the 
analysis.  Twenty individuals in the MDT (71%) were aged 65 years or older, 17 (61%) were 
diabetic, 22 (79%) were taking anti hypertensive medication and none had a diagnosis of 
osteoporosis.  Histological staging was available in all 28 participants; 14 (50%) had simple 
steatosis, 10 (36%) had NASH and 4 (14%) had cirrhosis.  None had been diagnosed with 
osteoporosis or were taking prophylactic bisphosphonates. 
The number of falls in the previous year did not correlate significantly with BMI or insulin 
resistance level.  In keeping with this there was no difference in the number of falls between 
diabetics [0 (0-12)] and non diabetics [0 (0-2), z 0.525, p 0.476].  This suggests that falls in people 
with NAFLD are unrelated to the presence of diabetes or the metabolic syndrome.  Four 
participants had a peripheral neuropathy on examination and interestingly each of these 
individuals had fallen recurrently in the previous year.  While this number may be too low to draw 
robust statistical conclusions, theoretically a peripheral neuropathy could contribute to falls. 
In keeping with the Phase 1 results there were also no difference in the number of falls between 
each histological stage [steatosis 0 (0-6), NASH 0.5 (0-3), cirrhosis 1 (0-12), H (2) 3.601, p 0.157). 
Other falls risk factors assessed included vision, which was not associated with number of falls 
[abnormal vision 0 (0-12) and normal vision 0 (0-3) respectively, z 0.406, p 0.725] and 
antihypertensive medication.  The difference in number of falls between those taking and those not 
taking antihypertensive medication approached significance but did not reach the 5% value [0.5 (0-
12) and 0 (0-12), z 1.086, p 0.064]. 
Number of falls did correlate with several autonomic measures including resting and nadir dBP 
and AUC, the results of which are displayed in Table 14.  Additionally, the physiotherapy 
assessment revealed an association between number of falls and fear of falling, Table 14, which is in 
keeping with the previous chapter concerning CLD as a whole.  Non-significant correlations are 
displayed in Appendix B.2, page 221.   
 









Fear of falling 0.454 
0.026 
Table 14.  NAFLD.  Phase 2 correlations with the number of falls. 
 
These correlations demonstrate that increasing numbers of falls are associated with a lower resting 
dBP and a lower nadir dBP upon standing.  Consistent with this BP association is the increasing 
AUC associating with increasing number of falls.  This is the degree to which the sBP drops on 
standing and the length of time it remains below baseline values.  An increasing fear of falls was 
also associated with an increasing number of falls.  Table 15 below displays which variables were 
included in the binary logistic regression model which aimed to identify which associations were 
independent associations with the outcome variable fallen or not fallen.  Age was included in the 
model as it was the intention to study older people with NAFLD but because of small numbers all 
ages were included in analysis. 
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95% confidence 
interval (OR) 






Constant 0.261 4.161 1.063   0.95 
Age 0.006 0.037 1.006 0.936 1.081 0.871 
dBP 0.003 0.062 1.003 0.888 1.134 0.956 
nadir dBP -0.042 0.073 0.958 0.831 1.106 0.56 
AUC 0.008 0.013 1.009 0.983 1.035 0.517 
FES-I 0.061 0.04 1.063 0.983 1.149 0.126 
R2 0.256 (Cox), Hosmer & Lemeshaw χ2 (8) 8.661, p 0.372 
Table 15.  NAFLD.  Binary logistic regression for Faller or Non-Faller. 
 
The 95% confidence intervals for the odds ratios of the logistic regression model can be seen in 
Figure 25 below. 
 
 
Figure 25.  NAFLD.  The 95% CI for the ORs derived from the binary logistic regression model. 
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The regression model described above does not identify variables as being independently 
associated.  This suggests that a single targeted falls intervention may not be appropriate and a 
multidisciplinary approach may be required.  To provide further evidence for possible therapeutic 
or preventative targets negative binomial regression was performed which explored associations 










Constant 0.778 3.203 2.176 0.004 1159.68 0.808 
Age 0.018 0.027 1.018 0.966 1.073 0.502 
dBP -0.002 0.044 0.998 0.915 1.087 0.955 
nadir dBP -0.047 0.058 0.954 0.852 1.069 0.42 
AUC -0.008 0.008 0.992 0.977 1.007 0.279 
FES-I 0.064 0.027 1.067 1.011 1.125 0.018 
Model likelihood ratio χ2 (5) 10.345, p 0.066 
Table 16.  NAFLD.  Negative binomial regression model for number of falls. 
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Figure 26.  NAFLD.  The 95% CI for the ORs derived from the negative binomial regression model. 
 
The regression model above identifies fear of falling as the only variable which is independently 
associated with the number of falls in the previous year; this may also be seen in Figure 26.  This 
has important clinical implications as fear of falling, a recognised risk factor for falls, is modifiable 
and represents a possible therapeutic target.  This was also seen in the full CLD group and it will be 
interesting to see in the subsequent chapters whether this will be a consistent finding in each 
specific CLD. 
1 8 . 7 .  I N J U R Y  A S S O C I A T I O N S  
The number of participants from Phase 2 when divided into Fallers and Non-Fallers and then 
subsequently into injured and non injured became too small to identify meaningful associations 
with injury. 
1 8 . 8 .  F A L L S  A N D  F U N C T I O N A L  A B I L I T Y  
Returning to the Phase 1 data the association between falling and functional ability was analysed.  
In order to maximise numbers all ages of NAFLD participants were included in the analysis.  There 
was no significant difference in functional ability across the fall categories from Recurrent-Fallers 
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[3.75 (0-70)], through Single-Fallers [6.25 (0-51.25)] to Non-Fallers [6.26 (0-61.25), H (2) 0.742, p 
0.702)].  In keeping with this, there was no correlation between the number of falls and the 
PROMIS-HAQ score (rs -0.139, p 0.442).  This is in contrast to the results of the previous chapter and 
may be suggestive that there is another process which contributes to functional difficulty rather 
than falls. 
1 8 . 9 .  S U M M A R Y  
Falls are common in older people with NAFLD, with 38% of the cohort having had a fall in the 
previous year.  This prevalence was significantly greater than in age- and sex-matched Community 
Controls.  In addition, when Fallers were sub-divided into Single- and Recurrent-Fallers there was 
also a significant difference between the older NAFLD group and the Community Controls with 
the prevalence of recurrent falls being twice as high in the older CLD cohort. 
Falls were not associated with age, disease severity and interestingly not with diabetes either.  MDT 
assessment found falls to be associated with dBP, nadir dBP on standing, AUC and fear of falling.  
Regression analysis revealed fear of falling as the only independent association with falls in people 
with NAFLD. 
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1 9 .  P R I M A R Y  B I L I A R Y  C I R R H O S I S  
1 9 . 1 .  C H A P T E R  A I M S  
• To establish the prevalence of falls in older people with PBC 
• To define the prevalence of fall related injury in older people with PBC 
• To explore factors associated with falling in older people with PBC, particularly 
dysautonomia 
1 9 . 2 .  I N T R O D U C T I O N  
Given that autonomic dysfunction is particularly prevalent in PBC it was hypothesised that falls 
would be particularly common in this disease group and would be related to autonomic function.  
The consequence of autonomic dysfunction could also potentially, lead to significant injury 
whereby cerebral hypoperfusion causing transient loss of consciousness could prevent protective 
mechanisms (e.g. grabbing onto supports or sticking out arms to prevent facial injury).  
Furthermore, the prevalence of osteoporosis is greater in PBC than in several other CLDs [79] and 
for this reason it may be anticipated that the prevalence of fall related fractures would be greater 
than in the control group. 
1 9 . 3 .  D E M O G R A P H I C S  
Data concerning sample sizes, demographics and liver disease severity are displayed in Table 17.  
The community control group was matched for age (±0 years) and sex with the older PBC group 
with the exception of the oldest PBC participant (95 years) who could only be matched to a younger 
community control (92 years). 
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  PBC <65 
years (n 36) 
PBC ≥65 





Age [years] 56 (40-64) 74 (65-95) 74 (65-92)  
Female (%) 32 (89) 57 (95) 57 (95) FET, p 0.456 
Diabetic (%) 1 (3) 4 (7) 3 (5) FET, p 0.898 
Albumin [g/L] 41 (26-49) 40 (28-45) 44 (39-49) H (2) 20.582, p <0.001 
Bilirubin 
[μmol/L] 
11 (5-75) 8 (4-21) 7 (4-18) H (2) 6.353, p 0.042 
ALP [U/L] 235 (48-1033) 149 (61-879) 80 (48-130) H (2) 38.901, p <0.001 
ALT [U/L] 51 (15-220) 27 (10-181) 18 (10-45) H (2) 35.181, p <0.001 
Cirrhosis (%) 2 (6) 7 (12) 0 FET, p 0.017 
Table 17.  PBC.  Demographic details. 
 
1 9 . 4 .  F A L L S  P R E V A L E N C E  
The prevalence of falls in the previous year in those aged over 65 years with PBC was high at 58%.  
This prevalence was significantly higher than in the Community Controls [χ2 (1) 7.552, p 0.006]; the 
high falls prevalence was also present in the younger PBC group, not differing significantly from 
the older group [χ2 (1) 1.119, p 0.29].  Recurrent falls were also very common in the older PBC group 
(23%) with significantly more than in the Community Control group [χ2 (2) 8.062, p 0.018].  The 
proportion of Recurrent Fallers was similar between the PBC age groups [χ2 (2) 1.125, p 0.57].  
Figure 27 displays the proportion of Fallers in each cohort. 
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Figure 27.  PBC.  Falls prevalence. 
 
While the proportion of Recurrent Fallers were significantly greater in the older PBC group than the 
community controls, the number of falls in those who had fallen were similar through each group 
and did not differ significantly [PBC <65 years 1 (1-3), PBC >65 years 1 (1-9), community controls 1 
(1-6), H (2) 1.148, p 0.568]. 
1 9 . 5 .  I N J U R Y  P R E V A L E N C E  
In order to compare injury rates, those older PBC participants who had fallen were age (±1 year) 
and sex matched to a community control that had fallen.  One of the PBC Fallers was 7 years older 
than the eldest control and as such could not be matched and was excluded from analysis. 
Given the high prevalence of autonomic dysfunction and osteoporosis in PBC it was perhaps 
surprising to note that the prevalence of injury, particularly that of fracture, was not significantly 
greater than in controls, Table 18.  However, given the numbers in each injury category it would be 
unwise to rely upon the statistical tests.  Regardless of the statistics, with such a high proportion of 
older PBC participants having had a fall the injury rate of 65% must not be ignored.  Indeed, in this 
PBC cohort eight participants had sustained a fall related fracture within the previous year. 
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 PBC <65 years 
(n 17) 
PBC >65 years 
(n 34) 
Community 
controls (n 34) 
Significance [χ2 
(df), p] 
Any injury (%) 10 (59) 22 (65) 25 (74) 1.252 (2), 0.523 
Soft tissue 
injury (%) 
10 (59) 22 (65) 23 (68) 0.386 (2), 0.877 
Accident & 
Emergency (%) 
4 (24) 9 (26) 9 (26) 0.061 (2), 1 
Fracture (%) 2 (12) 8 (24) 6 (18) 1.078 (2), 0.592 
Hospital 
admission (%) 
2 (12) 5 (15) 5 (15) FET, p 1 
Table 18.  PBC.  Fall related injury. 
 
1 9 . 6 .  F A L L  A S S O C I A T I O N S  
With 58% of the older PBC cohort having had a fall in the last year alone, it would appear 
important to explore factors associated with falling.  As with previous chapters age and LFTs could 
be explored in the larger Phase 1 cohort and the comprehensive MDT assessment in the Phase 2 
cohort. 
19.6.1. PHASE 1- ASSOCIATION WITH AGE AND DISEASE SEVERITY 
There was no demonstrable association between age, albumin, bilirubin, ALP or ALT with the 
number of falls. 
19.6.2. PHASE 2- MDT ASSOCIATIONS 
Fall associations were explored in participants of all ages to maximise numbers and power.  Forty 
participants underwent MDT assessment in which associations can be explored, 26 (65%) were aged 
over 65 years.  There were 4 participants with cirrhosis, 2 of which had fallen.  Despite the small 
numbers precluding further statistical analysis it appears from the Phase 1 data that there is no 
association between disease severity and number of falls.  Similarly there were 4 participants with 
diabetes, 2 of which had fallen.  Numbers were greater when analysing normal vision (n 24) versus 
abnormal vision (n 16), but as they were still relatively small the Kolmogorov-Smirnov test was 
used which did not reveal significant differences [0 (0-8) and 0 (0-12) respectively, z 0.516, p 0.396].  
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There was also no association with taking anti hypertensive medication (n 20) versus not taking it 
[n 20, 0 (0-12) and 0 (0-8) respectively, z 0.158, p 1].  Nine had a diagnosis of osteoporosis with falls 
being no more frequent than in those without it [0 (0-1) and 0 (0-12) respectively, z 0.558, p 0.424]. 
On autonomic testing the number of falls did not show an association with resting blood pressure.  
Although there was an association between LFnu and number of falls (rs -0.42, p 0.007) this result 
was inconsistent with the other HRV results which did not demonstrate significant associations.  To 
explore this possible relationship further, HRV was compared between Fallers and Non-Fallers; the 
results were consistent with the correlations described above, LFnu was the only HRV variable 
which demonstrated a significant difference between Fallers and Non-Fallers [37.1 (17.1-66.3), z 
1.408, p 0.024].  The remaining autonomic function results also displayed no association, including 
valsalva and BRS, and therefore the possibility that the association with LFnu represented a 
predominantly sympathetic abnormality seems unlikely.  Non-significant results are displayed in 
Appendix B.3, page 222. 
The relationship between falling and the OGS was significant in the PBC MDT cohort (rs 0.342, p 
0.031).  This finding was also present in the whole CLD analysis but not in the NAFLD cohort. 
The MDT physiotherapy assessment results revealed several significant correlations with number 
of falls and these are displayed in Table 19.  Each result is consistent in that poorer performance in 










Fear of falling 0.569 
<0.001 
Table 19.  PBC.  Phase 2 correlations with the number of falls. 
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Binary logistic regression was performed to identify possible independent associations with 
whether an individual had fallen or not.  Age was included in the model as all ages were included 
in the Phase 2 MDT data exploration to maximise numbers.  Including age in the model allows the 
model to control for factors which may be linked to ageing.  The variables included in the model are 
displayed in Table 20; none violated the assumptions required for logistic regression.  One residual 
case was identified from the regression; on inspecting the data for this case there was no apparent, 
robust reason why it should be excluded from the model and indeed removing it from the model 










Constant -33.766 23.226 0   0.146 
Age 0.08 0.86 1.083 0.916 1.281 0.352 
OGS 0.171 0.255 1.187 0.719 1.958 0.503 
Sit to stand test 0.216 0.181 1.241 0.871 1.77 0.232 
Balance 0.328 0.621 1.388 0.411 4.685 0.597 
Gait 0.674 0.767 1.962 0.437 8.816 0.379 
Fear of falling 0.322 0.167 1.379 0.994 1.915 0.055 
R2 0.465 (Cox), Hosmer & Lemeshaw χ2 (8) 3.893, p 0.867 
Table 20.  PBC.  Binary logistic regression model for Faller or Non-Faller. 
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Figure 28.  PBC.  The 95% CI for the ORs derived from the binary logistic regression model. 
 
The regression model demonstrates that fear of falling approaches the cut off significance level 
required to be an independent association with being a Faller, this can easily be seen in Figure 28 as 
the lower bound 95%CI just crosses 1 by only 0.006.  This is a particularly important finding given 
that fear of falling is a modifiable risk factor for falling, but may also support the case that these 
factors are closely linked and not independent of each other.  To explore these associations further, 
negative binomial regression was performed for the number of falls in the previous year and is 
displayed below in Table 21 and Figure 29. 
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95% confidence 
interval (OR) 






Constant -12.182 7.189 5.122 3.891 6.743 0.09 
Age -0.024 0.04 0.976 0.902 1.056 0.545 
OGS 0.136 0.126 1.146 0.895 1.466 0.279 
Fear of falling 0.115 0.059 1.122 0.999 1.259 0.052 
Sit to stand test 0.132 0.045 1.141 1.044 1.246 0.003 
Balance 0.056 0.233 1.057 0.669 1.67 0.811 
Gait 0.642 0.44 1.901 0.802 4.504 0.145 
Model likelihood ratio χ2 (6) 34.973, p <0.001 
Table 21. PBC.   Negative binomial regression for the number of falls. 
 
 
Figure 29.  PBC.  The 95% CI for the ORs derived from the negative binomial regression model. 
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The regression model displayed in Table 21 identifies the sit to stand test (STS, predominantly a 
measure of proximal muscle strength) as an independent association with number of falls.  The 
FES-I was very close to reaching significance with the lower bound 95% CI for FES-I crossing 1 by 
0.001.  Both of these factors are modifiable and are potential therapeutic/preventative targets for 
falling in PBC. 
1 9 . 7 .  F A L L S  A N D  F U N C T I O N A L  A B I L I T Y  
Returning to the Phase 1 data which had greater numbers of participants it was possible to explore 
the associations between functional ability and falls focussing on the older PBC group (n 60).  There 
was a strong, positive correlation between number of falls and the PROMIS-HAQ (increasing scores 
indicate increasing difficulty) whereby fewer falls associate with less difficulty (rs 0.407, p 0.003).  
Figure 30 demonstrates the significant difference in PROMIS-HAQ scores in Recurrent-Fallers [57.5 
(0-72.5), Single-Fallers [11.25 (0-43.75)] and Non-Fallers [3.75 (0-75), H (2) 9.83, p 0.007)]. 
 
 
Figure 30.  PBC.  Functional difficulty and falls. 
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1 9 . 8 .  S U M M A R Y  
Falls are very common in older people with PBC, with 58% having had a fall in the previous year, 
significantly more than in the age and sex matched Community Control group.  Recurrent falls 
occurred in 23% of the older PBC cohort which was significantly more than Community Controls.  
Factors which were associated with falling in PBC were orthostatic dizziness, lower limb strength, 
balance, gait and fear of falling.  Regression analysis revealed lower limb strength as the single 
factor which is independently associated with falling in PBC. 
Injuries were common, with almost two thirds sustaining a fall related injury and almost one 
quarter suffering a fracture.  Important findings, but these fall related injuries were not significantly 
more common than the control groups, as had been hypothesized. 
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2 0 .  A L C O H O L I C  L I V E R  D I S E A S E  
2 0 . 1 .  C H A P T E R  A I M S  
• To define the prevalence of falls in an ALD population 
• To identify modifiable fall associated risk factors 
• To establish the rate of fall related injury 
2 0 . 2 .  I N T R O D U C T I O N  
It could be assumed that falls would be a common event in people with ALD for several reasons.  
Firstly, increased levels of plasma alcohol can lead to poor judgement and slow reaction times both 
of which could contribute to mechanical falls and injury [236].  Secondly, there are longer lasting 
consequences of long term excess alcohol consumption such as peripheral neuropathy and 
cerebellar disease leading to postural and gait abnormalities.  Conversely, a fall in an intoxicated 
individual could go forgotten and unreported, or in those with more severe disease such as vitamin 
B1 deficiency or Korsakoff’s syndrome, there could be failure to form a memory for the fall.  It is 
possible that clinicians may assume that falls are related to the direct consequences of alcohol and 
assume that an abstainer who is falling is not being honest about their alcohol intake.  It would 
therefore be particularly important to explore fall associations in the ALD population. 
2 0 . 3 .  D E M O G R A P H I C S  
During Phase 1, 51 individuals with ALD completed the falls and injury tool.  Recruitment of ALD 
participants was slow due to the high ‘did not attend’ rate to their clinic appointments.  Eleven 
(22%) of the ALD cohort were aged 65 years or more.  Each of these was age and sex matched to a 
community control.  Details of these cohorts are displayed in Table 22. 
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  ALD <65 
years (n 40) 
ALD ≥65 
years (n 11) 
Community 
controls (n 11) 
Differences 
Age [years] 56 (31-64) 71 (67-83) 71 (67-83)  
Female (%) 12 (30) 3 (27) 3 (27) FET, p 1 
Diabetic (%) 0 0 0  
Albumin [g/L] 41 (20-49) 34 (28-47) 45 (41-47) H (2) 8.314, p 0.016 
Bilirubin 
[μmol/L] 
16 (4-316) 14 (8-72) 9 (6-14) H (2) 11.19, p 0.004 
ALP [U/L] 97 (40-1969) 95 (72-248) 73 (50-112) H (2) 8.177, p 0.017 
ALT [U/L] 43 (11-3210) 23 (11-51) 18 (11-35) H (2) 14.856, p 0.001 
Cirrhosis (%) 26 (65) 9 (82) 0 FET, p <0.001 
Table 22.  ALD.  Demographic details. 
 
2 0 . 4 .  F A L L S  P R E V A L E N C E  
The small size of the older ALD group resulted in small numbers in each of the fall categories and 
interpretation of the statistical comparisons must take this into consideration.  In the older ALD 
group 2 of the 11 individuals had fallen in the previous year.  The proportion of Fallers in the older 
ALD cohort was not statistically greater than in the younger ALD cohort [FET, p 0.706], nor than in 
the Community Controls [FET, p 0.476].  The same is true for the proportion of Recurrent Fallers 
[FET, p 1 and FET, p 0.476 for younger ALD and Community Controls respectively, Figure 31]. 
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Figure 31.  ALD.  Falls prevalence. 
 
2 0 . 5 .  I N J U R Y  P R E V A L E N C E  
Of the 2 Fallers who were aged over 65 years 1 sustained a fall related injury for which they 
attended Accident and Emergency and were admitted to hospital.  As none of the matched 
community controls had a fall in the previous year it was not possible to compare fall related injury 
rates. 
2 0 . 6 .  F A L L  A S S O C I A T I O N S  
It was possible to explore Phase 1 demographic data for fall associations despite not having Phase 2 
data.  Including those of all ages with ALD there was no association between age and number of 
falls (rs -0.011, p 0.939).  There was, however, an association between albumin and number of falls 
(rs -0.32, p 0.022) such that a lower level of albumin was associated with an increased number of 
falls.  Dividing the cohort into Fallers and Non-Fallers the levels of albumin did not quite reach 
statistical significance [median albumin in Non-Fallers 41 (29-49) and in Fallers 33 (20-47), z 1.342, p 
0.055 (Figure 32)].  There was no association between falls and the other LFTs [bilirubin (rs 0.251, p 
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Figure 32.  ALD.  Albumin and falls. 
 
2 0 . 7 .  S U M M A R Y  
In the older ALD cohort (n 11) 2 individuals reported a fall, these numbers are too small to draw 
meaningful conclusions.  However, the younger ALD group was larger and there was no 
association between age and falls.  As such, looking at all individuals with CLD the prevalence of 
falls appears to be much less than in the previous results (NAFLD, PBC and CLD). 
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2 1 .  P R I M A R Y  S C L E R O S I N G  C H O L A N G I T I S  
2 1 . 1 .  C H A P T E R  A I M S  
• To establish the prevalence of falls in a PSC cohort 
• To define the prevalence of fall related injury in people with PSC 
• To explore factors associated with falling in people with PSC 
2 1 . 2 .  I N T R O D U C T I O N  
It was recognised early in the study that the demographic of the PSC cohort was such that 
exploring falls and fall related injury would be limited if focussed on older adults and therefore all 
ages would be included. 
2 1 . 3 .  D E M O G R A P H I C S  
Data concerning sample size, demographics and liver disease severity are displayed in Table 23.  
Eight (28%) individuals were aged 65 years or over. 
 
  PSC <65 
years (n 21) 
PSC ≥65 
years (n 8) 
Community 
controls (n 8) 
Differences 
Age [years] 51 (33-64) 73 (66-91) 73 (66-91)  
Female (%) 5 (24) 5 (63) 5 (63) FET, p 0.247 
Diabetic (%) 0 0 2 (25) FET, p 0.057 
Albumin [g/L] 44 (31-49) 42 (30-45) 42 (38-46) H (2) 2.206, p 0.332 
Bilirubin 
[μmol/L] 
12 (7-64) 15 (7-67) 6 (5-12) H (2) 10.51, p 0.005 
ALP [U/L] 138 (60-886) 273 (89-486) 85 (48-113) H (2) 10.433, p 0.005 
ALT [U/L] 44 (15-118) 30 (19-59) 19 (10-28) H (2) 8.597, p 0.014 
Cirrhosis (%) 1 (5) 0 0 FET, p 1 
Table 23.  PSC.  Demographic details. 
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2 1 . 4 .  F A L L S  P R E V A L E N C E  
Five (17%) of the whole PSC cohort had fallen in the previous year, of these, 3 (10%) had fallen once 
and 2 (7%) had fallen recurrently (the 2 Recurrent-Fallers were both aged over 65 years).  Figure 33 
below demonstrates the proportion of Single-, Recurrent- and Non-Fallers in the older and younger 
PSC group.  An age and sex matched community control group for the older PSC individuals is 
displayed for interest although statistical analysis was not carried out due to the small numbers. 
 
 
Figure 33.  PSC.  Falls prevalence. 
 
2 1 . 5 .  I N J U R Y  P R E V A L E N C E  
Of the 5 individuals with PSC who had fallen in the last year 1 was injured.  This individual, in the 
older group, sustained a fall related fracture and was admitted to hospital, via Accident and 
Emergency. 
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2 1 . 6 .  F A L L  A S S O C I A T I O N S  
21.6.1. PHASE 1- ASSOCIATION WITH AGE AND DISEASE SEVERITY 
Analysing the 29 individuals from the Phase 1 cohort revealed no association between number of 














Table 24.  PSC.  Phase 1 correlations with the number of falls. 
 
21.6.2. PHASE 2- MDT ASSOCIATIONS 
As PSC is uncommon and affects principally younger males it was more challenging to recruit a 
PSC MDT cohort.  In total, 3 PSC participants were assessed and contributed to the full CLD 
analysis.  Here it is considered that 3 would be too small to draw meaningful conclusions from. 
2 1 . 7 .  F A L L S  A N D  F U N C T I O N A L  A B I L I T Y  
In the Phase 1 PSC cohort of 29 individuals there was no association between the number of falls 
and functional ability (PROMIS-HAQ, rs 0.332, p 0.079).  As there were only 5 who had fallen 
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numbers were too small to explore this association further with a 2 sample Kolmogorov-Smirnov 
test. 
2 1 . 8 .  S U M M A R Y  
In the whole PSC cohort the proportion of individuals who had fallen in the previous year was 
17%, but overall numbers were small.  Further analyses were redundant due to the small sample 
size, but in the 29 individuals who responded falls do not appear to be a huge problem. 
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2 2 .  D I S E A S E  C O M P A R I S O N S  
2 2 . 1 .  C H A P T E R  A I M S  
• To determine if falls prevalence differs between CLDs 
• To determine whether CLD type is independently associated with falling 
• To identify whether a specific CLD is associated with an increased prevalence of fall related 
injury 
2 2 . 2 .  D E M O G R A P H I C S  
Demographic data from the previous disease specific chapters are repeated below for ease of 
comparison, Table 25.  Data described relates to Phase 1 participants aged 65 years or more. 
 
 NAFLD (n 32) ALD (n 11) PBC (n 60) PSC (n 8) Comparisons 
Age [years] 70 (65-79) 71 (67-83) 74 (65-95) 73 (66-91) H 9.862 (3), p 0.02 
Female (%) 17 (53) 3 (27) 57 (95) 5 (63) FET, p <0.001 








9 (4-24) 14 (8-72) 8 (4-21) 15 (7-67) H 14.05 (3), p 
0.003 
ALP [U/L] 102 (57-150) 95 (72-248) 149 (61-879) 273 (89-486) H 13.74 (3), p 
0.003 
ALT [U/L] 47 (15-204) 23 (11-51) 27 (10-181) 30 (19-59) H 15.557 (3), p 
0.001 
Cirrhosis (%) 11 (35) 9 (82) 7 (12) 0 FET, p <0.001 
Table 25.  Disease comparisons.  Demographic data. 
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As expected there are obvious differences across the groups.  For example PBC would usually affect 
older females whereas PSC would usually affect younger males, likewise it would be expected that 
diabetes would be more frequent in NAFLD and that bilirubin and ALP would be higher in the 
cholestatic diseases. 
2 2 . 3 .  F A L L S  P R E V A L E N C E  
It became clear from the previous disease specific result chapters that there were differences in falls 
prevalence across the disease groups.  Figure 34 below demonstrates the proportion of Fallers and 
Non-Fallers in each disease cohort, aged over 65 years.  There was no significant difference 
identified across the groups when divided into Non-, Single- and Recurrent-Fallers (FET, p 0.079).  
However, as this result approached significance and numbers are small in each category the Single- 
and Recurrent-Faller groups were combined to form a Fallers group, which when compared to the 
proportion of Non-Fallers did reveal a significant difference across the disease specific groups (FET, 
p 0.041).  The figure demonstrates that older people with PBC have the greatest proportion of 
Fallers, triple that seen in ALD, while NAFLD and PSC groups have similar numbers of Fallers.  
Post-hoc analyses were not performed; rather the specific CLDs were incorporated into a regression 
model, results of which are below. 
 
 
Figure 34.  Disease comparisons.  Falls prevalence. 
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Supporting the above results, which suggest that while there is a difference in Fallers across the 
groups there is not a significant difference in recurrent falls, is the analysis of the number of falls 
experienced.  Figure 35 is useful to demonstrate the highly skewed falls count data with large zero 
counts and a large number of outlaying (•) and extreme values (*).  The median number of falls in 
each group is 0 with the exception of PBC, in which case the median is 1.  This difference does not 
reach statistical significance however [H 5.208 (3), p 0.157]. 
 
 
Figure 35.  Disease comparisons.  The number of falls experienced. 
 
2 2 . 4 .  I N J U R Y  P R E V A L E N C E  
Within those who had fallen the rates of injury were analysed.  Numbers were small and this 
should be considered when interpreting the results.  FET was performed as numbers were small, 
but this can increase the Type 1 error.  Table 26 displays the numbers of Fallers who sustained an 
injury, and also describes some specific injuries. 
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NAFLD (n 12) 4 3 3 2 2 
ALD (n 2) 1 0 1 0 1 
PBC (n 35) 22 22 9 8 5 
PSC (n 3) 1 1 1 1 1 
FET (p) 0.269 0.034 0.872 0.914 0.31 
Table 26.  Disease comparisons.  Fall related injury. 
 
Soft tissue injury, demonstrated a significant difference through the disease groups and this is 




Figure 36.  Disease comparisons.  Soft tissue injury. 
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Older individuals with PBC sustained the most soft tissue injuries with ALD having no soft tissue 
injury (which may be accounted for by the small number of Fallers in the older ALD cohort).  
Despite this, the results in general would suggest that injuries are important and substantial in all 
older CLD Fallers. 
2 2 . 5 .  F A L L  A S S O C I A T I O N S  
The results above suggest that falls are more common in older individuals with PBC and least 
common in older individuals with ALD.  However, while a statistical difference was shown across 
the different CLDs in relation to falls, there were also significant differences seen in the 
demographic data which ought to be considered.  For example, the PBC cohort may have more 
Fallers because they are an older cohort.  In order to investigate this further, regression analyses 
were performed.  All ages were included in the regression models in order to maximise sample 
size.  Age could be built into the model to control for this.  A nominal variable for the specific CLDs 
will be included in order to produce an OR for each specific CLD. 
Regression analyses were performed on the Phase 1 data for 2 reasons.  Firstly, several significant 
differences were found between the CLD disease cohort demographic data.  The effect of these 
differences could be explored with a greater sample size using the Phase 1 data.  Secondly, as it was 
not possible to recruit individuals with ALD for a MDT assessment the effects of ALD can not be 
explored in the Phase 2 regression analyses and the number of individuals in each CLD cohort who 
underwent was too small to perform regression analyses with disease type as a nominal variable. 
Differences in demographic data are displayed in Table 25.  Those which showed significant 
differences across the groups were included in the regression model to see if they accounted for the 
differences seen in the proportion of Fallers. 
Binary logistic regression for the dependent variable Faller or Non-Faller was performed and the 
model is described below in Table 27 and Figure 37.  As PSC was a redundant variable it was not 
included in the model. 
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95% confidence 
interval (OR) 






Constant -2.195 2.262 0.111   0.332 
Age 0.032 0.015 1.032 1.003 1.063 0.03 
Albumin -.0041 0.041 0.96 0.886 1.039 0.311 
Bilirubin 0.001 0.01 1.001 0.982 1.021 0.889 
ALP 0 0.001 1 0.998 1.003 0.9 
ALT 0.001 0.002 1.001 0.998 1.005 0.5 
Cirrhosis 0.493 0.397 1.637 0.752 3.561 0.214 
Diabetes -0.1 0.424 0.905 0.394 2.076 0.813 
Male 0.376 0.348 1.456 0.736 2.882 0.28 
NAFLD 0.583 0.665 1.791 0.487 6.59 0.381 
ALD 0.348 0.717 1.417 0.348 5.773 0.627 
PBC 1.289 0.646 3.631 1.024 12.876 0.046 
R2 0.137 (Cox), Hosmer & Lemeshaw χ2 (8) 3.809, p 0.874 
Table 27.  Disease comparisons.  The binary logistic regression model for Faller or Non-Faller. 
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Figure 37.  Disease comparisons.  The 95% CI for the ORs derived from the binary logistic regression model. 
 
The model described above (based on demographic data, not on fall risk factors) demonstrates that 
the odds of being a Faller is significantly greater in those with PBC than in those without PBC 
whereas the other CLDs are not independently associated with being a Faller.  In this model, age 
was also independently associated with being a Faller, although the OR is very slight. 
Negative binomial regression was then performed to identify whether specific CLDs were 
independently associated with the number of falls, PSC was also redundant in this model.  The 
model is described below in the Table 28 and Figure 38. 
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95% confidence 
interval (OR) 






Constant -0.62 1.5194 0.538 0.027 10.571 0.683 
Age 0.007 0.01 1.007 0.988 1.026 0.488 
Male 0.376 0.348 1.456 0.736 2.882 0.28 
Diabetes 0.823 0.275 2.278 1.328 3.907 0.003 
Albumin -0.035 0.026 0.966 0.918 1.016 0.179 
Bilirubin -0.01 0.007 0.99 0.976 1.004 0.152 
ALP 0.001 0.001 1.001 0.999 1.003 0.294 
ALT 0 0.001 1 0.999 1.002 0.677 
Cirrhosis -1.034 0.272 0.356 0.209 0.607 <0.001 
NAFLD 1.172 0.532 3.229 1.139 9.158 0.028 
PBC 1.555 0.525 4.735 1.692 13.245 0.003 
ALD 2.29 0.526 9.874 3.52 27.694 <0.001 
Model likelihood ratio χ2 (11) 57.129, p <0.001 
Table 28.  Disease comparisons.  Negative binomial regression model for the number of falls. 
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Figure 38.  Disease comparisons.  The 95% CI for the ORs derived from the negative binomial regression model. 
The binomial regression model demonstrates that each specific CLD (with the exception of PSC 
which could not be calculated in the model because it became redundant) is associated with the 
number of falls, independent of the demographic data.  This model also demonstrates independent 
associations for diabetes and being male whereas having cirrhosis is independently associated with 
reduced odds for number of falls. 
2 2 . 6 .  S U M M A R Y  
The prevalence of falls varies across the disease-specific older cohorts significantly.  The proportion 
of Fallers is greatest in PBC and declines through NAFLD, PSC and is least in ALD.  However, due 
to small sample sizes, particularly with respect to PSC and ALD, interpretation is tentative.  This 
caution is exaggerated in the injury analysis where it is probably not possible to draw even 
tentative conclusions. 
2 2 . 7 .  D I S C U S S I O N  
It is difficult to draw definite conclusions about the differences between the different CLD cohorts 
because sample size was small in a number of the cohorts, particularly when focussing on the older 
participants.  However, it was possible to include all ages in the regression models and control for 
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age, revealing that ALD, PBC and NAFLD are independently associated with falls when accounting 
for disease severity.  The draw back here is that the Phase 2 data was lacking for the ALD cohort 
and could not be included in a regression model. 
PBC and NAFLD had larger sample sizes and each of these specific CLDs had significantly greater 
numbers of Fallers than in age- and sex- matched Community Controls.  Interestingly, the 
associations with falling identified during Phase 2 revealed different associations in PBC and 
NAFLD.  Those associations in NAFLD tended to be related to blood pressure and fear of falling 
whereas in PBC they were related more to lower limb function (gait, balance, strength) and fear of 
falling.  While it was anticipated that the effects of diabetes, which is common in NAFLD, would 
cause autonomic dysfunction there was no identifiable association between diabetes and falling in 
NAFLD.  Surprisingly the only autonomic measure which was associated with falling in PBC was 
the OGS; given the almost universal prevalence of autonomic dysfunction in PBC this was 
unexpected.  Fear of falling, which was identified as an important factor in section 17.5.2, page 72 
was also found to be associated with falling in PBC and NAFLD, and independently so in NAFLD.  
Lower limb muscle strength was identified as the only independent association with falling in PBC 
and was consistent with the theoretical risk discussed in section 10.2.3, page 22.  The lack of a 
consistently independent association between the liver diseases suggests that either there is a 
unifying factor which has not been taken into account, that the complexity of falls aetiology 
precludes the discovery of a unifying factor or that each specific CLD does have differing 
contributing factors. 
The difference in fall associations between the specific CLDs may complicate the suggestions made 
regarding intervention and prevention programmes in the previous discussion which commented 
on CLD as a whole.  However, the suggested intervention was a multifactorial/multidisciplinary 
approach and not a single intervention.  As the aetiology of falls is complex, using specific falls 
prevention programmes for specific CLDs may not be appropriate.  A multidisciplinary approach 
enables a thorough assessment with an individualised management plan, regardless of the specific 
disease.  It would be unwise to suggest that those with PBC who have fallen should have leg 
strength assessed but those with NAFLD should not.  And while this leads to the question of how a 
MDT falls assessment/intervention should be different to a standard programme in the community, 
it misses the point.  The evidence presented here is in favour of further studies to assess the 
effectiveness of a falls intervention programme in CLD.  The dramatic shift in the age of people 
with CLD and the likely dramatic increase of the ‘geriatric syndromes’ in the CLD population could 
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potentially stretch current services available.  As the proportion of falls is so great, liver services or 
geriatric services may need to invest in the skills of a MDT and may require the evidence for such a 
move in order to secure funding. 
Unfortunately commenting on falls in ALD and PSC is limited, but some useful insights may still be 
drawn.  Those with ALD were particularly challenging to recruit.  The lack of interest which was 
seen during clinic recruitment and a lack of interest in undergoing the MDT assessment may 
suggest that a MDT intervention or prevention programme in ALD may not be worthwhile as 
individuals would not be willing to participate.  It is also important to recognise that those with 
ALD may not recall falls for reasons described in the introduction but further evidence would be 
required to support this.  It is disappointing that there was insufficient evidence to challenge 
possible misconceptions about the mechanisms of falls in those with ALD which may be unrelated 
to the direct effects of alcohol.  It was also difficult to recruit PSC participants to the Phase 2 MDT 
assessments.  This was a result of PSC being uncommon but also because the cohort tended to be 
younger, working males who found it difficult to be assessed during normal working hours.  It was 
not possible to offer an assessment at different times in order to control for the diurnal variation in 
the autonomic nervous system.  However, as the majority of PSC participants who responded to 
Phase 1 were aged less than 65 years and falls were uncommon in this cohort, it would seem that 
people with PSC would be unlikely to need the services of a MDT falls assessment/intervention. 
2 2 . 8 .  L I M I T A T I O N S  
Many of the limitations which were detailed in the whole CLD analysis (section 17.9, page 80) 
apply here also and will not be repeated.  The most obvious limitation is the small sample size in 
each older specific CLD.  However, this study was powered to address its principle aim, CLD, as a 
whole.  The specific disease analyses are secondary analyses only and analysis was always carried 
out with this in mind.  While the falls prevalence figures are interesting, with some specific CLDs 
such as PBC probably having a large enough sample size to have reasonably powered statistical 
calculations, interpretation of the fall-related injury prevalence is severely limited and in some cases 
not possible. 
It became clear during the analysis that the binary logistic models were a poor fit of the data.  The 
negative binomial regression models were reliably a good fit of the data with the models being 
significantly better than the constant alone.  The exception to this was seen in NAFLD where 
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neither regression model was a significant fit of the data which may imply that there are more to 
falls in NAFLD than can be assessed in a MDT. 
The omission of other CLDs such as AIH, viral hepatitis and HCC limits the generalisability of the 
results, particularly as the majority of people with AIH and HCC are older [25, 34].  However, there 
are no existing comprehensive, local databases for these conditions and recruitment methods 
would have been different and less robust, resulting in the same issue of poor generalisibility.
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R E S U L T S  -  P A R T  T H R E E
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2 3 .  F A L L S  A N D  L I V E R  T R A N S P L A N T A T I O N  
2 3 . 1 .  C H A P T E R  A I M S  
• To determine the prevalence of falls in a post liver transplantation cohort 
• To identify the frequency of fall related injury 
• To explore modifiable fall associations 
• To establish whether falls are less prevalent in a post transplant cohort compared to a non-
transplant cohort 
• To explore whether transplantation has a beneficial effect on Fallers with CLD 
• To identify whether those who fall pre-transplantation will fall sooner after transplant then 
Non-Fallers 
2 3 . 2 .  I N T R O D U C T I O N  
Those who had undergone LT were analysed separately from the other CLDs as they may be 
considered to have had definitive treatment.  Crudely speaking, LT can be considered as a cure for 
CLD and as such an improvement in liver disease markers, such as the LFTs, is seen.  Despite the 
laboratory improvements seen it remains controversial as to whether LT improves quality of life 
[237, 238, 239, 240].  It was unknown whether LT would have a favourable effect on falling but 
factors which were considered in hypothesis generating were the beneficial effects of 
transplantation on autonomic dysfunction, the possible negative effect of medications such as 
prednisolone (muscle weakness) and the possible inactivity of the post-operative period causing 
inactivity, deconditioning and orthostatic intolerance. 
To determine the effect of LT on falls 3 analyses were performed.  Firstly, the prevalence of falls and 
fall related injury in the previous year were defined and compared to controls in a similar manner 
to that seen in previous chapters.  Secondly, comparisons were made to a matched pre- (non-) 
transplant cohort; thirdly, falls were compared pre- and post-transplant from retrospective recall of 
those in the LT cohort; and finally a time to first event analysis was performed comparing those 
who had fallen and those who had not in the pre-transplant period. 
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2 4 .  F A L L S  I N  A N  O L D E R  P O S T - L T  C O H O R T  
2 4 . 1 .  D E M O G R A P H I C S  
The demographic details of the transplant recipients which were divided into the younger and 
older age groups are displayed in Table 29 below.  The Community controls were age (±0 years) 
and sex matched to the older LT cohort.  Details of transplant indication, time since transplant and 
age at transplant are also included. 
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 LT <65 years 
(n 61) 
LT >65 years 
(n 30) 
Community 
controls (n 30) 
Statistical 
differences 
Age [years] 53 (27-64) 68 (65-79) 68 (65-79)  
Female (%) 27 (44) 10 (33) 10 (33) χ2 (2) 1.714, p 
0.46 
Diabetic (%) 0 0 0  




10 (3-46) 8 (3-30) 8 (4-14) H (2) 1.263, p 
0.532 
ALP [U/L] 113 (50-799) 94 (50-375) 76 (50-113) H (2) 19.014, p 
<0.001 
ALT [U/L] 28 (9-235) 23 (8-80) 23 (9-32) H (2) 5.9, p 0.052 




























Months since LT 39 (2-155) 43 (3-121)  U 810.5, z -0.883, 
p 0.381 
Age at LT 51 (19-61) 65 (59-75)  U 14.5 z -7.603, p 
<0.001 
POD= Paracetamol overdose 
Table 29.  LT.  Demographic details. 
 
Time since transplant was similar between the older and younger recipients, with the median 
number of years since transplant being 4 years.  Given that there was no difference in time since 
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transplant there was a difference in age at time of transplantation with the median age in the older 
group being 65 years with the eldest recipient being 75 years old. 
2 4 . 2 .  F A L L S  P R E V A L E N C E  
The prevalence of falls in the previous year in a cohort of older transplant recipients was 20%.  The 
proportion of Recurrent-Fallers within this cohort is displayed in Figure 39 below.  Compared to 
the younger LT control group there were fewer Fallers, but only slightly and this difference was not 
significant [χ2 (1) 0.481, p 0.488].  Similarly, the difference in Recurrent-Fallers between the older 
and younger LT cohorts was not significant [FET, p 0.598].  The age- and sex-matched Community 
Control cohort, which was matched to the older LT cohort, had no Fallers.  While it may be 
considered that this could have occurred due to chance in the matching process the difference was 




Figure 39.  LT.  Falls prevalence. 
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The Figure above demonstrates a larger proportion of Recurrent-Fallers compared to Single-Fallers.  
This pattern was also seen in several of the specific CLD analyses but not quite to this extent.  This 
would suggest that when a transplanted individual falls, they are likely to do so recurrently.  This 
would be an important finding if injuries are significant in this group.  There was a statistically 
significant difference identified across the 3 cohorts in relation to the median number of falls 
experienced [LT <65 years 0 (0-23), LT ≥65 years 0 (0-3), Community controls 0, H (2) 9.591, p 0.007].  
When considering the falls prevalence in the CLDs in previous chapters, this falls prevalence 
appears slightly reduced.  This will be explored later in the chapter. 
2 4 . 3 .  I N J U R Y  P R E V A L E N C E  
As overall numbers of Fallers was relatively low statistical analyses would not be appropriate.  
Data is presented below (Table 30) for interest and for consistency but it would be unwise to make 
comparisons between the groups.  Data from the Community control group is from individuals 
who were matched for age (±1 year) and sex and who had fallen, in order to demonstrate fall 
related injury. 
 
 LT <65 years 
(n 16) 
LT >65 years 
(n 6) 
Community 
controls (n 6) 
Any injury 10 3 4 
Soft tissue injury 10 3 4 
Accident & 
Emergency 
5 1 1 
Fracture 4 0 0 
Hospital admission 3 0 0 
Table 30.  LT.  Fall-related injury prevalence. 
 
2 4 . 4 .  F A L L  A S S O C I A T I O N S  
It appears, at first sight, that the falls prevalence is lower in the older LT cohort than seen in 
previous chapters, although statistical comparison has not yet been made.  It may be therefore, that 
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fall associations will be different in this population.  Phase 1 demographic data will be explored 
first, followed by the comprehensive MDT data.  All ages are included in analysis to increase 
sample size; age will be included in any regression models to account for this. 
24.4.1. PHASE 1- ASSOCIATION WITH AGE, DISEASE SEVERITY AND ORTHOSTATIC 
SYMPTOMS 
There was no association demonstrated between number of falls and age nor the LFTs (Appendix 
B.4, page 223). 
One further association could be explored in the LT population which was not explored in the 
previous CLD chapters.  The transplant population data collection occurred after the data collection 
for the CLD populations because the falls and injury tool required modification.  As such, because it 
appeared that orthostatic symptoms and/or blood pressure were associated with falling in some of 
the MDT assessments, it was possible to include the OGS tool with the falls and injury postal tool to 
explore this association further.  The result was that orthostatic symptoms associated very strongly 
with the number of falls in the post-transplant cohort (rs 0.455, p <0.001).  As Spearman rank 
correlations do not display well on scatter graph this association is displayed in Figure 40 
comparing the OGS between the different fall categories, the significance remains on Kruskal-
Wallis analysis [H (2) 17.544, p <0.001]. 
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Figure 40.  LT.  Orthostatic symptoms and falls. 
 
24.4.2. PHASE 2- MDT ASSOCIATIONS 
Sixteen post-transplantation individuals underwent MDT assessment.  One explanation for the 
relatively small number compared to the NAFLD and PBC cohort is that the transplant database 
covers the whole United Kingdom as Newcastle is only 1 of 7 cities (1 of 9 centres) which provide 
liver transplantation.  As a result many of the individuals who responded to the postal tools who 
did not express an interest in the MDT assessment resided many miles away.  All 16 participants 
are included in analysis to maximise numbers. 
Ten (63%) were aged 65 years or more and 9 (56%) were taking anti-hypertensive medication.  Five 
(31%) had abnormal vision and 6 had osteoporosis. 
Interestingly, the only measure on MDT which correlated with the number of falls in the previous 
year was the nadir sBP on standing (rs -0.499, p 0.049), such that increasing numbers of falls 
associated with a lower orthostatic blood pressure.  This is displayed graphically below with the 
Kolmogorov-Smirnov non-parametric comparison [z 1.5, p 0.019] of Fallers and Non-Fallers (Figure 
41). 
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Figure 41.  LT.  Nadir sBP and falls. 
 
A binary regression model was not attempted due to small numbers in each fall category.  A 
negative binomial regression model was attempted however, to identify whether orthostatic 
symptoms, nadir sBP on standing were independently associated with being a Faller, while 
incorporating age into the model to account for all ages being included in the data analyses.  The 
model is displayed below and did not violate the assumptions of regression detailed in the 
Methods chapter (Table 31 and Figure 42). 
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95% confidence 
interval (OR) 






Constant 4.381 4.5215 79.879 0.011 563776 0.333 
Age -0.04 0.051 0.961 0.87 1.062 0.436 
Nadir sBP -0.033 0.248 0.967 0.922 1.015 0.18 
OGS 0.399 0.1253 1.49 1.166 1.905 0.001 
Model likelihood ratio χ2 (3) 16.533, p 0.001 
Table 31.  LT.  Negative binomial regression model for number of falls. 
 
 
Figure 42.  LT.  The 95% CI for the ORs derived from the regression model. 
 
The regression model detailed in Table 31 and Figure 42 demonstrates that symptoms of orthostatic 
dizziness are associated with number of falls independently of age and nadir sBP.  This is an 
important finding for 2 reasons.  Firstly, orthostatic symptoms are easy to identify and quantify 
with the OGS and secondly they are modifiable with conservative measures [241]. 
   135 
2 4 . 5 .  F A L L S  A N D  F U N C T I O N A L  A B I L I T Y  
Including all ages of transplant recipients from Phase 1 the associations between the PROMIS-HAQ 
and falling were explored.  Increasing numbers of falls were strongly associated with increasing 
difficulty with function (rs 0.469, p <0.001).  This association has been displayed graphically using 
the difference in median PROMIS-HAQ scores below in Figure 43 [Non-Faller 7.5 (0-75), Single 
Faller 5 (1.25-162.6), Recurrent Faller 46.25 (3.75-80), H (2) 20.357, p <0.001]. 
 
 
Figure 43.  LT.  Functional difficulty and falls. 
 
2 4 . 6 .  S U M M A R Y  
 The prevalence of falls in an older LT cohort is 20%, significantly more than in matched 
Community controls.  Recurrent falls appeared to be particularly prevalent amongst the Fallers.  
Falls in people who have undergone LT are unrelated to age and markers of liver disease, but are 
related to orthostatic symptoms and the degree to which systolic BP drops on standing.  Regression 
revealed that orthostatic symptoms are independently related falls.  Functional impairment is 
particularly severe in those who have fallen recurrently. 
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2 5 .  T H E  E F F E C T  O F  T R A N S P L A N T A T I O N  O N  F A L L S  A N D  I N J U R Y  
2 5 . 1 .  I N T R O D U C T I O N  
With the results appearing, at first glance, as though falls are less prevalent in the post-
transplantation cohort, compared to the CLD cohort, it is important to establish whether this 
difference exists and whether it is significant.  The ideal method to address this question would be 
to conduct a longitudinal study; however that is beyond the scope of this cross-sectional thesis.  
Three methods will be used here to attempt to answer this question.  The first method will compare 
a post-transplantation cohort to an age, sex and disease matched non/pre-transplantation cohort.  
This method has its disadvantages in that it compares 2 matched cohorts without the ability to 
directly assess the effect of transplantation on falls.  The second method is to compare retrospective, 
self-reported falls in the post-transplant cohort from their memory of before and after the 
transplant.  This has the advantage over the first method in that it controls for many confounding 
factors and allows for conclusions to be drawn upon the direct effect of transplantation; however it 
is restricted by the well known limited effect of retrospective recall.  It is hoped however, that these 
methods used alongside each other will provide supportive evidence.  A final analysis will study 
time to event, comparing the time to first post-transplant fall in those who had and those who had 
not fallen pre-LT. 
2 5 . 2 .   C O M P A R I N G  A  P O S T - T R A N S P L A N T A T I O N  C O H O R T  T O  A  
M A T C H E D  P R E - T R A N S P L A N T  C O H O R T  
The post-transplant cohort was matched for age (±3 years), sex and disease.  As falls data were only 
collected on NAFLD, ALD, PBC and PSC cohorts only those who were transplanted for these 
reasons were matched and included in this analysis.  This allowed controlling for confounding 
factors such as the effects of diabetes in NAFLD or autonomic dysfunction in PBC.  The matched 
CLD cohort will be referred to as the Non-Transplantation cohort. 
2 5 . 3 .  D E M O G R A P H I C S  
The demographic details for the Non- and the Post-Transplant cohorts are displayed below in Table 
32. 








Age [years] 59 (28-80) 59 (28-79) U 2379, z -0.006, p 0.996 
Female (%) 28 (41) 28 (41)  
Diabetic (%) 3 (4) 0 FET, p 0.245 
Albumin [g/L] 41 (30-49) 43 (31-50) U 1069.5, z -2.963, p 0.003 
Bilirubin [μmol/L] 14 (4-137) 9 (3-43) U 799.5, z -4.697, p <0.001 
ALP [U/L] 122 (40-886) 113 (50-799) U 1381, z -1.413, p 0.159 
ALT [U/L] 42 (12-116) 28 (8-235) U 1220.5, z -2.318, p 0.02 
Table 32.  LT.  Demographic details (Non- and Post-LT). 
 
As liver transplantation is a treatment, or a cure for some, it is unsurprising to note that the LFTs 
are, on the whole, significantly ‘better’ than those with CLD (Table 32).  There were surprisingly 
few diabetics in each cohort, but nevertheless, there were few in each group and the difference was 
not significant. 
2 5 . 4 .  F A L L S  P R E V A L E N C E  
A falls prevalence of 20% was seen in the older post-transplant cohort in the previous result 
chapter.  Here the focus was on determining the effect of transplantation on falls and so individuals 
of all ages are included.  The falls prevalence seen here is slightly different to prevalence described 
earlier as only those who were matched are included.  Figure 44 below displays the proportion of 
Fallers in the Non- and Post-transplant cohorts.  There is no difference between the 2 cohorts when 
divided into Fallers and Non-Fallers [χ2 (1) 0.322, p 0.706] nor when divided into Single-, Recurrent- 
and Non-Fallers [χ2 (2) 1.461, p 0.523]. 
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Figure 44.  LT.  Falls prevalence (Non- and Post-LT). 
 
The graph quite clearly shows that falls are no less common in the Post-Transplant cohort.  While 
this could infer that transplantation would not decrease the number of falls in someone with CLD it 
does not take into account the fact that often frailer people who may be expected to fall more often 
may be excluded from undergoing transplantation. 
2 5 . 5 .  I N J U R Y  P R E V A L E N C E  
Those who had fallen from the Post-Transplant group were matched to a Faller from the Non-
Transplant CLD group for age (±3 years), sex and CLD.  However due to relatively small numbers 
there were 3 cases which could not be matched for age within 3 years, these were matched within 6, 
9 and 11 years.  The age difference between the 2 groups did not reach statistical significance (z 
0.333, p 0.999).  The numbers of injuries sustained in the 2 groups are displayed in Table 33, below. 
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 Non-
Transplant 




Any injury 8 12 χ2 (1) 1.8, p 0.315 
Soft tissue injury 5 12 χ2 (1) 5.461, p 0.044 
Accident & 
Emergency 
6 5 χ2 (1) 0.131, p 1 
Fracture 3 3 FET 1 
Hospital admission 4 2 FET 0.658 
Table 33.  LT.  Fall related injury (Non- and Post-LT). 
 
The results above suggest that the prevalence of fall related injuries are similar in Non- and Post-
Transplanted populations, with the exception of soft tissue injuries which were significantly more 
common in the Post-Transplant group. 
2 5 . 6 .  E F F E C T  O F  T R A N S P L A N T A T I O N  I N  R E G R E S S I O N  
To build the effect of LT into a regression model the Phase 2 data were used.  All participants with 
CLD in Phase 2 were used and the fall associations from this cohort of 87 were explored.  
Significant associations are displayed in Table 34 below and non-significant associations are 
included in Appendix B.5, page 224. 
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 Variable rs, p 
OGS 0.326, 0.003 
sBP -0.241, 0.026 
nadir sBP -0.225, 0.037 
Active 
stand 
RRI 30:15 -0.214, 0.048 
VLF -0.255, 0.017 HRV 
PSD -0.221, 0.04 
Sit to Stand Test 0.302, 0.006 
Timed Up and 
Go 
0.34, 0.001 
Balance -0.28, 0.009 
Gait -0.268, 0.013 
MDT 
Fear of Falling 0.425, <0.001 
Table 34.  LT.  Phase 2 correlations with the number of falls (all Phase 2 participants). 
 
There was no significant difference in the number of falls between diabetics and non-diabetics [1 (0-
12) and 0 (0-30) respectively, U 557.5, z -1.59, p 0.115].  Similarly there was no association with 
vision [normal 0 (0-30), abnormal 0 (0-12), U 852.5, z -0.589, p 0.559] or cirrhosis [cirrhotic 1 (0-12), 
non-cirrhotic 0 (0-30), z 0.832, p 0.134]. 
Significant associations were used to build the regression model with the addition of the new 
binary, categorical variable, LT or no LT.  This would allow for identifying an association between 
falling and LT while controlling for the identified associations.  The binary logistic regression 
model for fall or no fall is described below in Table 35 and Figure 45. 
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95% confidence 
interval (OR) 






Constant -4.82 7.252 0.008   0.506 
OGS 0.107 0.122 1.113 0.876 1.415 0.38 
sBP -0.03 0.019 0.971 0.396 1.008 0.118 
RRI 30:15 -2.356 2.589 0.095 0.001 15.144 0.363 
VLF -0.011 0.006 0.989 0.978 1 0.055 
PSD 0.003 0.001 1.003 1.001 1.005 0.009 
Sit to Stand 0.116 0.072 1.124 0.976 1.294 0.106 
Balance 0.056 0.192 1.057 0.725 1.541 0.773 
Gait 0.265 0.385 1.303 0.613 2.772 0.492 
FES-I 0.133 0.051 1.142 1.033 1.262 0.009 
LT 1.508 1 4.516 0.636 32.063 0.132 
R2 0.451, χ2 (8) 6.053, p 0.641 
Table 35.  LT.  Binary logistic regression model Faller or Non-Faller, including having had a transplant as a 
variable. 
 
   142 
 
Figure 45.  LT.  The 95% CI for the ORs derived from the binary logistic regression model. 
 
The binary regression model described above demonstrates that while controlling for fall 
associations LT is not independently associated with having had a fall.  As has been consistent 
throughout the results chapters the FES-I is strongly, independently associated with falling and 
here in this model overall HRV (PSD) is also independently associated with having had a fall.  This 
finding was not present in previous results chapter except in the PBC results chapter which found 
an inconsistent association between HRV and falls.  Whether or not these HRV results are 
important it is not clear and therefore the most appropriate method is to interpret them alongside 
the other autonomic measures.  Furthermore, the aim of this regression analysis was to determine 
whether LT was associated with falling and as such, here, additional findings are of secondary 
importance.  The negative binomial regression model is displayed below in Table 36 and Figure 46. 
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95% confidence 
interval (OR) 






Constant -6.217 4.105 0.002 0.002 6.226 0.13 
LT 0.85 0.604 2.339 0.716 7.643 0.16 
OGS 0.159 0.07 1.172 1.022 1.345 0.023 
sBP -0.006 0.01 0.994 0.976 1.013 0.556 
RRI 30:15 -2.866 2.179 0.057 0.001 4.073 0.188 
VLF -0.002 0.002 0.998 0.995 1.001 0.118 
PSD 0.001 <0.001 1.001 1 1.001 0.009 
Sit to Stand 0.097 0.029 1.101 1.041 1.165 0.001 
Balance 0.102 0.113 1.107 0.887 1.381 0.369 
Gait 0.343 0.24 1.409 0.881 2.253 0.153 
FES-I 0.063 0.027 1.065 1.01 1.124 0.021 
Model likelihood ratio χ2 (10) 52.555, p <0.001 
Table 36.  LT.  Negative binomial regression model for number of falls, including having had a transplant as a 
variable. 
. 
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Figure 46.  LT.  The 95% CI for the ORs derived from the negative binomial regression model. 
The negative binomial regression model supports the above model in that it also shows that LT is 
not independently associated with falling.  The variables which were identified as being 
independently associated with falling were different to those in the binary regression model and 
are more consistent with previous result chapters (fear of falling, lower limb weakness, orthostatic 
dizziness but also PSD-a measure of overall HRV).  This regression model is also more reliable than 
the binary logistic model. 
   145 
2 6 .  T I M E  T O  F I R S T  F A L L  P O S T - L T  
2 6 . 1 .  I N T R O D U C T I O N  
Eighty-nine individuals returned the falls and injury data collection tool with complete falls data 





No fall Fall 
No fall 37 16A Pre-
Transplant Fall 15B 21 
A=group A, B= group B 
Table 37.  LT.  Falls Pre- and Post-LT. 
 
McNemar’s test revealed no statistical difference across the contingency table [χ2 (1) 0, p 1], which 
provides further support that transplantation has neither a beneficial effect nor detrimental effect 
on falling. 
In an attempt to further identify features which may be associated with falling and the possible 
effect of LT on falls comparisons were made between group A and group B (only those who had 
fallen post-LT versus those who had fallen pre-LT but not afterwards).  Phase 1 data was available 
for comparison and did not identify any difference between these 2 groups, Table 38. 
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 Group A Group B z, p 
Age 61 (41-68) 58 (27-68) 0.778, 0.43 
OGS 3 (0-17) 3 (0-17) 0.256, 0.99 
Albumin 43 (38-50) 44 (30-50) 0.782, 0.355 
Bilirubin 8 (4-17) 8 (3-20) 0.487, 0.829 
ALP 113 (55-475) 109 (51-256) 0.602, 0.766 
ALT 32 (16-235) 25 (15-154) 0.794, 0.433 
Table 38.  LT.  Phase 1 data for those who only fell before LT compared to those who only fell after LT. 
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2 6 . 2 .  T I M E  T O  F I R S T  F A L L  F O L L O W I N G  T R A N S P L A N T  
Of the 37 Post-Transplant Fallers, 35 retrospectively recorded the length of time to their first fall 
following transplantation.  The median length of time to first fall was 182 days (26 weeks) ranging 
from 0 to 1460 days (0 to 209 weeks).  Time to event did not correlate age, OGS or LFTs, see Table 
39. 
 
 rs, p 
Age -0.019, 0.913 
OGS -0.041, 0.814 
Albumin -0.023, 0.9 
Bilirubin -0.025, 0.894 
ALP 0.009, 0.959 
ALT 0.019, 0.919 
Table 39.  LT.  Phase 1 correlations with time to first fall after LT. 
 
The effect of transplantation on falls was analysed using Cox regression analysis.  A fall Post-LT 
was considered the dependent variable, while controlling for having had a fall pre-transplant, the 
OGS and age.  The Model is displayed below in Table 40, with the resulting hazard ratios (HR) in 
Figure 47. 
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95% Confidence intervals (OR)  b SE HR 




0.274 0.366 1.315 0.642 2.694 0.454 
OGS 0.02 0.036 1.02 0.95 1.095 0.578 
Age 0.021 0.018 1.021 0.986 1.058 0.245 
Table 40.  LT.  Cox regression model for time until first fall following LT. 
 
 
Figure 47.  LT.  The 95% CI for the HRs derived from the Cox regression model. 
 
The effect of transplant on falls can further be described in Figure 48 below.  This displays the time 
until first fall following transplant for those who had fallen pre-transplant and those who were fall-
free pre-transplant.  The lines cross several times and demonstrate no difference in time to event. 
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Figure 48.  LT.  Cumulative frequency of being fall free over time since LT. 
 
Cox regression analysis revealed that having had a fall pre-LT did not increase the risk of having a 
fall post-LT.  As this study was cross-sectional with retrospective recall of falls it was not possible to 
analyse possible confounding factors which may explain why some individuals fell post-LT but not 
before.  The effect of LT on autonomic dysfunction and falls would be of particular interest but 
could only be analysed in a longitudinal study. 
2 6 . 3 .  S U M M A R Y  
The prevalence of falls and fall related injury are similar in a LT cohort to a non-transplant-CLD 
cohort but significantly greater than a community control group.  Falling is related to the nadir sBP 
on standing and to symptoms of orthostatic dizziness.  LT appears to have neither a beneficial or 
detrimental effect on falling and does not prevent falls occurring in those who have fallen pre-LT.  
A small proportion of individuals, who underwent LT and did not fall in the pre-LT period, went 
on to have a fall following LT.  It would be interesting to study this group further, particularly 
focussing on changes in autonomic function following transplantation. 
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2 6 . 4 .  D I S C U S S I O N  
Falls are significantly more common than in community controls and are similar to those seen in 
CLD.  Indeed, 26% of the younger and 20% of the older LT cohort had fallen in the previous year 
with 59% of Fallers sustaining an injury.  These figures demonstrate that falls are common and 
must be taken seriously by clinicians who are faced with LT patients.  Numbers were relatively 
small in the injury analysis and as such it is unwise to draw definitive conclusions.  However, with 
the high incidence of bone disease in those who have undergone LT with additional risk factors for 
the elderly, the potential for devastating injury is high [242, 243].  Although it has become 
widespread to prescribe bisphosphonates in the LT population there is conflicting data concerning 
the prevention of fractures [79].  Studies which have focussed on an improvement in bone density 
have not, in general, assessed the effect on fractures.  There are at least 2 studies which have 
included both bone density and fracture rates which did not demonstrate a reduction in fractures 
[244, 245].  Other observational studies which have shown a reduction in fracture rates over longer 
periods of time may be confounded by the fact that the use of tacrolimus is increasing whereas the 
use of cyclosporine, which is associated with osteoporosis, is decreasing [246].  The importance of 
these results, alongside the results of this study, stress the importance of preventing falls and 
thereby preventing possible fall associated fractures and morbidity. 
A longitudinal study would be ideal to reveal risk factors for falling post-LT however this cross-
sectional study was able to reveal several factors associated with falling which are considered as 
risk factors in the general population.  Those factors which showed no association with falling are 
also worth considering.  Falls are not associated with advancing age which is often the explanation 
of many patients and clinicians alike.  Furthermore, falls were not associated with markers of liver 
disease severity in the post-LT cohort.  The single factor which did associate with falling in Phase 1 
was orthostatic dizziness (OGS).  As the OGS has previously been shown to correlate strongly with 
comprehensive laboratory autonomic assessment this result suggests that autonomic dysfunction is 
associated with falling in post-LT individuals.  This association was explored further in the Phase 2 
MDT phase of the study.  Autonomic assessment was able to demonstrate that the nadir systolic 
blood pressure was significantly lower in those who had fallen, further evidence for the role of 
autonomic dysfunction as a cause for falling.  Regression analysis revealed that it was the 
symptoms of orthostatic dizziness rather than the actual sBP which was independently associated 
with falling.  The OGS is a self-completed tool comprising questions which relate to everyday 
situations in which individuals may experience postural dizziness and therefore reflects real life 
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situations and symptoms whereas the autonomic assessment performed in Phase 2 is an artificial 
and isolated single situation.  However, there may be an alternative explanation for why symptoms 
are independently associated with falls regardless of the sBP drop, cerebral auto-regulation.  There 
is evidence that symptoms of postural dizziness can be related to abnormalities of the cerebral 
circulation in the context of a normal systemic blood pressure [247].  In addition, there is some 
evidence that cerebral auto-regulation (CA) is impaired in CLD (specifically PBC) [248, 249].  When 
functioning well, CA maintains cerebral blood flow and perfusion within an acceptable limit even 
during large changes in systemic blood flow/pressure.  Symptomatic OH is thought to occur when 
the cerebral blood flow/perfusion pressure is unable to respond to a large change in systemic BP, 
either because the change is too large or because there is impairment of CA.  Further research 
would be required to support this suggestion. 
Orthostatic dizziness as a risk factor for falling is important to identify as it is modifiable with 
simple, conservative measures such as an increased fluid intake, compression stockings and 
physical manoeuvres [241].  The NICE guidelines recommend performing a cardiovascular 
examination as part of the multifactorial risk assessment for people at risk of falling and with the 
evidence presented in section 10.2.1, it would seem essential that assessing for OH should form a 
standard MDT falls assessment. 
A variety of analyses failed to demonstrate a positive or negative effect of LT on falls and while the 
matched analyses demonstrated significantly better LFTs than those with CLD it is important to 
remember that laboratory results must not be taken as the sole indicator of an improvement.  
Quality of life studies have demonstrated that LT does not consistently improve life quality in the 
long term [250, 251, 252, 253].  Here it has been demonstrated that falls are strongly associated with 
increased functional difficulty and while it is not possible to determine cause or effect a common 
sense approach would indicate that falls do reduce quality of life and increase functional 
impairment.  Falls are an important issue and they will occur with increasing frequency in the LT 
population as the age of people who undergo transplantation and re-transplantation is increasing 
[27, 254].  Clinicians need to be aware of the challenges which their patients will face and services 
need to be prepared for these changes. 
2 6 . 5 .  L I M I T A T I O N S  
A response rate to the postal data collection tool of 57% was reasonable but larger numbers would 
have increased sample size, power and generalisability.  It is well documented in the literature that 
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a follow up telephone call or sending a second copy of the tool can increase response rates, as can a 
telephone call prior to sending.  None of these methods were undertaken and it must be considered 
that these individuals, who had given prior consent to be contacted, should not feel under duress or 
feel hassled to complete the tools.  Indeed, at the outset of the study the Caldicott Principles were 
reviewed and one of these principles was to use patient identifiable data only when absolutely 
necessary.  As the study was designed and powered to calculate falls prevalence in the CLD 
population it was not considered absolutely necessary to contact the non-responding LT 
individuals to increase sample size. 
The geographical distribution of the LT cohort also appeared to have an impact upon recruitment 
for the MDT assessment with those residing further away tending to not express an interest in 
further assessment.  As such the sample size for the Phase 2 MDT LT cohort was smaller than 
anticipated.  This small sample size prevented a binary logistic regression from being performed 
due small numbers in each fall category.  However, it was possible to explore falls associations in 
the negative binomial regression model. 
As Newcastle upon Tyne Hospitals NHS Trust receives patients for LT from anywhere within the 
UK the LT cohort is derived from a different geographical region to both the CLD cohort and the 
Community Control cohort.  The effect of this difference is unknown but it can not be incorporated 
into analysis and controlled for.  It is also worth considering that only those who were transplanted 
in the previous 5 years were included in the cohort.  This could affect the reported prevalence of 
falls in LT as it is unknown whether the very long term effect of LT will have an impact of falls. 
Determining the effect of LT on falls would be limited given the cross-sectional design of this study.  
However an attempt was made to overcome these limitations by performing different analyses, 
each of which would provide supportive evidence.  The first analysis which compared a post-LT 
cohort to a matched CLD cohort who had not undergone LT was limited by not directly being able 
to analyse the effect of transplantation, rather it compared a LT cohort to a non-LT cohort.  
However, this method had the advantage over the second analysis used (which was dependent on 
longer term, retrospective recall) as the first analysis compared falls in the previous year.  The 
second analysis was performed using only the LT cohort with recall of falls pre- and post-LT.  
Retrospective recall is notoriously poor and increasingly so as length of time from event increases.  
The result could be that the prevalence of falls pre-LT could be under-reported and as such the 
effect of LT on falls could be underestimated here. 
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2 7 .  A  P I L O T  S T U D Y  T O  E X P L O R E  T H E  R E L A T I O N S H I P  B E T W E E N  
O R T H O S T A T I C  S Y M P T O M S  A N D  C E R E B R A L  A U T O R E G U L A T I O N  
2 7 . 1 .  C H A P T E R  A I M S  
• To compare cerebral autoregulation in a liver disease cohort to a control group 
• To identify any relationship between orthostatic symptoms and cerebral autoregulation 
• To explore whether falls may be associated with cerebral autoregulation 
2 7 . 2 .  B A C K G R O U N D  
In reviewing the results of the work presented in this thesis and in formulating the discussion and 
conclusions, an unexpected finding arose.  In section 17.5.2, page 72, the negative binomial 
regression model demonstrates an independent association between the number of falls and 
symptoms of postural dizziness in people with CLD.  The same finding is presented in the post-LT 
regression model in section 24.4.2, page 132.  While this may not appear to be particularly 
outstanding the association between orthostatic symptoms and falls is unrelated to all measures of 
BP, including the degree to which it drops on standing. 
From clinical experience and from published descriptions of cohorts with OH it is well known that 
OH causes light-headedness, dizziness and orthostatic intolerance [255, 256, 257].  However, these 
symptoms can also be caused by other conditions in which OH is not present, such as postural 
tachycardia syndrome (POTS).  Conversely, OH can also be present in the absence of symptoms 
[257].  The difference between symptomatic and asymptomatic OH is thought to be the result of 
cerebral autoregulation, whereby an individual with dysfunction of cerebral autoregulation is 
unable to maintain perfusion pressure in the presence of a decrease in systemic BP [258].  These 
conclusions, however, are based on a small number of studies composed of small sample sizes, and 
use novel research methodology to estimate, rather than directly measure, cerebral autoregulation. 
2 7 . 3 .  I N T R O D U C T I O N  
Studies relating to the control of the cerebral circulation are relatively young, principally because of 
the difficulties in measuring the blood flow of vessels encased within the human skull.  However, 
the concept of cerebral autoregulation (CA) attracted increasing attention over the second half of 
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the 20th century when it became possible to estimate cerebral blood flow using indicator flow 
techniques [259].  This method, being time consuming, only allowed for mean values of cerebral 
blood flow (CBF) over several minutes and could not reflect dynamic, rapid responses to changes in 
blood pressure [260].  In the 1980s transcranial Doppler (TCD) ultrasound became available and 
dramatically changed the way CA could be studied.  The resulting knowledge allowed for an 
increase in the understanding of the relationship between arterial pressure, intracranial pressure 
and cerebrovascular resistance in maintaining CBF; the process being termed CA. 
CA is essential to maintain stable and constant blood flow to the brain in the presence of fluctuating 
systemic BP in order to supply the high and constant demand for metabolic substrates.  It is vital to 
have intact CA in the presence of episodic drops in systemic BP, such as during standing from a 
supine position, in order to initiate protective mechanisms, preventing cerebral ischaemia and 
infarction.  A normal response to a reduction in BP and hence blood flow arises from a withdrawal 
of stretch on the cerebral arterialar wall smooth muscle, initiating both a local biochemical response 
and a global autonomic response, inducing smooth muscle relaxation thereby increasing CBF 
(Figure 49) [261].  A great deal is unknown about CA, particularly the autonomic reflexes involved; 
if further understanding is to be achieved it is likely that new techniques will need to be developed 
alongside an improved understanding of the complex, confounding metabolic factors involved. 
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Figure 49.  TCD.  Normal response of cerebral arteriole diameter during a decline in BP 
 
27.3.1. TRANSCRANIAL DOPPLER 
TCD is a highly useful clinical and research tool because it is entirely non-invasive.  Furthermore, it 
is cheap, does not require pharmacological agents and provides real-time, dynamic measurements 
of CBF.  It is preferable to other non-invasive methods such as functional MRI, as it is low cost and 
is more sensitive to rapid changes in cerebral blood flow velocity (CBFV) [262].  With the 
contiguous development of non-invasive, beat-to-beat BP measurement techniques it became 
possible to study dynamic, rapid changes in CBF velocity (CBFV) as changes in BP occurred. 
In order to quantify CBFV a cerebral artery must be insonated with a transcranial Doppler probe 
(Figure 50).  The skull poses a significant problem when using ultrasonic radiation as the waves are 
absorbed or reflected by the bony skull.  Fortunately there are four windows through which it can 
be possible to visualise the arteries.  The most commonly used window is the transtemporal 
window, through which three arteries can be visualised, with the middle cerebral artery (MCA) 
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being the most commonly used in the literature [263].  CBF is estimated from the blood flow 
velocity, calculated using Doppler, and the diameter of the vessel, which is thought to remain 
constant in the MCA [264]. 
 
 
Figure 50.  TCD.  The TCD probe insonates the right MCA via the right temporal window 
 
27.3.2. INDUCING HAEMODYNAMIC CHANGES 
In order to assess CA it is necessary to induce and monitor changes in systemic BP to identify 
appropriate changes in CBFV.  There are several methods which can be employed to induce 
hypotension.  One of the first methods to be used was ‘step decreases in blood pressure’ which 
used large, inflated thigh cuffs, which when rapidly deflated induced a drop in systemic BP [265].  
This method is uncomfortable for the participant and as there are other more comfortable methods 
available it would unethical to perform this method. 
Lower body negative pressure can be used to induce hypotension [266].  During this procedure the 
participant’s body is encased, from below the diaphragm, in a sealed box, which via a vacuum, has 
a lower than atmospheric pressure.  The negative pressure within the sealed box causes veno-
dilatation and hypotension, however these changes may occur slowly and so rapid changes in 
CBFV can not be measured.  The procedure could continue with the aim of inducing a vasovagal 
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response with a rapid decline in BP; however this would risk inducing syncope and is considered 
unnecessary when alternative, simpler methods are available.  A variation of this method would be 
the head-up tilt test, but in addition to the risk of syncope there are significant changes in end-tidal 
carbon dioxide which can influence CBFV [267]. 
An obvious method to induce rapid, transient hypotension would be active standing from a supine 
position.  This would also have the added advantage of being particularly relevant to the work 
presented in this thesis.  However, in order to induce a transient hypotension the participant would 
be required to stand relatively quickly which in the case of some participants would be challenging; 
furthermore the participants would be wearing the beat-to-beat BP monitoring equipment, thereby 
disabling one arm, and the TCD equipment fixed in place to the head, making the process of 
standing from a supine position very difficult.  It is also essential the TCD probe remains fixed in 
place throughout as the CBFV is partly based on the diameter of the vessel insonated; any change in 
the position or angle of the probe would make comparison to the baseline value worthless. 
A much more simple, safe and reliable method of inducing BP change is the valsalva manoeuvre.  
The methods used to perform this have been described in section 15.6.3.4, page 55.  Essentially, the 
valsalva induces hypotension by increasing intrathoracic pressure so that venous return to the right 
atrium is reduced.  The added benefit is that on release of the strain there is a reflex hypertension as 
venous return is restored and the sympathetic drive is active, this allows for measuring the CBFV 
response to hypertension.  The valsalva is simple and painless for the participant and as it is 
performed while motionless it reduces movement of the TCD probe.  The principle disadvantage of 
the valsalva is the variability in technique and effort between participants such that a poor 
haemodynamic response may be induced, however this can be limited using the best-of-three 
principle and the response can be assessed real-time while it occurs. 
27.3.3. MEASURES OF DYNAMIC CA 
The measurement of CA is based on cerebral blood flow velocity (CBFV), which is estimated using 
TCD insonation of the right MCA, alongside the beat-to-beat monitoring of systemic BP.  Using 
these measurements and following equations, CA can be estimated: 
Cerebrovascular resistance (CVR) provides an estimate of the resistance of the small cerebral blood 
vessels based on the following formula (calculated by the Task Force® Monitor programme): 




BPCVR =  
Pulsatility Index (PI) is an additional measure of vessel resistance based on the following 




CBFVCBFVPI −=  
The Autoregulatory Index (AI) is a reflection of the CBFV response to a change in BP.  The AI-2 is 
the response of the CBFV to the change in BP between phase 2a and phase 2b of the valsalva (i.e.  











AI-4 is the response of CBFV to the change in BP between phase 1 and phase 4 of the valsalva (i.e. 







AI =−  
For both AIs it would be expected that normal CA would result in values of greater than 1.00. 
The Autoregulatory Slope Index (ASI) reflects the difference in the change of BP and the change in 
CBFV as a percentage (where phase 2a is the start of the phase 2 slope and +3s is the value 3 
























The ASI has the advantage over the AI because it allows a small time difference, in effect, to allow 
the CBFV to respond to the change in BP.  The ASI also allows for the decrease in cerebral perfusion 
pressure (CPP) resulting from the cerebrospinal fluid transmission of intrathoracic pressure.  The 
decrease in CPP results in cerebral vasodilatation just as a decrease in BP during phase 2 of the 
valsalva would also result in vasodilatation.  But as release of strain at phase 4 of the valsalva 
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results in an immediate increase in CPP, and therefore vasoconstriction, any remaining 
vasoconstriction 3 seconds after release will be the result of CA. 
27.3.4. CEREBRAL AUTOREGULATION IN CLD 
As the prevalence of AD is relatively high in people with CLD it could be anticipated that CA is 
impaired in those with CLD.  However, studies assessing CA in people with CLD have generally 
focussed only on those with severe or cirrhotic disease [268, 269, 270].  Furthermore, these studies 
have small sample sizes, lack power calculations and in almost all cases study resting CBF rather 
than dynamic CBF.  These studies are summarized in Appendix C where the inconsistency in 
results can be seen.  It is unknown how cirrhosis, or even CLD, causes or contributes to impaired 
CA.  One study noted an impaired sympathetic response of CA during hypotension, on spectral 
analysis and others have noted in longitudinal studies that CA improves following transplant [271, 
272]. 
When CA is absent or impaired CBF is dependent on adequate levels of systemic BP; however, if 
systemic BP falls and CA can not respond adequately, CBF will decrease and cerebral ischaemia 
and infarction could result.  It is in this situation that symptoms of orthostatic dizziness occur and 
why it is hypothesized that CA is present in CLD [258]. 
2 7 . 4 .  M E T H O D S  
27.4.1. RESEARCH DESIGN 
A cross-sectional approach was undertaken in this small, pilot study of CA in CLD.  Almost all 
existing studies are limited to participants with cirrhosis; however this pilot study included 
participants regardless of disease severity.  All subjects included underwent TCD during a resting 
period and during a valsalva manoeuvre in order to assess resting and dynamic CA.  Results from 
the CLD cohort were compared to a non-liver disease, control cohort. 
27.4.2. ETHICAL APPROVAL 
This small, pilot study was approved by the North Tyneside Local Ethics Committee.  All 
participants were fully informed of the study and provided written consent. 
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27.4.3. SUBJECTS 
Subjects with PBC were enrolled from the Newcastle upon Tyne Hospitals autoimmune liver clinic.  
The CLD participants were limited to people with PBC.  From the MDT assessments described 
earlier in this thesis, the PBC cohort had significantly greater levels of orthostatic dizziness and 
therefore represented an ideal group in which to explore the relationship between CA and postural 
dizziness.  In addition, as the prevalence of AD is high in PBC there was a greater chance of 
impaired CA being found on TCD which was necessary to relate to symptoms on the OGS.  Each 
participant had confirmed PBC, as defined in section 15.5.3, page 46. 
Controls were recruited as friends or family of those participants with PBC and had no history of 
liver disease, cerebro-vascular disease or conditions which could contribute to AD, namely diabetes 
and Parkinson’s disease. 
27.4.4. DATA COLLECTION 
Autonomic data was collected using identical principles of autonomic assessment as detailed in 
section 15.6.2, page 47 in order to reduce variation in diurnal autonomic function and circulating 
catecholamines.  To monitor systemic BP participants were monitored with the Task Force® 
equipment described in section 15.6.2. 
27.4.5. TRANSCRANIAL DOPPLER 
TCD signals were recorded continuously using LabWindows® software which was coupled to the 
Task Force® Monitor in order to completely synchronise BP and CBFV recordings.  While in a 
supine position a 4 MHz ultrasound probe (Digilite®, RIMED Ltd, Israel) was used to insonate both 
the common and internal carotid arteries of the participants, in order to exclude those participants 
with 50% or greater carotid artery stenosis.  Following this, a 2 MHz ultrasound probe was used to 
locate the right MCA through the right temporal window.  In those in whom it was not possible to 
locate the right MCA an attempt to localise the left MCA was made, however in those cases where 
the right MCA could not be localised, it was also not possible to insolate the MCA on the left.  Once 
the temporal window was located a Muller-Moll probe fixation device was used to hold the probe 
in place.  Continuous systolic, diastolic and mean CBFV was recorded and displayed on the Task 
Force® Monitor alongside the continuous systolic, diastolic and mean BP. 
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27.4.6. ASSESSMENT OF AUTOREGULATION 
Measures of resting CBF, CVR and PI were taken from the final 2 minutes of supine rest in order to 
achieve stable cardiovascular values.  Following this, participants were assisted into a sitting 
position where they remained for 2 minutes to achieve stability before beginning the valsalva.  The 
valsalva manoeuvre was performed in an identical manner to that described in section 15.6.3.4, 
page 55.  Continuous TCD and BP recordings were observed and recorded throughout the 
manoeuvre and assessed for optimal technique.  Two valsalvas were performed by each participant 
with a 2 minute rest between each.  If both attempts were judged to be poor then a third was 
attempted. 
End-tidal CO2 was recorded using a nasal cannula and infrared capnography (Oxipulse® 
Capnograph system, SIMS-BCI, USA) during the rest period in order to monitor potential 
confounding from the effects of swings in arterial CO2 concentrations on cerebral arteriolar 
diameter; however as the valsalva involved exhaling into a closed system through the mouth the 
end-tidal CO2 could not be measured via the nasal cannula during valsalva. 
27.4.7. DATA ANALYSIS 
Recordings of the continuous TCD and BP measurements were assessed to identify the different 
phases of the valsalva manoeuvre and the changes which occurred in CBFV during the changes in 
BP.  The results were then used to calculate the indices of CA which are described earlier. 
Non-parametrically distributed data are described with the median alongside the minimum and 
maximum value.  Differences in non-parametrically distributed data were analysed using the 
Kolmogorov-Smirnov z test, which has better power than the Mann-Whitney U test when assessing 
small sample sizes.  Associations were assessed using the Spearman rho (rs).  Results were 
considered significant when p <0.05. 
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2 7 . 5 .  R E S U L T S  
27.5.1. RECRUITMENT 
 
Figure 51.  TCD.  Recruitment of the TCD cohorts. 
 
Figure 51 above displays the process of recruitment to the study and the resulting cohort size. 
27.5.2. DEMOGRAPHICS 
Table 41 below describes the PBC participants and the controls.  They were similar in terms of age, 
baseline BP and HR.  It also demonstrates that resting levels of CBFV, CVR and PI were similar 
between the PBC participants and the Controls. 
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 PBC (n 10) Controls (n 6) z, p 
Age (years) 65 (50-77) 52 (28-66) 0.968, 0.176 
sBP (mm Hg) 124 (60-149) 123 (110-143) 0.387, 0.992 
dBP (mm Hg) 80 (29-100) 84 (64-105) 0.452, 0.96 
HR (bpm) 68 (54-83) 61 (58-75) 0.71, 0.577 
End tidal CO2 5.6 (4.4-5.9) 5 (4.9-5.1) 1.162, 0.134 
sCBFV (cm/s) 66 (42-75) 65 (38-80) 0.645, 0.713 
dCBFV (cm/s) 24 (12-37) 29 (17-48) 0.645, 0.713 
CVR 2.3 (1.1-4.5) 2.2 (1.5-3.1) 0.581, 0.835 
PI 0.9 (0.7-1.7) 0.8 (0.5-0.9) 1.162, 0.092 
Table 41.  TCD.  Descriptive data of the cohorts. 
 
27.5.3. DYNAMIC CEREBRAL AUTOREGULATION 
A normal CA response to a change in BP is to maintain CBFV within a narrow range, ensuring 
continual supply of nutrients to the brain.  During the valsalva the BP is forced to decrease with a 
reflex increase in BP following release of strain.  Figure 52 below displays the sBP and the CBFV for 
a Control participant with the resting period leading up to the vertical dotted line; after the dotted 
line the sBP decreases during phase 2a of valsalva and on release of strain, at the dashed vertical 
line there is an overshoot of sBP.  It can be seen that the CBFV, the bottom line, is tightly controlled 
even during fluctuations in sBP. 
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Figure 52.  TCD.  Normal CBFV response to valsalva in a control subject. 
 
Figure 53 below displays the valsalva and CBFV for one of the PBC participants.  The first thing to 
note is that there is no sympathetic sBP overshoot following the release of strain, vertical dashed 
line.  Perhaps more interesting is the degree to which the CBFV fluctuates in line with the sBP.  This 
shows an absence of CA, such that as sBP decreases there is no cerebral vasodilatation and the 
CBFV decreases. 
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Figure 53.  TCD.  Abnormal CBFV response to valsalva in a PBC participant. 
 
If the change in CBFV was to be plotted against the change in sBP during the valsalva (from phase 
2a to phase 4) the resulting slope should be close to horizontal, indicating a constant CBFV.  This 
normal response can be seen in the Control participants; Figure 54 displays the change in CBFV for 
each individual in the Control group; each having a reasonably stable CBFV (y axis) with a change 
in BP (x axis). 
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Figure 54.  TCD.  Change in CBFV per change in sBP in the Controls. 
 
The horizontal lines displayed in Figure 54 are in contrast to those seen in the PBC participants 
below in Figure 55.  Here, almost all individuals display large changes in CBFV during a change in 
systolic BP.  The majority of the individuals display a typical response to changes in BP when there 
is impairment of CA; as the BP increases the CBFV increases.  Four of the PBC participants display 
a negative slope, which implies abnormal autoregulation, but not in the expected direction.  In 
some populations, namely those with VVS or CSS, there is evidence for an abnormal, paradoxical 
cerebral arteriolar vasoconstriction in response to hypotension [258, 273, 274, 275].  It could 
therefore be that those PBC participants with significant negative slopes are having abnormal, 
paradoxical vasoconstriction, resulting in reduced CBFV. 
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Figure 55.  TCD.  Change in CBFV per change in sBP in the PBC participants. 
 
The difference in the gradient of these lines is similar to the ASI, which is the change in CBFV 
standardised by the change in BP from phase 2 to phase 4 of the valsalva.  The difference reaches 
significance and is displayed in Table 42.  It also displays the difference in the AI-2 and AI-4 
between the cohorts.  The results here are slightly conflicting with the difference in the AI-4 
reaching significance whereas the results in the AI-2 are similar between the cohorts.  This may be 
because the AI-2 concerns the changes during phase 2 of the valsalva and occurs over a short period 
of time, as AI-4 occurs from phase 2 to phase 4 there is a longer period of time to detect an 
abnormal response. 
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 PBC Control z, p 
AI-2 -0.19 (-5.05-1.83) 0.92 (0.36-2.27) 1.095, 0.166 
AI-4 0.71 (0.1-1.22) 0.97 (0.93-1.24) 1.356, 0.031 
ASI -6.42 (-28.96-8.56) 11.8 (-1.99-13.38) 1.461, 0.019 
Table 42.  TCD.  Indices of CA in PBC and Control participants. 
 
27.5.4. CEREBRAL AUTOREGULATION AND ORTHOSTATIC SYMPTOMS 
As falls were associated with orthostatic symptoms but not measures of BP it was hypothesized 
that orthostatic symptoms would be related to impaired CA.  However, measures of resting and 
dynamic CA did not correlate with symptoms of orthostatic dizziness (OGS, Table 43). 
 
 rs, p 
sCBFV 0.333, 0.347 
dCBFV 0.241, 0.503 
CVR 0.56, 0.879 
PI -0.235, 0.514 
AI-2 0.13, 0.721 
AI-4 0.111, 0.76 
ASI -0.469, 0.171 
Table 43.  TCD.  Associations between CA and the OGS. 
 
27.5.5. CEREBRAL AUTOREGULATION AND FALLS 
The relationship between falls and CA was analysed to establish whether there was an association.   
Table 44 displays the measures of CA in the Fallers and the Non-Fallers.  There was one measure 
which demonstrated a significant difference between the groups, the AI-2.  However, the 
relationship was the opposite of what would have been anticipated; the poorest AI-2 values were 
seen in the Non-Fallers compared to the Fallers.  However the numbers in the analysis were very 
small and the results displayed are for interest; conclusions should be heavily tempered. 
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 Fallers Non-Fallers z, p 
CBFV 67.6 (42.2-75.4) 62.5 (52.5-73.1) 0.516, 0.924 
CVR 2 (1.1-3.6) 2.8 (1.9-4.5) 0.904, 0.295 
PI 1 (0.8-1.1) 1.1 (0.7-1.7) 0.775, 0.552 
AI-2 0.8 (-5-1.8) -1.4 (-5.1-0.0) 1.291, 0.048 
AI-4 0.8 (0.5-1.2) 0.2 (0.1-1.2) 1.162, 0.095 
ASI -6.4 (-29-15.2) -3.3 (-11.7-6.6) 0.904, 0.295 
Table 44.  TCD.  Association between CA and falls. 
 
2 7 . 6 .  S U M M A R Y  
In this small, pilot study there is evidence that dynamic, but not resting, CA is impaired in people 
with PBC, including those with early stage disease.  The original hypothesis that orthostatic 
symptoms in PBC are related to impaired CA could not be confirmed, nor was it possible to 
demonstrate an association between falls and CA. 
2 7 . 7 .  D I S C U S S I O N  
This study is one of the first to describe CA in a cohort of non-cirrhhotic CLD patients, each with 
PBC.  The results demonstrate a normal, resting CA which becomes impaired during dynamic 
changes in BP.  Dynamic changes in BP occur frequently throughout the day, for example, during 
standing from sitting, while coughing or sneezing, while defecating and while lifting heavy loads.  
As AD is common in CLD, particularly in PBC, these dynamic changes can be exaggerated, as 
displayed in Figure 52, where there is a large phase 2 decrease in BP.  With such exaggerated 
changes in BP it is essential that the brain can maintain constant blood flow in order to prevent 
ischaemia and infarction.  However, as is described here, in PBC the response to episodes of 
induced hypotension during strain is impaired and results in substantial reductions in cerebral 
blood flow. 
The valsalva manoeuvre proved to be an effective method of inducing dynamic BP changes in all 
participants, despite concerns about its validity.  For the purposes of this small study it was an ideal 
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method as it is non-invasive, comfortable for participants to perform and limited the movement of 
the TCD probes.  However, it has been suggested that the valsalva is not appropriate to assess CA 
because of the changes it induces in intracranial pressure and therefore in cerebral perfusion 
pressure [276].  However, the changes in intracranial pressure can be considered as instantaneous 
and as constant during phase 2 of the valsalva so that any changes in CBFV during phase 2 are 
occurring as a result of changes in BP (i.e. CA) and are occurring regardless of the ICP [277].  There 
is also a suggestion that a raised end-tidal CO2 at the end of the valsalva would contribute to an 
increase in cerebral vasodilatation, however this is not supported by published evidence; indeed, 
evidence suggests negligible to no change occurs in end-tidal CO2 following valsalva [278, 279].  
This is fortunate as changes in end-tidal CO2 could not be measured during valsalva in the 
equipment used here, and therefore could not be controlled for when analysing changes in CBFV. 
The AI-2, AI-4 and the ASI have all been validated in healthy controls and in cohorts with impaired 
CA [277, 278].  The ASI has the advantage over the AIs because it allows for changes in CBFV to 
occur following changes in BP, rather than at the same time, before CA may have responded, 
particularly in the AI-2 where changes must be noted over a short period and is particularly 
sensitive to the effort invested into the valsalva.  New indices continue to be developed, and as yet 
there is no consensus in the measurement or analysis of CA.  This leads to the absence of a gold 
standard, conflicting results and lack of clinical utility. 
This study is not longitudinal and can not directly assess the implications of such impairments in 
CA.  There is surprisingly little published data concerning the clinical consequences of impaired 
CA.  However, there is data to suggest that syncope, falls and dizziness result from hypotensive 
episodes when CA is impaired [258, 280].  There is also a risk of hepatic encephalopathy being 
precipitated during episodes of hypotension and impaired CA [268, 269, 281].  Although this study 
was unable to confirm the hypothesis that impaired CA is associated with falling as has been 
demonstrated in other studies, it may be limited by its small sample size.  However, it does 
demonstrate that the methods used here are simple and effective and could easily be performed in 
a cohort of a pre-determined sample size and power.  In such a study it would be interesting to 
fully consider the relationship between CA, orthostatic symptoms and falls. 
It is worth considering here that the association between falls and orthostatic dizziness, 
independent of BP, could be related to the methodology used in measuring BP.  Despite OH being a 
well described, well known and common condition there remain several uncertainties relating to its 
diagnosis and investigation.  Firstly, it is universal practise to rest a patient supine, prior to 
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standing, in order to achieve stable, baseline values.  However, there is great heterogeneity in the 
length of time used to achieve baseline values.  Times vary from 5 to 20 minutes in published 
research methodologies, but lack referenced evidence-base [257, 282, 283, 284].  The Consensus 
statement of the definition of OH, authored by the American Autonomic Society and the American 
Academy of Neurology is a widely cited article concerning methods of diagnosing OH; however it 
makes no recommendations concerning baseline values [179].  Conversely, the European 
Federation of Neurological Sciences’ guideline on the diagnosis of OH states ‘the patient should 
rest whilst supine for ideally 5 min…’ but no evidence is cited for this recommendation [285].  
Potentially the baseline values used when assessing postural BP could make a significant difference 
to the degree of BP drop which is noted as the patient stands.  Whether this could be enough to 
explain the association between falls and dizziness, independently of BP drop is unknown and the 
question remains unanswered.  In addition to the lack of recommendation regarding baseline 
values, guidelines have not progressed alongside the advances in technology, leading to a lack of 
certainty in particular situations.  For example, advances in continuous beat-to-beat BP monitoring 
have enabled the detection of single, or very short lived drops in BP which meet the criteria for a 
diagnosis of OH but which have unknown clinical significance. 
2 7 . 8 .  L I M I T A T I O N S  
As has been mentioned previously there is great heterogeneity in the data collection and analysis of 
CBF with no current, accepted gold standard.  In addition, a great deal is unknown about CA and 
many undiscovered factors which contribute to CBF, independently of CA could exaggerate results.  
In relation to TCD there is controversy regarding the possible changes in diameter of the MCA; in 
order for CBFV recordings to be accurate it is essential that the MCA diameter is constant.  Animal 
studies have demonstrated changes in MCA diameter under direct sympathetic stimulation [286]; 
this has not been confirmed in humans.  Indeed, direct visualisation of the MCA using angiography 
and during neurosurgery has demonstrated little to no change in diameter during sympathetic 
stimulation [264, 287]. 
An obvious limitation is the small sample size of the cohorts.  This seriously limits the 
generalisability of the results, even more so as the CLD cohort consisted of only PBC participants.  
However, the sample size is in keeping with many other studies relating to CA (see Appendix C) 
and can be used to inform future larger studies.  Undertaking TCD can be time consuming due to 
the variability in the location of the temporal window, the size of the window and the angle 
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required to visualise the MCA.  Once located, it is challenging to fix the probe in place without 
inadvertently moving the probe slightly, in which case the signal will be lost.  For this reason, 
limited numbers of participants can be booked into one session. 
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2 8 .  P O T E N T I A L  B A R R I E R S  T O  E F F E C T I V E  F A L L S  P R E V E N T I O N /  
I N T E R V E N T I O N  P R O G R A M M E S  
2 8 . 1 .  C H A P T E R  A I M S  
• Identify independent factors which could be targeted to increase the uptake or adherence to 
physical therapy 
• Understand whether people with CLD appreciate the benefits of exercise 
• Determine whether there is a lack of confidence to exercise in people with CLD 
• Identify modifiable factors associated with  having difficulty performing activity 
2 8 . 2 .  I N T R O D U C T I O N  
As the primary aims and objectives of this thesis were being met it became clear that one of the 
potential strategies which would be required for a targeted falls intervention/prevention program 
would be a multidisciplinary approach.  Results presented earlier in this thesis demonstrated that 
falls were associated with both fear of falling, muscle weakness and orthostatic symptoms.  While 
medical assessment and intervention may be required to address diabetes, blood pressure and 
perhaps leg weakness, physiotherapy intervention would be essential to address fear of falling and 
treat muscle weakness.  Intervention which addresses fear of falling typically takes the form of 
physical therapy/exercise [228, 288].  Therefore it is essential if clinicians are to promote physical 
therapy, to understand what factors could prevent individuals from taking up and adhering to 
prescribed activity. 
The NICE falls guidelines recommend that individualised, multidisciplinary fall intervention is 
offered to people who sustain a fall related injury in order to promote physical independence.  As 
part of the recommended intervention the guidelines suggest addressing potential barriers to fall 
prevention programmes such as fear of falling and self-efficacy.  Furthermore, The ProFaNE 
Consensus recommends using physical activity as an outcome in falls intervention programmes to 
improve an individual’s autonomy and independence [227]. 
There are several known factors which can influence an individual’s likelihood of engaging in 
physical therapy.  Self-efficacy expectations are an individual’s judgement of confidence to carry 
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out specific behaviours [289].  It determines whether an individual chooses to perform exercise, the 
effort they invest and the length of time that they will continue to exercise [290].  Self-efficacy has 
previously been identified as one of the most important strategies to engage individuals with 
NAFLD in lifestyle modification, including physical activity [291] and as such represents a 
potentially important barrier to falls intervention and prevention programmes in people with CLD. 
Outcome expectations are beliefs that beneficial results will be produced by performing physical 
activity [292].  An understanding of the benefits of exercise is associated with physical function in 
other chronic diseases such as coronary heart disease and cancer survivors [293, 294] and so it may 
be expected that an appreciation of the benefits of physical activity in people with CLD would be 
associated with increased levels of physical function. 
Paradoxically, although the treatment for fear of falling is physical therapy, fear of falling strongly 
influences engagement in physical activity, with greater levels of fear of falling correlating with 
lower levels of activity performed, worsening gait and balance and a poorer quality of life [113, 
295].  It would seem important therefore that fear of falling should be recognised and targeted early 
to prevent a vicious cycle of fear and inactivity. 
An additional factor which may influence engagement with physical activity in CLD is fatigue.  
Fatigue is common in CLD [120, 167] and may be associated with poorer levels of physical activity 
[296].  Given these multiple factors which could act as barriers to physical activity, particularly in a 
falls intervention/prevention programme, it is important to explore these factors further. 
2 8 . 3 .  M E T H O D S  
28.3.1. STUDY DESIGN 
A cross sectional approach was undertaken, using self-complete, postal data collection tools.  All 
participants were mailed a letter detailing the purpose of the study, the data collection tools and a 
pre-paid return envelope.  The ethical considerations to this study are covered by the ethical 
permissions discussed in section 15.3, page 44. 
28.3.2. STUDY POPULATIONS 
Three CLD populations were targeted for data collection.  PBC, NAFLD and ALD were chosen as 
they had the greatest proportion of fallers (54%, 29% and 26% respectively); these cohorts also 
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represent the most common CLDs who have a database of individuals who have consented to be 
contacted.  The PBC database population has been described previously in Chapter 2 Methods.  An 
alternative approach was taken to data collection from the NAFLD and ALD populations.  It was 
felt that the data collection method employed in the previous falls and injury chapters was sub-
optimal due to the high non-attendance rate to clinic appointments.  In addition, participants were 
being asked to complete several tools which may have been too lengthy for the clinic waiting room 
setting.  For these reasons the data collection tools were mailed out in the same manner as the PBC 
cohort above.  Although in the previous chapters it was felt that response rates to postal tools in 
NAFLD and ALD would be too low it was considered preferable to the clinic data collection. 
28.3.3. DATA COLLECTION TOOLS 
28.3.3.1  Outcome Expectation for Exercise Scale (OEES) 
The OEES consists of nine questions relating to the subjective benefits of exercise [297].  Participants 
indicate whether they strongly agree through to strongly disagree with the statements concerning 
exercise.  This gives an overall score out of 45 which is divided by 9 to give the OEES score; lower 
scores showing greater expectations of exercise.  This scale has undergone reliability and validity 
testing with strong evidence for both [297]. 
28.3.3.2 Self Efficacy for Exercise Scale (SEES) 
The SEES is a tool used to assess an individual’s confidence to perform exercise [290].  Participants 
indicate with a score out of 10 (1 for not confident, through to 10 for very confident) how confident 
they feel to perform the nine activities which are listed.  A value between 9 and 90 is reached and 
divided by 9 to give the SEES score.  Reliability and validity have been confirmed for this tool [290]. 
28.3.3.3 Falls Efficacy Scale International (FES-I) 
This tool is described in section 15.6.2.5, page 50. 
28.3.3.4 Fatigue Impact Scale (FIS) 
The FIS allows for quantification of an individuals level of fatigue and the impact this has upon 
their daily functions [298].  There are 40 items which are scored as 0 (no problem) through to 4 
(extreme problem).  It has previously been validated in CLD populations [299]. 
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28.3.3.5 PROMIS-HAQ 
Activity was analysed from a functional perspective using the PROMIS-HAQ [300].  This tool is 
described in section 15.6.2.5, page 50.  One specific question concerning physical activity is included 
in the PROMIS-HAQ and this question was used here to quantify an individuals ability to perform 
activity (from completely, mostly or moderately through to a little or not at all).  Reliability and 
validity have been confirmed [301]. 
28.3.4. DATA ANALYSIS 
All continuous data were non-parametric and are summarised with the median and range.  
Spearman rank correlation was performed to explore associations between the dependent variable, 
which was ordinal, and the continuous variables.  The Mann-Whitney U test was used to identify 
statistical differences between 2 data sets and is described in section 15.7, page 56.  Ordinal logistic 
regression was the most appropriate form of regression for the ordinal, dependent variable.  It is 
preferred to linear regression because of the non-standardised distance between each category and 
allows more outcome categories for the dependent variable than binary logistic regression.  The 
model is displayed in an identical manner to the binary logistic regression models described in 
section 15.7, page 56. 
2 8 . 4 .  R E S U L T S  
28.4.1. RECRUITMENT 
The combined databases provided a population size of 819 individuals.  Each of these was 
contacted and 441 (54%) returned the data collection tools.  The final cohort consisted of NAFLD 
52%, ALD 26% and PBC 22%. 
28.4.2. DEMOGRAPHICS 
Details concerning age, sex and LFTs are displayed below in Table 45. 
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 Cohort (n 441) 
Age (years) 62 (19-95) 
Female (%) 225 (51) 




ALP [U/L] 117 (48-864) 
ALT [U/L] 34 (15-187) 
Cirrhosis (%) 110 (25) 
Table 45.  Barriers.  Demographic details. 
 
28.4.3. ACTIVITY 
Level of activity ranged from 0 (completely able to perform) to 4 (unable to perform) with a median 
of 1 (mostly able to perform activities).  The proportions of individuals experiencing the different 
levels of difficulty are described below in Figure 56 (0 no difficulty, 1 a little difficulty, 2 some 
difficulty, 3 much difficulty, 4 unable to do).  Forty per cent experienced at least some difficulty and 
21% were able to perform only a little or no activity. 
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Figure 56.  Barriers.  The proportion of individuals for each degree of difficulty with activity. 
 
28.4.4. BARRIERS TO ACTIVITY 
The possible barriers to activity measured in the CLD population are displayed in Table 46 with 




SEES (confidence to exercise) 4 (1-10) 
OEES (expectations of exercise) 2.38 (1-5) 
FES-I (fear of falling) 27 (16-64) 
FIS (fatigue) 60 (0-160) 
Table 46.  Barriers.  The potential barriers to activity. 
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Unfortunately there are no ‘cut off’ values to determine what proportions of individuals have 
abnormal levels of those variables in the table.  However, the results suggest that on the whole, 
individuals have relatively low confidence to exercise; indeed, 24% scored the lowest score possible, 
indicating that a quarter of people with CLD are not confident to perform physical activity.  They 
also suggest that in general, people with CLD need informing of the benefits of activity, with only 
13% scoring the highest score possible for appreciating the benefits and 3% not appreciating any 
benefit of exercise at all.  Ninety-six percent of the participants had at least some fear of falling 
(although there is no control group to compare this to) and 94% had at least some level of fatigue, 
meaning that most of the individuals have potential barriers to physical activity.  Given these 
results it is important to explore their associations with levels of activity to identify whether they 
represent barriers in the CLD population. 
28.4.5. ASSOCIATIONS WITH ACTIVITY 
Demographic associations with the degree of difficulty experienced during activity are displayed in 
Table 47.  An increasing age is associated with increasing levels of difficulty whereas decreasing 
levels of both albumin and bilirubin are associated with increasing difficulty.  Activity was similar 
between those with cirrhosis [1 (0-4)] and those without cirrhosis [1 (0-4) U 2858, z -0.145, p 0.678].  
One possible explanation for the association between albumin and activity is the influence of 
advancing age which associates with lower levels of albumin [302].  This can be explored further in 
the regression analysis below. 
 
 rs, p 
Age 0.126, 0.013 
Albumin -0.212, <0.001 
Bilirubin -0.2, 0.001 
ALP 0.025, 0.671 
ALT -0.079, 0.188 
Table 47.  Barriers.  The associations between activity and demographic details. 
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Figure 57 below displays the median values for OEES, SEES, FIS and FES-I for each grade of 
difficulty with activity.  Each measure demonstrated a significant association with the degree of 
difficulty performing activity Table 48.  Low confidence to perform exercise was associated with 
increasing difficulty with activity, appreciating the benefits of exercise was associated with 
significantly less difficulty and increasing levels of fatigue and of fear of falling was associated with 
more difficulty with activity. 
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Figure 57.  Barriers.  Associations between activity and potential barriers to it. 
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Figure 57.  Barriers.  Associations between activity and potential barriers to it.
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Potential barrier rs, p 
SEES -0.403, <0.001 
OEES 0.371, <0.001 
FIS 0.381, <0.001 
FES-I 0.673, <0.001 
Table 48.  Barriers.  Associations between difficulty with activity and potential barriers to activity. 
 
28.4.6. EXPLORING INDEPENDENT ASSOCIATIONS 
Incorporating the aforementioned significant associations into an ordinal logistic regression model 
revealed an increasing fear of falling as the sole independent association with the degree of 










Age 0.04 0.032 1.04 0.977 1.107 0.214 
Albumin 0.02 0.069 1.02 0.891 1.169 0.771 
Bilirubin 0.008 0.016 1.008 0.977 1.04 0.617 
SEES -0.208 0.119 0.812 0.643 1.026 0.081 
FES-I 0.087 0.039 1.091 1.011 1.177 0.026 
OEES 0.185 0.359 1.203 0.595 2.432 0.606 
FIS 0.001 0.012 1.001 0.978 1.025 0.937 
Model χ2 (7) 47.136, p <0.001 
Table 49.  Barriers.  The ordinal logistic regression model for difficulty with activity. 
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Figure 58.  Barriers.  The 95% CI for the ORs derived from the ordinal logistic regression model. 
 
28.4.7. DISEASE SPECIFIC BARRIERS 
Further analysis was performed to explore whether these barriers were consistent in each specific 
CLD or whether differing CLD, experience different barriers to activity.  Ordinal logistic regression 
was performed for each cohort including only those associations with activity which were present 
in that specific cohort; age was also included in each model to allow conclusions to be drawn 
irrespective of age. 
28.4.7.1 NAFLD 
Fatigue was excluded from the regression model due to multicollinearity. 
   187 
95% confidence 
interval (OR) 






Age -0.003 0.033 0.997 0.935 1.064 0.94 
Albumin -0.03 0.091 0.97 0.812 1.159 0.739 
Bilirubin 0.016 0.016 1.016 0.985 1.048 0.313 
SEES -0.215 0.125 0.807 0.632 1.03 0.085 
FES-I 0.108 0.027 1.114 1.058 1.174 <0.001 
OEES -0.089 0.305 0.915 0.503 1.662 0.77 
Model χ2 (6) 33.812, p <0.001 
Table 50.  Barriers NAFLD.  The ordinal logistic regression model for difficulty with activity. 
 
The results in Table 50 demonstrate that fear of falling is the single independent association with 
difficulty with activity, and is so, regardless of age. 
28.4.7.2 ALD 
The SEES was excluded from the regression model because of multicollinearity. 
95% confidence 
interval (OR) 






Age 0.02 0.029 1.021 0.964 1.08 0.483 
FES-I 0.077 0.026 1.08 1.026 1.136 0.003 
OEES 0.983 0.318 2.672 1.434 4.98 0.002 
FIS 0.002 0.008 1.002 0.986 1.019 0.776 
Model χ2 (4) 26.603, p <0.001 
Table 51.  Barriers ALD.  The ordinal logistic regression model for difficulty with activity. 
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The results of the regression model (Table 51) for the ALD cohort demonstrates that fear of falling is 
independently associated with difficulty with activity, consistent with the NAFLD cohort.  In 
addition, an understanding of the benefits of exercise was independently associated with less 
difficulty with activity, which suggests that in ALD educating people who require physical therapy 
is an important consideration. 
28.4.7.3 PBC 
No variable suffered multicollinearity and as such, all significant associations in the PBC cohort 
were included in the model below. 
95% confidence 
interval (OR) 






Age 0.029 0.037 1.029 0.957 1.107 0.441 
SEES -0.114 0.112 0.892 0.717 1.11 0.305 
FES-I 0.128 0.035 1.137 1.062 1.217 <0.001 
OEES 0.545 0.36 1.724 0.851 3.493 0.13 
FIS 0.022 0.013 1.022 0.996 1.05 0.098 
Model χ2 (5) 52.354, p <0.001 
Table 52.  Barriers PBC.  The ordinal logistic regression model for difficulty with activity. 
 
2 8 . 5 .  S U M M A R Y  
Several barriers have been identified as having strong associations with physical difficulty.  
Fortunately each of these barriers (with the exception of age) is potentially modifiable and if 
targeted could increase engagement in physical activity and increase uptake and adherence to falls 
intervention/prevention programmes.  Regression analysis revealed that an increasing fear of 
falling is independently associated with more difficulty in performing activity.  The difficulty here 
is that physical activity is the treatment for fear of falling which in itself is a barrier to physical 
activity. 
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2 8 . 6 .  D I S C U S S I O N  
Previous results chapters have demonstrated that fear or falling and lower limb muscle weakness 
are independently associated with falling.  Potential intervention for both of these fall risk factors 
includes physiotherapy, which would typically take the form of physical therapy/exercise.  
However, physical therapy and exercise may be difficult to ‘prescribe’ as several potential barriers 
have been demonstrated here.  While each of these barriers is known to affect uptake and continued 
adherence to physical exercise programmes they are probably not well understood in the clinical 
setting, particularly in the context of CLD. 
This exploratory study revealed that the amount of difficulty experienced while performing 
physical activity was strongly associated with an understanding of the benefits of exercise.  This is 
hugely important because it demonstrates a lack of knowledge concerning exercise in the CLD 
population which has the potential to be improved.  Although there is a lack of evidence to suggest 
that outcome expectations are modifiable it is a logical assumption that counselling a patient about 
the benefits of exercise could improve their understanding.  Unfortunately, there is also a lack of 
evidence to suggest that improving outcome expectations will be beneficial.  However, it would be 
reasonable to assume that it would, given the strong association between the OEES and physical 
activity.  Regardless of this lack of evidence, clinicians must be responsible for educating their 
patients about health promotion strategies [303]; with particular relevance to the NAFLD 
population in whom lifestyle modification has become standard advice [291, 304]. 
Confidence to perform activity was strongly associated with the degree of difficulty experienced 
during physical activity.  This seems obvious but the point is that clinicians need to be aware of 
these factors when promoting physical therapy, such as in a falls intervention programme.  
Improving an individual’s confidence to exercise improves adherence to exercise programmes [290] 
and has been shown to be an important consideration for those with NAFLD [291].  However, more 
evidence base is required to suggest the most appropriate strategies to improve self-efficacy; at 
present, evidence is at best, vague [305]. 
It was unsurprising to demonstrate that greater levels of fatigue were associated with increased 
difficulty with activity.  Fatigue can be a debilitating symptom, is common in CLD, has complex 
aetiology and is challenging to treat [167, 306, 307].  It represents a particularly difficult barrier to 
physical exercise programmes given the lack of effective treatments available.  However, on 
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regression analysis fatigue was not independently associated with physical activity and although it 
is important, it is not as amenable to intervention as other factors which were identified. 
As with previous results chapters, fear of falling emerges as an important and independent 
association.  Here, it is independently associated with increased difficulty with activity [OR 1.085 
(1.043-1.128)].  Although this is problematic because fear of falling is a barrier to its own 
intervention, physical activity, it is potentially modifiable.  It represents a real, potential 
opportunity to dramatically improve the quality of life of people with CLD.  Fear of falling 
intervention strategies have the potential, in CLD, to prevent falls, improve functional ability, 
increase physical activity and to prevent social isolation, depression and institutionalisation [308]. 
The associations identified in the demographic data revealed strong relationships between age, 
albumin and bilirubin with the amount of difficulty experienced during activity; however an 
increasing age was not associated with more difficulty in the regression model.  Older people with 
CLD may represent a challenging group in whom to offer physical activity as a therapeutic strategy 
for reasons not covered here, e.g. arthritis.  However, this challenge should not preclude this group 
from physiotherapy but should alert the clinician to the increased difficulties experienced by this 
group.  The relationship between albumin and physical activity did not remain significant in the 
regression model.  The most likely explanation for this is the confounding relationship between age 
and albumin, in which albumin is known to reduce with age (albeit within the normal range) [302]. 
2 8 . 7 .  L I M I T A T I O N S  
It would have been preferable to have included a broader range of CLDs to improve generalisabilty 
of the results.  However, the number of individuals included was relatively large and does provide 
important considerations for future studies. 
It is necessary to point out that the dependent variable, difficulty with activity, is not a measure of 
activity performed.  While the measure used is useful pragmatically and provides an 
understanding of an individual’s ability/difficulty with activity it does not provide a quantifiable 
level of activity performed.  This may be misleading if an individual has rated themselves as having 
difficulty with activity but still engages in it, or an individual who never performs any activity may 
have described themselves as having no difficulty. 
Both the OEES and the SEES were designed for and validated in the elderly and have not been 
validated, as yet, in the younger general population or in a CLD population.  It must be recognised 
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therefore, that the results may not be wholly accurate in the younger individuals who participated.  
The same is true for the FES-I which has been discussed previously in section 15.6.2.5, page 50.  The 
OEES and SEES have however, been validated in other younger disease groups and are therefore 
not exclusive to older people [309, 310].  Furthermore, the original development and validation 
studies do not specify an age at which they used to include their participants, referring to them only 
as ‘older adults’’.  In this study 57% were aged over 60 years and 38% were aged over 65 years and 
so it could be argued that the majority of participants were older adults. 
A significant omission from the analysis is the inclusion of a measure of autonomic dysfunction.  
Given that orthostatic dizziness was associated with falling in the previous results chapters it 
would have been interesting to have assessed its association with activity.  However, at the time of 
investigating the factors associated with activity it had not become apparent that OGS scores were 
higher in the Fallers.  A more robust model may have been possible by including further details 
such as arthritis, angina and breathing difficulties, each of which could potentially be a barrier to 
physical therapy.  But while the regression model above may not have included all potential 
barriers to activity it displays some very strong associations which are clinically relevant and 
previously unknown in the CLD population.  This exploratory work may help inform future 
studies concerning physical activity in people with CLD. 
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S U M M I N G  U P  A N D  F U T U R E  C O N S I D E R A T I O N S
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2 9 .  S U M M I N G  U P  
As hypothesised, falls are extremely common in older people with CLD.  This unique, cross-
sectional study has demonstrated a significantly greater proportion of older people having a fall in 
the previous year than in age- and sex-matched Community Controls.  Despite the high prevalence 
of falls, fall-related injury was no more common in the older CLD cohort; this was an unexpected 
finding, negating one of the prospective, original hypotheses.  Through multidisciplinary 
assessment of a sub-group of people with CLD, fall associations were explored.  Statistical analysis 
revealed that orthostatic dizziness, lower limb strength and fear of falling were each independently 
associated with falling.  The significance here is that each of these fall associations is modifiable.  
The importance of falling in CLD was further highlighted by the strong association between falling 
and increased functional difficulty. 
On exploring disease-specific falls prevalence, both NAFLD and PBC had significantly greater 
proportions of people who fell and who fell recurrently than in age- and sex-matched Community 
Controls.  Statistical comparisons were limited for the PSC and ALD cohorts due to relatively small 
numbers responding to recruitment.  Phase 2 revealed that fear of falling was independently 
associated with falling in the NAFLD cohort; in the PBC cohort lower limb strength was 
independently associated with falling.  Once again, these independent associations are potentially 
modifiable and offer evidence to support future prevention/intervention studies employing the 
skills of a multidisciplinary team. 
The post-LT cohort was analysed with a number of different methods.  Firstly the cohort was 
compared to an age- and sex- matched Community Control cohort, demonstrating a significantly 
greater prevalence of falls in the post-LT cohort.  Comparison was then made to a matched CLD 
cohort who had not undergone LT.  Rates of falling were similar in the two cohorts; furthermore the 
rates of falling were similar in the post-LT cohort to the rate of falling retrospectively recalled from 
a time before the cohort underwent LT.  Fall associations during Phase 2 of the study revealed that 
orthostatic symptoms, heart rate variability, lower limb weakness and, once again, fear of falling 
were independently associated with falling. 
The results suggest that in designing a falls treatment or prevention programme for older people 
with CLD a multidisciplinary approach will most likely be required, with a particular focus on the 
treatment of fear of falling.  Fortunately fear of falling is amenable to treatment with physical 
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therapy in the form of exercises.  Further analysis of the CLD cohort revealed several associations 
with difficulty performing activity and represent potential barriers to the uptake and/or adherence 
to a physical therapy programme.  Fear of falling was identified as the sole independent association 
with difficulty performing activity.  Fear of falling is therefore a barrier to the treatment of fear of 
falling and represents a significant therapeutic target to prevent falls and increase uptake of 
physical therapy. 
The association between postural dizziness and falls, independently of BP, remains unexplained.  A 
small, pilot study undertaken to explore CA as the unifying factor, demonstrated that impairment 
of CA was significant in PBC but was unrelated to orthostatic symptoms.  This suggests that there 
may be an underlying process which we do not yet understand or that the methods used to assess 
BP, falls or postural dizziness are inadequate. 
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3 0 .  F U T U R E  C O N S I D E R A T I O N S  
As is the case with much evidence base, studies including or relating specifically to older people are 
few, although the need for such evidence is certainly not lacking.  This need will only increase 
dramatically over the next decade as the older population expands.  One sub group of this 
expanding population is the older CLD population, which may arguably expand at a greater rate 
than other older populations.  The work presented in this thesis provides evidence to contextualise 
the problem of falls in the older CLD population, a process recommended by the MRC in the 
development of complex intervention studies.  However, this work goes further and provides 
exploratory data to inform the design of the complex intervention which would be required to 
investigate the benefit of a multifaceted falls prevention/intervention programme. 
If the results above were to be used to inform a falls intervention or prevention trial it would 
appear appropriate to address those risk factors identified.  Whether the intervention would focus 
on all associations or only those which were independently associated with falling (postural 
dizziness, lower limb strength and fear of falling) a MDT approach would be required, utilising the 
skills of a physician, nurse, physiotherapist and arguably an OT and cognitive therapist. 
There is great heterogeneity in the literature concerning multidisciplinary/ multifactorial fall 
interventions.  This heterogeneity results from wide variations in falls research.  The first major 
problem is the lack of a standard definition of a fall [233], although with groups such as the 
Prevention of Falls Network Europe (ProFaNE) it is hoped that one definition will become 
standard.  Though the majority of publications do not define what they consider to be a fall, the 
most common definition used (amongst those who do define a fall) is ‘unintentionally coming to 
the ground or some lower level and other than as a consequence of sustaining a violent blow, loss 
of consciousness, sudden onset of paralysis as in stroke or an epileptic seizure’.  However, this 
definition would not include those who fall as a result of syncope, for example as a result of 
syncopal OH.  The definition suggested by ProFaNE is much more encompassing ‘an unexpected 
event in which the participants come to rest on the ground, floor or other lower level’ [227].  
Heterogeneity is further created by differing inclusion criteria in fall intervention studies, for 
example including or excluding those with cognitive impairment or including only recurrent 
fallers.  But perhaps one of the most important issues which has contributed to conflicting results 
regarding multifactorial falls intervention is the differences in the multifactorial component.  
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However, it is not just the multifactorial intervention which is important, the process in which it is 
delivered is equally as crucial [311]. 
In forming a Phase 2 exploratory trial (based on the MRC linear research framework) the 
aforementioned considerations must be taken into account.  In support of a multifactorial 
intervention in the older CLD cohort is the results seen in the general population.  Here the 
aetiology of falls are complex and trials which have compared single intervention to multifaceted 
interventions have demonstrated benefits in having a multidisciplinary approach [312] whereas 
interventions lead by a single health professional have not shown reductions in falls [313, 314].  
Furthermore, one meta-analysis of 5 high-quality multifactorial intervention studies (in older, 
falling, community dwelling adults) demonstrated a pooled risk ratio of 0.86 (95% CI 0.76, 0.98) for 
preventing a further fall.  As falls in CLD appear to have complex aetiology it would seem 
appropriate to adopt this multidisciplinary approach; including the assessment and management of 
orthostatic dizziness, limb weakness and fear of falling. 
In designing the data collection for such a falls prevention/treatment programme consideration 
would have to be given to the method used for prospectively collecting falls data.  At present, there 
is no single, fully reliable method with a tendency for most methods to be based, at least in part, on 
retrospective recall, and therefore under-reporting incidence.  Secondly, the length of follow-up 
may be crucial as the effect of an intervention programme may be underestimated if it is too short.  
The study presented here supports the use of negative binomial regression to model falls data in 
future studies as the falls data was highly skewed with high zero frequencies; furthermore the 
binomial regression models were a better fit of the data than the categorical binary logistic 
regression models. 
The final results chapter demonstrated several potential barriers to intervention with physical 
therapy.  These are important considerations in the design of a multifaceted falls prevention 
programme and represent difficulties which may lead to poor adherence and high drop out rates if 
not addressed. 
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3 2 .  A P P E N D I C E S  
A P P E N D I X  A .  F A L L S  A N D  I N J U R Y  P O S T A L  T O O L  
Please place a tick in the Yes or No box. 
 
  Yes 
 
 No  




 If no go to 
question 9 
2 Have you fallen in the last year? 
 
   
3 If so, how many falls have you had in 
the last year? 
 
 
4 Did you blackout or lose consciousness 
when you fell? 
 
  
5 Did you go to Accident & Emergency 
following your fall? 
 
  




7 Did you need any stitches or medical 




8 Were you admitted to hospital as a 
result of your fall? 
 
  
9 Would you be happy for us to contact 
you again about developing services 
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A P P E N D I X  B .  N O N - S T A T I S T I C A L L Y  S I G N I F I C A N T  R E S U L T S  
Appendix B.1. CLD. 
Non significant correlations with number of falls, section 17.5, page 71. 
 Variable rs p 
Albumin -0.106 0.106 
Bilirubin -0.027 0.683 
ALP 0.062 0.347 
ALT -0.054 0.409 
Demographics 
BMI 0.024 0.024 
sBP -0.152 0.209 
dBP -0.046 0.707 
nadir sBP -0.127 0.295 
nadir dBP -0.015 0.903 
RRI 30:15 -0.147 0.225 
Active stand 
AUC 0.085 0.485 
LFnu -0.216 0.071 
HFnu 0.119 0.322 
VLF -0.216 0.071 
LF -0.158 0.189 
HF -0.114 0.346 
PSD -0.186 0.121 
HRV 
LFnu:HFnu -0.164 0.173 
Slope mean 0.019 0.875 BRS 
BEI -0.209 0.081 
Valsalva RRI ratio 0.079 0.547 Valsalva 
Overshoot 0.087 0.508 
Cognition -0.055 0.648 MDT 
Hand grip -0.135 0.262 
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Appendix B.2. NAFLD. 
Non significant correlations with number of falls, section 18.6, page 88. 
 Variable rs p 
Age 0.125 0.207 
Albumin 0.044 0.662 
Bilirubin -0.035 0.728 
ALP 0.011 0.911 
ALT -0.037 0.711 
BMI 0.033 0.881 
Demographics 
IR -0.279 0.467 
OGS 0.089 0.679 
sBP -0.354 0.07 
nadir sBP -0.34 0.083 
Active stand 
RRI 30:15 -0.378 0.052 
LFnu 0.017 0.932 
HFnu -0.017 0.932 
VLF -0.174 0.375 
LF 0.039 0.845 
HF -0.149 0.449 
PSD -0.18 0.359 
HRV 
LFnu:HFnu 0.017 0.932 
Slope mean -0.134 0.504 BRS 
BEI -0.241 0.217 
Valsalva RRI ratio 0.081 0.712 Valsalva 
Overshoot 0.123 0.577 
Cognition -0.125 0.527 
Hand grip -0.156 0.428 
Sit to Stand Test 0.159 0.439 
Timed Up and Go 0.318 0.099 
Balance 0.055 0.781 
MDT 
Gait -0.161 0.413 
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Appendix B.3. PBC. 
Non significant correlations with number of falls, section 19.6, page 98. 
 Variable rs p 
Age 0.065 0.529 
Albumin 0.114 0.394 
Bilirubin -0.147 0.281 
ALP -0.197 0.137 
ALT -0.073 0.585 
Demographics 
BMI -0.106 0.514 
sBP -0.1 0.951 
dBP 0.198 0.222 
nadir sBP 0.025 0.88 
nadir dBP 0.243 0.13 
AUC -0.046 0.78 
Active stand 
RRI 30:15 -0.012 0.943 
HFnu 0.233 0.148 
VLF -0.202 0.212 
LF -0.185 0.253 
HF -0.054 0.739 
HRV 
PSD -0.16 0.324 
Slope mean 0.163 0.315 BRS 
BEI -0.045 0.784 
Valsalva RRI ratio 0.215 0.223 Valsalva 
Overshoot 0.095 0.591 
Cognition 0.126 0.444 
Hand grip -0.159 0.326 
MDT 
Timed Up and Go 0.261 0.103 
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Appendix B.4. LT. 
Non significant correlations with number of falls, section 24.4, page 130. 
 Variables rs p 
Age -0.134 0.204 
Albumin -0.027 0.805 
Bilirubin 0.025 0.823 
ALP 0.203 0.063 
ALT 0.1 0.364 
Demographics 
BMI -0.333 0.244 
sBP -0.43 0.097 
dBP -0.009 0.972 
nadir dBP -0.058 0.83 
AUC 0.126 0.641 
Active stand 
RRI 30:15 -0.353 0.18 
LFnu -0.387 0.138 
HFnu 0.38 0.147 
VLF -0.274 0.304 
LF -0.054 0.844 
HF 0.361 0.17 
LFnu:HFnu -0.387 0.138 
HRV 
PSD -0.062 0.819 
Slope mean 0.093 0.743 BRS 
BEI 0.153 0.586 
Valsalva RRI ratio -0.087 0.767 Valsalva 
Overshoot -0.156 0.595 
Cognition 0.079 0.773 
Hand grip 0.104 0.702 
Sit to Stand Test 0.234 0.421 
Timed Up and Go 0.39 0.136 
Balance -0.434 0.093 
Gait -0.246 0.376 
MDT 
FES-I 0.13 0.631 
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Appendix B.5. CLD and LT. 
Non significant correlations with number of falls in the combined cohort, section 25.6, page 139. 
  rs p 
Age 0.024 0.823 
Albumin -0.142 0.212 
Bilirubin -0.044 0.703 
ALP 0.072 0.528 
ALT -0.047 0.682 
Demographics 
BMI -0.052 0.651 
dBP -0.055 0.617 
nadir dBP -0.052 0.638 
Active stand 
AUC 0.116 0.29 
LFnu -0.174 0.107 
HFnu 0.099 0.363 
LF -0.185 0.086 
HF -0.12 0.27 
HRV 
LFnu:HFnu -0.136 0.21 
Slope mean -0.028 0.801 BRS 
BEI -0.141 0.196 
Valsalva RRI ratio 0.033 0.781 Valsalva 
Overshoot 0.013 0.911 
Cognition -0.012 0.911 MDT 
Hand grip -0.094 0.385 
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A P P E N D I X  C .  S T U D I E S  O F  C E R E B R A L  A U T O R E G U L A T I O N  I N  C L D  
Study Sample size Method Result 
Almdal 1989 [281] 28 Indicator flow ↓ CBF in cirrhosis + HE.  No association between CBF and liver function 
Burra 2004 [315] 50 SPECT ↓ regional CBF.  All controls were under investigation for headache 
Dam 1998 [272] 23 SPECT ↓ CBF in cirrhosis which resolved post-LT, except in those with ALD 
Dillon 1995 [316] 37 TCD ↓ CBFV in cirrhosis (Child’s B & C but not in Child’s A), 65% had ALD 
Frokjaer 2006 [268] 14 TCD Reports impaired CA in cirrhosis but no different to controls on testing with FET 
Iverson 2009 [317] 12 PET ↓ CBF in cirrhosis + HE but normal if HE is absent 
Iwasa 2000 [318] 28 SPECT ↓ regional CBF in cirrhosis which associated with increasing disease severity 
Iwasa 2003 [319] 14 SPECT ↓ regional CBF in cirrhosis 
Lagi 1997 [270] 15 TCD ↓ recovery of CBF to ↓ BP in cirrhosis but normal resting CBF 
Lagi 2002 [271] 10 TCD ↓ response to ↑ BP in cirrhosis 
Larsen 1995 [320] 10 TCD CBF and CA similar in cirrhosis to controls 
Yamamoto 2005 [321] 43 SPECT ↓ regional CBF in cirrhosis 
Yazgan 2003 [322] 31 SPECT ↑ & ↓ regional CBF in cirrhosis.  No association with liver disease severity 
 
